Clinical trial NCT03611751
Conditions: Psoriasis
Sponsor: Bristol-Myers Squibb
Start date: 2018-07-26; Completion date: 2020-11-30
Enrollment: 1020 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Detailed description:

Arms: arm 1: BMS-986165 oral administration arm 2: Placebo oral administration arm 3: Active comparator oral administration
Interventions: intervention 1: BMS-986165 intervention 2: Placebo intervention 3: Apremilast
Intervention descriptions: intervention 1: Specified dose on specified days intervention 2: Specified dose on specified days intervention 3: Specified dose on specified days

Protocol documents:
Prot_000.pdf: 
Official Title of Study: 
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study 
with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in 
Subjects with Moderate-to-Severe Plaque Psoriasis 
 
 
NCT Number: NCT03611751 
Document Date (Date in which document was last revised): May 21, 2020  


Protocol Number:
IM011047
IND Number:
131,993
EX-US
Non-IND
EUDRACT Number:
2018-001925-24
Date, Version:
21 May 2020, Global Protocol v7.0,
Revised Protocol 09 Final Approved
Clinical Protocol IM011047
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled 
Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and 
Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Short Title: Efficacy, Safety, and Durability of Response of BMS-986165 versus Placebo and 
Active Comparator in Subjects with Psoriasis
Clinical Trial Physician
Medical Monitor
24-hr Emergency Telephone Number
USA: 
International: 
Bristol-Myers Squibb Research and Development
3401 Princeton Pike
Lawrenceville, NJ 08648
Avenue de Finlande 4
B-1420 Braine-l’Alleud, Belgium
This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates 
(BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of 
assessing whether your organization will participate in and/or the performance of the proposed BMS sponsored study. Any 
permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your 
independent ethics committee(s). Any other use, copying, disclosure, or dissemination of this information is strictly 
prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be 
added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as 
the contents of this document. Any person who receives this document without due authorization from BMS is requested 
to return it to BMS or promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to 
partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
2
DOCUMENT HISTORY
Document
Date of Issue
Approver(s)
Summary of Change
Original 
Protocol
11-May-2018
Not applicable
Amendment 01
15-June-2018
Clarified that Psoriasis 
Symptoms and Signs Diary 
(PSSD) daily data collection 
will begin at the Screening 
Visit and, for randomized 
subjects, will continue daily 
through Week 52.
Amendment 02
20-Nov-2018
Updated the Sponsor’s 
contact information, made 
typographic corrections to 
the protocol, clarified certain 
procedures, updated wording 
in Appendix 3 to be 
consistent across studies of 
BMS-986165, described 
treatment assignment details, 
and revised certain exclusion 
criteria to be consistent with 
certain elements of the Phase 
2 study of BMS-986165 in 
psoriasis as well as other 
Phase 3 studies in psoriasis
Amendment 03
12-Dec-2018
German-Specific 
Amendment
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
3
Amendment 04
13-Mar-2019
Italy-Specific Amendment
Amendment 05
14-May-2019
As this is designed to be a 
global study across multiple 
countries, randomization in 
each country will be targeted 
to approximately 35% or less 
of the total sample size. This 
change is being implemented 
to achieve geographical 
representation across 
countries and to minimize the 
potential for any single 
country to have a 
disproportionate impact on 
the overall efficacy and/or 
safety profile.
Other changes include:
-Updated text in the 
definition of sPGA in Section 
8.1.1.1 to be consistent with 
the description in 
Appendix 5. 
-Updated the description for 
the following endpoints: 
‘Time to relapse until Week 
52’ and ‘Time to rebound in 
subjects re-randomized to 
placebo’
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
4
-Added the ‘Time to relapse
until Week 52’ endpoint to
Section 9.3.2.1 and to the
Testing Order of Key
Secondary Endpoints table in
Section 9.4.3 in place of the
‘Maintenance of PASI 75’
endpoint.
-Section 9.4.4 was updated to
define relapse during the
Randomized Withdrawal and
Maintenance Period.
Amendment 06
06-June-2019
Revised the testing order 
(hierarchy) of key secondary 
endpoints 
 and 
revised the text in Sections 
9.3.2.1 and 9.3.2.2 
accordingly as follows: 
x Removed endpoints 
containing ‘PSSD sign 
score.’ The reason for this 
change is that PSSD sign 
score is redundant with 
components assessed by 
PASI and sPGA which 
are already in the 
hierarchy.
x Removed ‘change from 
baseline in DLQI score.’ 
The reason for this change 
is that DLQI endpoint 
‘DLQI 0/1 among 
subjects with baseline 
DLQI score ≥2’ is 
clinically meaningful and 
is already in the hierarchy.
Amendment 07
12-Jul-2019
Germany-Specific 
Amendment – Included 
changes listed above for 
Global Amendment 02, 05
and 06.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
5
Global Revised 
Protocol 08
17-Dec-2019
Made the following updates:
x
provided clarifications in 
the protocol to aid sites 
and subjects in the 
conduct of the study.
x
added and updated 
relevant protocol 
deviation criteria for the 
Per Protocol Set
x
corrected typographical 
errors
x
added a new analysis for 
systemic treatment-naïve 
subjects to the set of 
subgroup analysis for the 
coprimary efficacy 
endpoints
Global Revised 
Protocol 09
(im011047-
revprot07)
21-May-2020
This global protocol 
amendment outlines changes 
for subjects who are unable 
or unwilling to attend 
protocol-specified trial visits 
and procedures during the 
COVID-19 pandemic,
including:
x method of study 
treatment assignment 
when COVID-19 related 
issues result in the Week 
24 visit and/or 
subsequent visits being 
missed or conducted
x statistical impacts due to 
COVID-19
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
6
SUMMARY OF CHANGES
Rationale:
The primary purpose of this global revised protocol is to outline changes resulting from visits being 
missed or conducted remotely due to the COVID-19 pandemic, including:
•
method of study treatment assignment when COVID-19-related issues result in the 
Week 24 and/or subsequent visits being missed or conducted remotely 
•
statistical impacts due to COVID-19
Changes made to the previous version of the global protocol and the rationale for these changes 
are noted below in the summary of key changes table. All changes applied to the protocol body 
were applied to the synopsis, as necessary; synopsis changes are not included in the summary of 
key changes table. Only major additions and deletions are provided in this summary document; all 
minor grammatical, formatting, stylistic changes, or clarifications as well as organizational 
changes are not included.
Protocol Section
Revised Protocol Text
Rationale for Change
6.2.1 Method of 
Study Treatment 
Assignment at 
Week 24 and 
Subsequent Visits 
Impacted by 
COVID-19-related 
Issues 
New Section Text:
6.2.1 Method of Study Treatment Assignment at Week 24 and 
Subsequent Visits Impacted by COVID-19-related Issues 
At Week 24, when COVID-19-related issues result in the subject 
visit being missed or conducted remotely the study treatment 
assigned by the IRT system will not be determined by the PASI 75 
response, because PASI assessments will not be done.  The study 
treatment assigned by the IRT system will be defaulted to BMS-
986165 6 mg QD for the duration of the study.
For all subsequent visits post Week 24, when COVID-19-related 
issues result in the subject visit being missed or conducted 
remotely, the study treatment assigned by the IRT system will not 
be determined by the PASI relapse response, because PASI 
assessments will not be done. Study treatment assignment will be 
done as per the following:
o
Missed visits: the study treatment assigned by the IRT system 
will be the study treatment assigned at the previous visit  
o
Visits conducted remotely: the study treatment assigned by
the IRT system will be defaulted to BMS-986165 6 mg QD for the 
duration of the study
To address study treatment assignment 
at Week 24 and post Week 24 for 
subjects who have visits missed or 
conducted remotely. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
7
Protocol Section
Revised Protocol Text
Rationale for Change
9.8 Statistical 
Impacts Due to 
COVID-19
9.8.1 Impact on
Efficacy Endpoints
9.8.2  Impact on 
Safety Variables
New Section Text:
9.8  Statistical Impacts Due to COVID-19
9.8.1  Impact on Efficacy Endpoints 
There are no COVID-19-related impacts to the Week 16 efficacy 
endpoints as all subjects remaining in the trial completed the 
Week 16 visit prior to COVID-19 site restrictions. Efficacy 
endpoints involving Week 24 and later visits may be impacted by 
COVID-19 in the form of missing data and/or study treatment 
assignment defaulting to BMS-986165. 
Censoring rules will be applied to the PASI 75 time-to-relapse 
endpoint for re-randomized subjects due to the following
COVID-19-related issues post Week 24:
x
Subject’s study treatment assignment was defaulted to 
BMS-986165 because they had a remote safety 
monitoring visit due to COVID-19 and efficacy 
assessments were not performed. The subject will be 
censored at the time of the remote visit if relapse had 
not been observed already;
x
Subject has missing visit(s) (ie, efficacy assessments 
not performed) after Week 24 and assuming relapse 
was not observed prior to missed visit(s):
o
If the subject returns at a later visit and is 
found to have relapsed, midpoint imputation 
will be used to determine time-to-relapse (ie, 
midpoint of the censoring interval).
o
If the subject returns at a later visit and has not 
relapsed, then the subject will continue to be 
evaluated for relapse.
o
If the subject is discontinued from study 
treatment, then the subject will be censored at 
the time of study treatment discontinuation.
Sensitivity analyses for time-to-relapse may be performed with 
additional details provided in the statistical analysis plan prior to 
database lock.
Data handling due to COVID-19-related issues for other efficacy 
endpoints 
 will be described in the statistical 
analysis plan prior to database lock.
9.8.2  Impact on Safety Variables 
No modifications are planned for the analysis of safety data due to 
COVID-19-related issues. There will not be any additional safety 
data handling considerations for missing data or treatment 
interruptions due to COVID-19.
To specify impact on efficacy endpoints 
and safety variables due to COVID-19. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
8
TABLE OF CONTENTS
TITLE PAGE...................................................................................................................................1
DOCUMENT HISTORY.................................................................................................................2 
SUMMARY OF CHANGES...........................................................................................................6 
TABLE OF CONTENTS.................................................................................................................8 
1.1 
Synopsis......................................................................................................................11 
1.2 
Schema........................................................................................................................17 
1.3 
Schedule of Activities (SOA) .....................................................................................17 
2 
INTRODUCTION ......................................................................................................30 
2.1 
Study Rationale...........................................................................................................30 
2.2 
Background.................................................................................................................31 
3 
OBJECTIVES AND ENDPOINTS............................................................................33 
4 
STUDY DESIGN .......................................................................................................35 
4.1 
Overall Design............................................................................................................35 
4.2 
Number of Subjects ....................................................................................................39 
4.3 
End of Study Definition..............................................................................................39 
4.4 
Scientific Rationale for Study Design ........................................................................40 
5 
STUDY POPULATION.............................................................................................40 
5.1 
Inclusion Criteria ........................................................................................................41 
5.2 
Exclusion Criteria.......................................................................................................42 
5.3 
Lifestyle Restrictions..................................................................................................46 
5.4 
Screen Failures............................................................................................................46 
6 
TREATMENT ............................................................................................................47 
6.1 
Treatments Administered............................................................................................49 
6.2 
Method of Treatment Assignment..............................................................................49 
6.3 
Blinding ......................................................................................................................51 
6.4 
Dosage Modification ..................................................................................................52 
6.5 
Preparation/Handling/Storage/Accountability............................................................52 
6.6 
Treatment Compliance................................................................................................53 
6.7 
Concomitant Therapy .................................................................................................53 
6.8 
Treatment After the End of the Study.........................................................................54 
7 
DISCONTINUATION CRITERIA............................................................................55 
7.1 
Discontinuation from Study Treatment ......................................................................55 
7.2 
Discontinuation from the Study..................................................................................56 
7.3 
Lost to Follow-up .......................................................................................................57 
8 
STUDY ASSESSMENTS AND PROCEDURES......................................................57 
8.1 
Efficacy Assessments .................................................................................................58 
8.2 
Adverse Events ...........................................................................................................62 
8.3 
Overdose.....................................................................................................................65 
8.4 
Safety ..........................................................................................................................65 
8.7 
Health Economics OR Medical Resource Utilization and Health Economics...........72 
9 
STATISTICAL CONSIDERATIONS .......................................................................72 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
9
 
9.2 
Populations for Analyses ............................................................................................73 
9.3 
Endpoints....................................................................................................................73 
9.4 
Efficacy Analyses .......................................................................................................78 
9.5 
Safety Analyses ..........................................................................................................82 
9.6 
Other Analyses............................................................................................................84 
9.7 
Interim Analyses.........................................................................................................85 
9.8 
Statistical Impacts Due to COVID-19 ........................................................................85 
10 
REFERENCES ...........................................................................................................87 
11 
APPENDICES ............................................................................................................91 
APPENDIX 1 
ABBREVIATIONS AND TRADEMARKS .............................................92 
APPENDIX 2 
STUDY GOVERNANCE CONSIDERATIONS......................................96 
APPENDIX 3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING .............................104 
APPENDIX 4 
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS 
AND METHODS OF CONTRACEPTION............................................108 
APPENDIX 5 
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF 
PSORIASIS (sPGA) ................................................................................112 
APPENDIX 6 
PSORIASIS AREA AND SEVERITY INDEX (PASI)..........................113 
APPENDIX 7 
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA) ..................................................................................................114 
APPENDIX 9 
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS  
(PGA-F) ...................................................................................................116 
APPENDIX 11 
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA).......................................................................119 
APPENDIX 13 
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD) .....................121 
APPENDIX 14 
DERMATOLOGY LIFE QUALITY INDEX (DLQI)............................122 
 
 
 
 
 
APPENDIX 20 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE....................................................................134 
APPENDIX 21 
EIGHT ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8)........135 
APPENDIX 22 
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS.........................................................................................136 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
10
LIST OF TABLES
Table 1: 
Screening Procedural Outline (IM011047)................................................18 
Table 2: 
On Treatment Procedural Outline (IM011047): Week 0 through 
Week 20 .....................................................................................................21 
Table 3: 
On Treatment Procedural Outline (IM011047): Week 24 Through 
Week 52 .....................................................................................................25 
Table 4: 
Objectives and Endpoints ..........................................................................33 
Table 5: 
Study Treatments for IM011047................................................................48 
Table 6: 
Selection and Timing of Dose....................................................................49 
LIST OF FIGURES
Figure 1: 
Study Design Schematic ............................................................................38 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
11
1
PROTOCOL SUMMARY
1.1
Synopsis
Protocol Title:
A Multi-Center, Randomized, Double-Blind, Placebo-
and Active 
Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate 
the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Short Title: Efficacy, Safety, and Durability of Response of BMS-986165 versus Placebo and 
Active Comparator in Subjects with Psoriasis
Study Phase: 3
Rationale:
BMS-986165 could be a therapeutic option for the treatment of subjects with moderate-to-severe 
plaque psoriasis based on results of a recently completed 12-week randomized Phase 2, 
placebo-controlled, parallel-group study (Study IM011011) with 5 different BMS-986165 
treatment arms: 3 mg every other day (QOD); 3 mg once daily (QD); 3 mg twice daily (BID); 
6 mg BID and 12 mg QD. Overall, 267 subjects were randomized (44 to 45 subjects per treatment 
arm) in the Phase 2 study. All BMS-986165 treatment groups, except 3 mg QOD, achieved the 
primary endpoint of superiority compared with placebo in the proportion of subjects experiencing 
at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) after 12 weeks of 
treatment. Compared with the placebo treatment group (6.7%), 38.6% (P = 0.0003), 68.9% 
(P < 0.0001), 66.7% (P < 0.0001), and 75% (P < 0.0001) of the subjects treated with BMS-986165 
at 3 mg QD, 3 mg BID, 6 mg BID, and 12 mg QD doses achieved a PASI 75 response, respectively. 
The PASI 75 responses plateaued at a dose of 3 mg BID. The current Phase 3 study is designed to 
confirm the efficacy and safety of BMS-986165 6 mg QD, which is expected to have equivalent 
efficacy as the 3 mg BID dose in Phase 2, in a larger global population of subjects with stable 
moderate-to-severe plaque psoriasis and will assess the durability of a PASI 75 response after 
treatment withdrawal. 
Study Population:
Men and women ≥18 years of age diagnosed with stable (defined as no morphology changes or 
significant flares of disease activity in the opinion of the investigator) moderate-to-severe plaque 
psoriasis for ≥ 6 months and with ≥10% of body surface area (BSA) involvement, who have a 
static Physician’s Global Assessment (sPGA) ≥3, a PASI score ≥12, and who are candidates for 
phototherapy or systemic therapy may be eligible to participate in the study.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
12
Objectives and Endpoints:
Objective
Endpoint
Primary
x
Assess whether BMS-986165 is superior 
to placebo at Week 16 in the treatment of 
subjects with moderate-to-severe plaque 
psoriasis
x
sPGA 0/1
x
PASI 75
Selected Secondary Endpoints
x
Assess whether BMS-986165 is superior 
to apremilast at Week 16
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Assess whether BMS-986165 is superior 
to apremilast at Week 24
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
Assess whether BMS-986165 is superior 
to placebo over the first 16 weeks of 
treatment
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Evaluate 
improvement 
in 
patient-reported 
outcomes 
for 
BMS-986165 compared with placebo 
through Week 16
x
Evaluate 
improvement 
in 
patient-reported outcomes for BMS-
986165 
compared 
with 
apremilast 
through Week 24
x
Change from baseline in Psoriasis 
Symptoms and Signs Diary (PSSD) 
symptom score, sign score, and total 
score
x
Change from baseline in Dermatology 
Life Quality Index (DLQI) score
x
Evaluate maintenance and durability of 
efficacy of BMS-986165 during the 
randomized withdrawal period through 
Week 52 among Week 24 PASI 75
responders continuing on treatment 
compared with those re-randomized to 
placebo
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
13
Objective
Endpoint
x
Time to relapse until Week 52
Overall Design:
This will be a 52-week, multi-center, randomized double-blind, double-dummy, placebo- and 
active comparator-controlled study in subjects with stable moderate-to-severe plaque psoriasis. 
Subjects will undergo screening evaluations within 28 days prior to administration of study 
medication to determine eligibility.
Active Comparator-Controlled Period
Following the screening process, qualified subjects will be randomized in a 2:1:1 ratio to one of 
the following 3 treatment groups:
x
BMS-986165 6 mg QD
x
Placebo
x
Apremilast 30 mg BID (with initial titration per label)
Randomization should not occur until at least 8 days after the screening visit to allow collection 
of PSSD data during screening in order to calculate a baseline PSSD score. Randomization will be 
stratified by geographic region (US/rest of the world), previous biologic use for psoriasis, psoriatic 
arthritis or other inflammatory disease (yes/no), and body weight (≥90 kg and <90 kg). As this is 
designed to be a global study across multiple countries, randomization in each country will be 
targeted to approximately 35% or less of the total sample size. This change is being implemented 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
14
to achieve geographical representation across countries and to minimize the potential for any single 
country to have a disproportionate impact on the overall efficacy and/or safety profile.
x
At Week 16, subjects receiving placebo will be switched in a blinded manner to 
BMS-986165 6 mg QD.
Subjects in the other treatment groups will continue their current regimen through Week 24.
Randomized Withdrawal and Maintenance Period
At Week 24, subjects originally randomized to BMS-986165 6 mg QD who do not achieve 
PASI 75 response will continue to receive BMS-986165 6 mg QD in a blinded manner. Subjects 
who achieve PASI 75 response will enter the randomized withdrawal and maintenance period. 
These subjects will be re-randomized in a blinded manner to one of the following 2 treatment 
groups in a 1:1 ratio:
x
BMS-986165 6 mg QD
x
Placebo
If the subjects re-randomized to placebo experience a relapse as defined below at any visit during 
this period, they will be treated with BMS-986165 6 mg QD until the end of the maintenance 
period (Week 52).
At Week 24, subjects receiving apremilast who achieve PASI 75 response will be switched in a 
blinded manner to placebo. If a subject experiences a relapse at any visit during this period, the 
subject will be treated with BMS-986165 6 mg QD until the end of the maintenance period 
(Week 52). Subjects who do not achieve PASI 75 response at Week 24 will be switched to BMS-
986165 6 mg QD.
During the randomized withdrawal period, relapse will be defined as at least a 50% loss of 
Week 24 PASI percent improvement from baseline.
Please refer to Section 6.2.1 for information regarding the method of study treatment assignment 
when COVID-19-related issues result in the at Week 24 and/or post Week 24 visits being missed 
or conducted remotely. 
Any subject with sPGA ≥ 3 at Week 24 may be treated with restricted topical medications, such 
as topical high potency corticosteroids (WHO Classes I-V), only at this time point at the discretion 
of the investigator.
Number of Subjects: 
Approximately 1000 qualified subjects will be randomized in a 2:1:1 ratio to BMS-986165 
6 mg QD, apremilast 30 mg BID, and placebo, respectively. This sample size will provide 
adequate power (≥90%) to compare BMS-986165 6 mg QD with placebo for each of the coprimary 
efficacy endpoints (sPGA 0/1 and PASI 75 at Week 16) and BMS-986165 6 mg QD compared
with apremilast for sPGA 0/1 and PASI 75 (Week 16).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
15
Treatment Arms and Duration:
Study treatment: Subjects in all treatment groups will take oral doses of the investigational 
product (IP) for 52 weeks during treatment as follows: BMS-986165 6 mg QD, apremilast 30 mg
BID (titrated as per label), or placebo QD.
Study Treatment for IM011047
Medication 
Potency 
IP/Non-IP
BMS-986165 tablet
6 mg
IP
apremilast tablet
10 mg*
IP
apremilast tablet
20 mg†
IP
apremilast tablet
30 mg‡
IP
placebo tablet
n/a
IP
IP = investigational produce; n/a = non-applicable
*Used for titration Day 1 through Day 3 morning dose
†Used for titration Day 3 evening dose through Day 5 morning dose.
‡From Day 5 evening dose onwards
Statistical Methods:
General Methodology
The primary efficacy analysis population will be the Full Analysis Set (FAS). The FAS will 
include all randomized subjects who are dispensed study drug. 
The analysis model for the coprimary efficacy endpoints and secondary binary endpoints will use 
stratified Cochran-Mantel-Haenszel (CMH) tests stratified by geographic region (US and rest of 
world), prior biologic treatment use for psoriasis, psoriatic arthritis or other inflammatory disease
(yes/no), and body weight (≥90 kg and <90 kg) to compare the response rates of BMS-986165
6 mg QD to placebo. If expected cell counts are not sufficient for each strata level, then strata 
levels will be combined for the analysis. Non-responder imputation will be used for binary 
endpoints for subjects who discontinue study or treatment of study prior to Week 16, start a 
protocol prohibited medication/therapy that could improve psoriasis during the first 16 weeks of 
treatment, or who have otherwise missing endpoint data at the specified timepoint.
The analysis model for continuous secondary endpoints will use analysis of covariance 
(ANCOVA) with treatment, geographic region (US and rest of world), prior biologic treatment 
use for psoriasis, psoriatic arthritis or other inflammatory disease (yes/no), and body weight 
(≥90 kg and <90 kg) as fixed effects. The baseline value will be added into the model as a 
covariate. Treatment differences based on least-squares (LS) means and the corresponding 2-sided
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
16
95% confidence intervals will be provided for the difference between BMS-986165 6 mg QD and 
placebo or active comparator depending on the endpoint being assessed.
For continuous secondary efficacy endpoints, baseline observation carried forward (BOCF) will 
be used for subjects who discontinue study treatment due to:
x
Lack of efficacy
x
Adverse events
Additionally, BOCF will be used for subjects who start a protocol prohibited medication/therapy 
that could improve psoriasis. LOCF will be used for all other missing data.
The Kaplan-Meier product limit method will be used to estimate the distribution curves for 
time-to-relapse during the randomized withdrawal period. Treatment comparisons of subjects re-
randomized during the Maintenance Period for BMS-986165 6 mg QD and placebo will be 
performed using the log-rank test stratified by geographic region (US and rest of world), prior 
biologic treatment use for psoriasis, psoriatic arthritis or other inflammatory disease, and body 
weight (≥90 kg and <90 kg). 
Testing Strategy for Efficacy Endpoints
The primary family of coprimary endpoints will each be tested at a Type I error =0.05 first and, if 
significant for both endpoints, testing will proceed for the secondary family of key secondary 
endpoints
. The primary family of coprimary endpoints will be the serial gatekeeper for 
proceeding with testing of the secondary family of key secondary efficacy endpoints.
Primary Family – Coprimary endpoints compared with placebo; both must be significant at a Type 
I error=0.05 in order to proceed with the secondary family tests for the key secondary endpoints: 
x
Primary 1: Proportion of subjects who achieve sPGA 0/1 at Week 16
x
Primary 2: Proportion of subjects who achieve PASI 75 at Week 16
In order to control for Type I error rate inflation within the secondary family of key secondary 
endpoints, separate testing branches with a 2-sided Type I error=0.025 will be used for 
comparisons of BMS-986165 6 mg QD compared to placebo and BMS-986165 6 mg QD 
compared to apremilast. A hierarchical testing method within each testing branch will be 
implemented for the key secondary endpoints. The hierarchical test may only proceed to the next 
key secondary endpoint within each testing branch if the null hypothesis is rejected at a Type I 
error=0.025. If an endpoint fails at any step, then all subsequent comparisons will be considered 
descriptive.
Please refer to Section 9.8.1 for the impact on efficacy endpoints due to COVID-19.
Safety Analysis
Safety data will be summarized using descriptive statistics (n, mean, standard deviation, median, 
minimum, and maximum) for continuous variables and frequency distributions (counts and 
percentages) for categorical variables.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved      BMS Confidential
17
Please refer to Section 9.8.2 for the impact on safety variables due to COVID-19.
1.2
Schema
*Upon relapse (at least a 50% loss of Week 24 PASI percent improvement from baseline), subjects will be switched 
to BMS-986165 6 mg QD.
†Apremilast is titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing.
Abbreviations: BID = twice daily; PASI = Psoriasis Area and Severity Index; QD = once daily; R = randomize
The coprimary endpoints will be evaluated at Week 16. The duration of the study for each 
subject will be up to 52 weeks on treatment, and 4 additional weeks for safety follow-up.
1.3
Schedule of Activities (SOA)
The schedules of assessments and procedures are documented in Table 1 for screening, Table 2
for the active comparator-controlled period (through Week 20), and Table 3 for the Randomized 
Withdrawal and Maintenance Period (Week 24 and after).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
18
Table 1:
Screening Procedural Outline (IM011047)
Procedure
Screening
V1
Notes
Eligibility Assessments
Informed Consent
X
A subject is considered enrolled only when a protocol specific informed consent is 
signed
Enroll Subject
X
Obtain number from IRT
Inclusion/Exclusion Criteria
X
Includes duration of plaque psoriasis and documentation of presence of plaque psoriasis 
by the investigator
Medical History
X
See Section 5.2 for complete eligibility criteria associated with medical history. Of note, 
subjects need to be screened for any current uncontrolled neuropsychiatric illness or 
history of suicidality; any history of TB; any congenital or acquired immunodeficiency; 
any significant drug allergy such as anaphylaxis; any cancer currently or in the previous 
5 years. Investigators are encouraged to check whether subjects have had preventive 
health measures such as cancer screening (e.g. Pap smear, colonoscopy, mammograms) 
that is up to date according to local guidelines.
History of Tobacco Use
X
Include description of current tobacco use.
Psoriasis-related History
X
Includes scalp symptoms, PsA/joint pain, nail involvement, palmoplantar involvement, 
genital involvement, history of other forms of psoriasis
Psoriasis-related Systemic Treatment
X
History of: conventional systemic (eg, methotrexate), biologic, and/or phototherapy. For 
each therapy, include length of time on treatment and reason(s) for discontinuation (eg, 
lack of efficacy, intolerance, side effects, loss of access to treatment) if applicable.
Other Prior and Concomitant Treatments
X
This includes topical treatments for psoriasis and all medications for other conditions 
such as cardiovascular and mood disorders. 
Safety Assessments
Physical Examination 
X
Complete PE
Physical Measurements
X
Includes height and weight
Vital Signs
X
Includes (ear or oral) body temperature, respiratory rate, seated blood pressure, and heart 
rate. Blood pressure and heart rate should be measured after the subject has been resting 
quietly for at least 5 minutes.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
19
Table 1:
Screening Procedural Outline (IM011047)
Procedure
Screening
V1
Notes
Electrocardiogram 
X
ECGs should be recorded after the subject has been supine for at least 5 minutes
Chest Imaging (eg, Chest x-ray)
X
Chest imaging is required if not performed within 6 months of Screening Visit, copy of 
radiology report must be on file and reviewed by the investigator. Section 8.4.4
Neuropsychiatric Illness Assessment
X
Based on subject/family response, medical history/medical records, investigator 
judgment
PHQ-8
X
For establishing baseline depression severity.
Suicidal Ideation and Behavior Assessment
X
Based on subject/family response, medical history/medical records, investigator 
judgment
eC-SSRS
X
eC-SSRS Assessment: Response of “Actual Suicide Attempt-Lifetime” or suicidal 
ideation (Severity of 4 or 5) or suicidal behavior will be exclusionary. Rescreening will 
not be allowed. Section 8.4.7
Monitor for Serious Adverse Events 
X
All SAEs must be collected from the date of subject’s written consent until 30 days post 
discontinuation of dosing or subject’s participation in the study.
Laboratory Tests
Section 8.4.5
Hematology
X
Complete Blood Count (CBC) with differential
Chemistry Panel
X
Lipid Panel
X
Urinalysis
X
Hemoglobin A1C
X
TSH
X
If TSH above normal reference range, test free T4; if TSH below normal range, test free 
T4 & T3
hs-CRP
X
Serology
X
Includes HCV antibody, HBsAg, HBsAb, HBcAb, HBV DNA, and HIV antibodies.
Tuberculosis Test
X
In accordance with QuantiFERON-TB Gold; details are described in Section 5.2
Criterion 3)d.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
20
Table 1:
Screening Procedural Outline (IM011047)
Procedure
Screening
V1
Notes
Pregnancy Test (serum)
X
For WOCBP only
FSH 
X
To confirm menopausal status (see APPENDIX 4)
Clinical Efficacy/Health Outcomes
sPGA
X
PASI
X
BSA
X
PASE Questionnaire
X
For subjects with peripheral joint complaints to screen for presence of psoriatic arthritis
PSSD
X
All consented subjects will be given a diary device at the Screening Visit and will begin 
recording psoriasis signs and symptoms on a daily basis in the diary device. Subjects 
who are not randomized will stop recording and return their diary device to the site. 
Subjects who are randomized will continue recording their psoriasis signs and symptoms 
on a daily basis in the diary device through Week 52.
BSA = body surface area; DNA = deoxyribonucleic acid; ECG = electrocardiogram; eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; FSH = follicle-stimulating 
hormone; HBV = hepatitis B virus; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus;  
HIV = human immunodeficiency virus; hs-CRP = High-sensitivity C-reactive protein; IRT = Interactive Response Technology; PASE = psoriatic arthritis screening and 
evaluation; PASI = Psoriasis Area and Severity Index; PE = physical examination; PHQ-8 = Eight-item Patient Health Questionnaire; PsA =  psoriatic arthritis; PSSD = Psoriasis 
Symptoms and Signs Diary; SAE = serious adverse event; sPGA = static Physician Global Assessment; T3 = triiodothyronine; T4 = thyroxine; TB = tuberculosis; TSH = thyroid-
stimulating hormone; V = Visit; WOCBP = women of childbearing potential
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
21
Table 2:
On Treatment Procedural Outline (IM011047): Week 0 through Week 20
Procedure
Week 0
Baseline / D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
Clinical Efficacy/Health 
Outcomes
DLQI
X
X
X
X
X
X
X
X
sPGA
X
X
X
X
X
X
X
X
PASI
X
X
X
X
X
X
X
X
ss-PGA*
X
X
X
X
X
X
PGA-F†
X
X
X
X
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
22
Table 2:
On Treatment Procedural Outline (IM011047): Week 0 through Week 20
Procedure
Week 0
Baseline / D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
Palmoplantar PGA‡
X
X
X
X
X
X
X
PSSD
Safety Assessments
Complete PE
X
X
Targeted PE
X
X
X
X
X
X
See Section 8.4.1
Body Weight
X
X
X
Vital Signs
X
X
X
X
X
X
X
X
Electrocardiogram 
X
X
PHQ-8
X
X
X
See Section 8.4.6.1
eC-SSRS Assessment
X
X
X
Suicidal Ideation and 
Behavior since last 
visit
Adverse Event Assessment
X
X
X
X
X
X
X
X
Concomitant Medication Use
X
X
X
X
X
X
X
X
Laboratory Tests
Hematology 
X
X
X
X
X
X
X
X
Lymphocyte Subsets (TBNK)
X
X
X
Chemistry Panel
X
X
X
X
X
X
X
X
If CK >2.5 × ULN, 
reflex testing is 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
23
Table 2:
On Treatment Procedural Outline (IM011047): Week 0 through Week 20
Procedure
Week 0
Baseline / D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
required (see Section 
8.4.5)
Hemoglobin A1C
X
X
hs-CRP
X
X
X
X
X
X
Fasting Lipid Panel
X
X
X
Fasting Plasma Glucose
X
X
X
Urinalysis
X
X
Serum Immunoglobulin Levels 
(IgM, IgG, IgA, IgE)
X
X
X
Pregnancy Test (Urine)
X
X
X
X
X
X
WOCBP only
Study Treatment
Randomize
X
Dispense Study Treatment
X
X
X
X
X
X
X
Study Treatment Compliance
X
X
X
X
X
X
X
See Section 6.6
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
24
Table 2:
On Treatment Procedural Outline (IM011047): Week 0 through Week 20
Procedure
Week 0
Baseline / D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
 eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; CK = creatine kinase; 
 D = Day; d = days; DLQI = Dermatology Life Quality 
Index; 
 ECG – electrocardiogram; 
 hs-
CRP = High-sensitivity C-reactive protein; 
 PASI = Psoriasis Area and Severity Index; PE = physical examination; PGA-F = Physician 
Global Assessment-Fingernails; 
 PSSD = Psoriasis Symptoms and Signs Diary; 
 sPGA = static 
Physician Global Assessment; 
 TBNK = T cells, B cells, and natural killer cells; ULN = upper limit of normal; 
 
 V = Visit; Wk = Week; WOCBP = women of childbearing potential
*In subjects with scalp psoriasis at baseline; †In subjects with nail psoriasis at baseline; ‡In subjects with palmoplantar psoriasis at baseline; §If sample is missed, it may 
be taken at any visit once informed consent is obtained.
When multiple assessments are conducted at a single visit, the following is the recommended order in which they should be done:
1)
Health outcomes assessments
2)
Safety assessments (eg, vitals, AEs)
3)
Clinical efficacy assessments
4)
Laboratory tests (eg, safety laboratory tests, 
)
On fasting days, safety assessments can be done first followed by blood draws, and then health outcomes and finally efficacy assessments.
The dose of the drug on a visit day is to be taken after blood draws.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
25
Table 3:
On Treatment Procedural Outline (IM011047): Week 24 Through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52#
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Up*
(Week 56)
D393
(±3 d)
V18
Notes
Clinical Efficacy/Health 
Outcomes
DLQI
sPGA
PASI
X
X
X
X
X
X
X
X
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
26
Table 3:
On Treatment Procedural Outline (IM011047): Week 24 Through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52#
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Up*
(Week 56)
D393
(±3 d)
V18
Notes
PSSD
Safety Assessments
Full Physical Examination
X
X
X
Targeted Physical 
Examination
X
X
X
X
X
X
Body Weight
X
X
X
X
Vital Signs
X
X
X
X
X
X
X
X
X
Electrocardiogram
X
X
PHQ-8
X
X
X
See Section 8.4.6.1
eC-SSRS
X
X
X
Suicidal Ideation and 
Behavior since last visit
Adverse Event Assessment
X
X
X
X
X
X
X
X
X
Concomitant Medication 
Use
X
X
X
X
X
X
X
X
X
Laboratory Tests
Hematology 
X
X
X
X
X
X
X
X
X
Lymphocyte Subsets 
(TBNK)
X
X
Chemistry Panel
X
X
X
X
X
X
X
X
X
If CK > 2.5 x ULN, 
reflex testing is required 
(see Section 8.4.5)
Fasting Lipid Panel
X
X
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
27
Table 3:
On Treatment Procedural Outline (IM011047): Week 24 Through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52#
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Up*
(Week 56)
D393
(±3 d)
V18
Notes
Fasting Plasma Glucose
X
X
hs-CRP
X
X
X
Hemoglobin A1C
X
X
Urinalysis
X
X
X
Serum Immunoglobulin 
Levels (IgM, IgG, IgA, IgE)
X
X
Pregnancy Test (Urine)
X
X
X
X
X
X
X
X
X
WOCBP only
Study Treatment
Blinded PASI Response 
Transferred Electronically 
to IRT
X
X
X
X
X
X
X
X
To determine PASI 75
response at Week 24 and 
to monitor for relapse and 
rebound afterwards
Dispense Study Treatment
X
X
X
X
X
X
X
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09 Final Approved
BMS Confidential
28
Table 3:
On Treatment Procedural Outline (IM011047): Week 24 Through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52#
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Up*
(Week 56)
D393
(±3 d)
V18
Notes
Study Treatment 
Compliance
X
X
X
X
X
X
X
X
 CK = creatine kinase; 
 D = Day; d = days; DC = discontinuation; 
 eC-SSRS = electronic Columbia-
Suicide Severity Rating Scale; 
 hs-CRP = high-sensitivity C-reactive 
protein; Ig = immunoglobulin; IRT = interactive response technology; 
 PASI = Psoriasis Area and Severity Index; 
 
 PHQ-8 = Eight-item Patient Health Questionnaire; 
 
 sPGA = static Physician Global Assessment; 
 TBNK = T cells, B cells, and natural killer cells; ULN = upper 
limit of normal; V = Visit; 
 WOCBP = women of childbearing potential
*For subjects who do not continue in a long-term extension study: 
 
#For subjects who discontinue study treatment prior to Week 52, please refer to Section 7.1 for more details.
When multiple assessments are conducted at a single visit, the following is the recommended order in which they should be done:
1)
Health outcomes assessments
2)
Safety assessments (eg, vitals, AEs)
3)
Clinical efficacy assessments
4)
Laboratory tests (eg, safety laboratory tests, 
)
On fasting days, safety assessments can be done first followed by blood draws, and then health outcomes and finally efficacy assessments.
The dose of the drug on a visit day is to be taken after blood draws.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
29
STUDY ACKNOWLEDGMENT/DISCLOSURE
I understand that this protocol contains information that is confidential and proprietary to Bristol-Myers Squibb 
Company (BMS). Any supplemental information that may be added to this document is also confidential and 
proprietary to BMS and must be kept in confidence in the same manner as the contents of this protocol.
I have read the original protocol/revised protocol and agree that it contains all necessary details for carrying out the 
study as described. I will conduct this protocol as outlined therein and will make a reasonable effort to complete the 
study within the time designated.
I will provide copies of the protocol and access to all information furnished by BMS to study personnel under my 
supervision. I will discuss this material with them to ensure that they are fully informed about the investigational 
product and the study.  
I will provide protocol information to my Institutional Review Board(s) [IRB(s)] or Independent Ethics Committee(s) 
[IEC(s]. I understand that original protocol/revised protocols must be reviewed by the Institutional Review Board or 
Independent Ethics Committee overseeing the conduct of the study and approved or given favorable opinion by all 
necessary Health Authorities before implementation unless to eliminate an immediate hazard to subjects.
I agree that the contents of the protocol may not be disclosed to any other person or entity or used for any other purpose 
without the prior written consent of BMS. The foregoing shall not apply to disclosure required by governmental 
regulations or laws; however, I will give prompt notice to BMS of any such disclosure.
I agree that the study data derived from this protocol may only be used and disclosed in furtherance of the protocol, 
for the medical treatment of a study subject or for publication of study results in accordance with the terms of the 
clinical trial agreement or as otherwise permitted by the terms of the clinical trial agreement.
I agree not to collect or use samples (eg, tissue, blood, serum, urine) or collect data (other than for diagnostic or 
treatment purposes) from the study subjects while enrolled in the study, except as expressly permitted by the protocol 
or the terms of the clinical trial agreement.
I understand that I may terminate or suspend enrollment of the study at any time if it becomes necessary to protect the 
best interests of the study subjects. Unless otherwise provided in the clinical trial agreement, the study may be 
terminated at any time by BMS, with or without cause.
Original Protocol  
Revised Protocol  6
Protocol Number:  IM011047
Site Number: 
Date of Protocol or Revised Protocol:  21 May 2020
IND Number:  131,993
EUDRACT Number:  2018-001925-24
Investigator 
Date
(signature)
__________________________________________________  
(printed name*)
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
30
2
INTRODUCTION
Psoriasis is a chronic inflammatory skin disorder, characterized primarily by erythematous scaly 
plaques, that affects up to 3% of the general population. Men and women are equally affected and 
it can present at any age.1,2 Several studies have observed a bimodal distribution of psoriasis onset 
with the first peak ranging from 15 to 22 years of age, and the second peak ranging from 55 to 
60 years of age.3, 4, 5 The most common form of psoriasis (58% to 97% of cases) is plaque psoriasis 
(psoriasis vulgaris), with less common forms being guttate, pustular, inverse (flexural), and 
erythrodermic psoriasis. The disease can have a fluctuating relapsing course, with flares that may 
be induced by factors such as infections, trauma, smoking, and stress.3 Psoriasis can involve skin 
in any part of the body; particularly disabling is the involvement of specific anatomic regions, such 
as hands and feet (palmoplantar), face, scalp, and nails. Disease severity can be classified by body 
surface area (BSA) involvement with mild defined as ≤10% BSA, and moderate-to-severe as
> 10% BSA.6 Psoriasis has a profound impact on quality of life and can lead to psychological, 
social, and economic consequences, especially in moderate-to-severe disease. This condition is 
also associated with an increased risk of depression, occurrence of sleep disturbances, social 
stigma, and decreased work productivity.7,8 Commonly associated comorbidities found in 
psoriasis patients include diabetes mellitus and metabolic syndrome. In patients with more severe 
forms of the disease, life expectancy is decreased due to an increase of cardiovascular risk.9
Treatments include topical preparations, eg, corticosteroids, vitamin D analogues, calcineurin 
inhibitors, and salicylic acid; phototherapy modalities, including psoralens with ultraviolet A 
(PUVA) and narrow band ultraviolet B (UVB); and systemic therapies. In moderate-to-severe 
disease, systemic treatments are usually needed and may include oral agents (retinoids, 
methotrexate, cyclosporine, and apremilast) or injectables (eg, biologics such as tumor necrosis 
factor (TNF) inhibitors etanercept, infliximab, and adalimumab) anti-IL-12/23p40 antibody 
(ustekinumab), IL-17 antagonists (secukinumab, ixekizumab, brodalumab), and anti-IL-23p19
antibody (guselkumab). Many of these treatments are associated with increased risk of adverse 
events (AEs) such as hepatotoxicity and neutropenia (methotrexate);10
nephrotoxicity 
(cyclosporine);11 depression and weight loss (apremilast);12 serious infections (cytokine 
inhibitors);13,14,15,16 and candidiasis and Crohn’s disease (IL-17 antagonists).16, 17, 18
Although effective therapeutic options are available, under-treatment or non-treatment of psoriasis 
has been reported in up to half of surveyed patients (based on absence of treatment and/or 
dissatisfaction with treatment).19 Many patients with severe disease are still being managed with 
only topicals,4,8 and many patients consider their psoriasis treatment to be inadequate. 
Accordingly, there remains a need for more effective oral options, when compared with currently 
available agents, that would improve efficacy responses and increase adherence to treatment.
2.1
Study Rationale
BMS-986165 could be a therapeutic option for the treatment of subjects with moderate-to-severe 
plaque psoriasis based on results of a recently completed 12-week randomized Phase 2, 
placebo-controlled, parallel-group study with 5 different BMS-986165 treatment arms: 3 mg every 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
31
other day (QOD); 3 mg once daily (QD); 3 mg twice daily (BID); 6 mg BID; and 12 mg QD 
(Study IM011011). Overall, 267 subjects were randomized (44 to 45 subjects per treatment arm) 
in the Phase 2 study. All BMS-986165 treatment groups, except 3 mg QOD, achieved the primary 
endpoint of superiority compared with placebo in the proportion of subjects achieving at least a 
75% improvement in the Psoriasis Area and Severity Index (PASI 75) after 12 weeks of treatment. 
Compared with placebo treatment group, in which 6.7% of the subjects achieved PASI 75 
response, 38.6% (P = 0.0003), 68.9% (P < 0.0001), 66.7% (P < 0.0001), and 75% (P < 0.0001) of 
subjects treated with 3 mg QD, 3 mg BID, 6 mg BID, and 12 mg QD achieved PASI 75, 
respectively. The PASI 75 responses plateaued at a dose of 3 mg BID. Also, there was a clinically 
significant proportion of subjects treated with BMS-986165 achieving an sPGA score of 0 or 1 
compared with placebo at Week 12. Compared with the placebo treatment group in which 6.7% 
of the subjects achieved an sPGA score of 0 or 1, 41.5%, 75.6%, 65.9%, and 75% of the subjects 
treated with 3 mg QD, 3 mg BID, 6 mg BID, and 12 mg QD achieved an sPGA score of 0 or 1, 
respectively with responses again plateauing at dose of 3 mg BID. The Phase 3 dose selected 
(6 mg QD) is expected to demonstrate equivalent efficacy to the 3 mg BID dose. Please refer to 
This Phase 3 study is designed to confirm the efficacy and safety of BMS-986165 6 mg QD and 
demonstrate its superiority to a widely used oral agent, apremilast, in a larger global population of 
subjects with moderate-to-severe plaque psoriasis. 
2.2
Background
Tyrosine kinase 2 (TYK2) is a nonreceptor tyrosine kinase associated with receptors for the 
p40-containing cytokines interleukin (IL)-12 and IL 23, as well as the Type I interferon (IFN) 
receptor, and is required for the activation of their downstream signaling pathways. TYK2 
catalyzes the phosphorylation of the intracellular receptor domains and signal transducer and 
activator of transcription (STAT) proteins resulting in the activation of STAT-dependent 
transcription and functional responses specific for these cytokines.20,21,22 Because TYK2-
dependent cytokines (eg, Type I IFNs, IL-12, IL-23) are distinct from those dependent on closely 
related Janus kinase (JAK) family members JAK1/JAK3 (eg, IL-2, IL-15, IL-7) or JAK2 (eg, 
erythropoietin, thrombopoietin, granulocyte macrophage colony-stimulating factor, a TYK2 
inhibitor would be expected to have a highly differentiated profile from inhibitors of other JAK 
family kinases. TYK2 dependent pathways and the cytokine networks they modulate (eg, IL-
23/IL-17, IFNα) have been implicated in the pathophysiology of multiple immune-mediated 
diseases, including psoriasis, lupus, spondyloarthritides, and Crohn’s disease.
BMS-986165 is a potent, highly selective, oral small molecule inhibitor of TYK2. A 
comprehensive in vitro and in vivo characterization of BMS-986165 has been established and 
supports the development of this compound in humans. Inhibition of TYK2 is expected to provide 
therapeutic benefit for subjects with psoriasis for multiple reasons: 1) Many of the pathways in the 
TYK2 signaling cascade (IL-23 and the downstream mediators IL-17, IL-22, and IFNα) have been 
implicated in pathogenesis of psoriasis.7 2) Biologic agents targeting the IL-17, IL-23p19, and 
IL-12/23 p40 pathways have been approved for and are highly efficacious in the treatment of 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
32
psoriasis.
 
 
 
2.2.1
Early Clinical Development
The clinical data available to date supporting the safety, pharmacokinetics (PK), and 
pharmacodynamics (PD) of BMS-986165 are from 5 completed Phase 1 studies in healthy subjects 
(IM011002, IM011015, IM011016, IM011031, and IM011039) and 1 completed Phase 2 study in 
adult subjects with moderate-to-severe plaque psoriasis (IM011011).
Overall, BMS-986165 has been generally well-tolerated across all studies, and no safety issues 
have been identified to limit the investigation of the dose of BMS-986165 up to 12 mg QD in 
further clinical studies. A detailed description of the chemistry, pharmacology, efficacy, and safety 
of BMS-986165 is provided in the Investigator Brochure (IB).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
33
3
OBJECTIVES AND ENDPOINTS
Table 4:
Objectives and Endpoints
Objective
Endpoint
Primary
x
Assess whether BMS-986165 is superior to placebo at 
Week 16 in the treatment of subjects with moderate-to-
severe plaque psoriasis
x
static Physician Global Assessment (sPGA) 
0/1 response
x
Psoriasis Area and Severity Index (PASI) 75 
response (defined as a 75% improvement in 
PASI score from baseline)
Key Secondary 
x
Assess whether BMS-986165 is superior to apremilast at 
Week 16
x
sPGA 0/1 response
x
PASI 75 response
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
x
Assess whether BMS-986165 is superior to apremilast at 
Week 24
x
sPGA 0/1 response
x
PASI 75 response
x
PASI 90 response
x
Assess whether BMS-986165 is superior to placebo over 
the first 16 weeks of treatment
x
sPGA 0/1 response
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
34
Table 4:
Objectives and Endpoints
Objective
Endpoint
x
Assess whether BMS-986165 is superior to placebo in 
scalp psoriasis through Week 16 among subjects with a 
baseline scalp severity Physician’s Global Assessment 
(ss-PGA) score ≥3
x
ss-PGA 0/1 response 
x
Assess whether BMS-986165 is superior to apremilast in 
scalp psoriasis through Week 16 among subjects with a  
baseline ss-PGA score ≥3
x
ss-PGA 0/1 response
x
Assess whether BMS-986165 is superior to placebo in 
nail psoriasis through Week 16 among subjects with a 
baseline Physician’s Global Assessment of Fingernail 
psoriasis (PGA-F) score ≥3
x
PGA-F 0/1 
x
Assess whether BMS-986165 is superior to placebo in 
palmoplantar psoriasis through Week 16 among subjects 
with a baseline palmoplantar Physician’s Global 
Assessment (pp-PGA)  score ≥3
x
pp-PGA 0/1 response
x
Evaluate improvement in patient-reported outcomes for 
BMS-986165 compared with placebo through Week 16
x
Evaluate improvement in patient-reported outcomes for 
BMS-986165 compared with apremilast through 
Week 24
x
PSSD symptom score of 0 (among subjects 
with a baseline PSSD symptom score ≥ 1)
x
DLQI 0/1 (among subjects with a baseline 
DLQI score ≥ 2)
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
35
Table 4:
Objectives and Endpoints
Objective
Endpoint
x
Evaluate maintenance and durability of efficacy of 
BMS-986165 during the randomized withdrawal period 
through Week 52 among Week 24 PASI 75 responders 
continuing on treatment compared with those 
re-randomized to placebo
x
Time to relapse until Week 52
4
STUDY DESIGN
4.1
Overall Design
This will be a 52-week, multi-center, randomized double-blind, double-dummy, placebo- and 
active comparator-controlled study to evaluate the safety and efficacy of BMS-986165 vs placebo
and apremilast. The maintenance and durability of BMS-986165 efficacy will also be evaluated. 
A total of 1000 qualified subjects with moderate-to-severe plaque psoriasis will be enrolled.
The duration of study participation is approximately 60 weeks and will be divided into the 
following periods: screening (up to 4 weeks), treatment (24 weeks), re-randomization and 
withdrawal (28 weeks), and follow up (4 weeks).
Physical examinations (PEs), 12-lead electrocardiograms (ECGs), clinical laboratory evaluations,
and other assessments will be done at select visits during the study. Subjects in this study will be 
monitored for AEs. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
36
4.1.1
Active Comparator-controlled Period (Week 0-24)
4.1.1.1
Screening Period
Subjects will be evaluated during the screening period to ensure that they meet eligibility criteria 
for this study. A detailed medical history will be done at this time, as well as a complete PE. 
Psoriasis-related history, which will include length of diagnosis (duration of disease), body surface 
involvement, and history of systemic treatment, will be assessed here. Depression and suicidality 
assessments will also be performed. An evaluation for tuberculosis (TB) will be done based on 
medical history, recent chest imaging, and a QuantiFERON-TB Gold test.
4.1.1.2
Treatment Period
Qualified subjects who have completed the screening procedures and have met the 
inclusion/exclusion criteria will be randomized on Day 1 in a 2:1:1 ratio, respectively, to one of 
the following 3 treatment groups:
x
BMS-986165 6 mg QD
x
Placebo
x
Apremilast titrated to 30 mg BID as follows:
o
Day 1: 10 mg tablet in the morning
o
Day 2: 10 mg tablet in the morning and evening
o
Day 3: 10 mg tablet in the morning and 20 mg tablet in the evening
o
Day 4: 20 mg tablet in the morning and the evening
o
Day 5: 20 mg tablet in the morning, and 30 mg tablet in the evening
o
Day 6 and thereafter: 30 mg tablet in the morning and the evening
Dummy tablets (placebo to the BMS-986165 6 mg tablet, placebo to apremilast 30 mg tablet BID, 
and placebo to apremilast 10 mg, 20 mg, and 30 mg during titration) will be administered to the 
subjects to maintain blinding. Additional details are provided in Section 6.1.
Randomization should not occur until at least 8 days after the screening visit to allow collection 
of PSSD data during screening in order to calculate a baseline PSSD score. Randomization will be 
stratified by geographic region (US and rest of world), previous biologic use for psoriasis, psoriatic 
arthritis or other inflammatory disease (yes/no), and body weight (≥90 kg and <90 kg). As this is 
designed to be a global study across multiple countries, randomization in each country will be 
targeted to approximately 35% or less of the total sample size. This change is being implemented 
to achieve geographical representation across countries and to minimize the potential for any single 
country to have a disproportionate impact on the overall efficacy and/or safety profile.
4.1.1.3
Week 16
The coprimary endpoints (sPGA 0/1 and PASI 75) will be assessed at Week 16. Subjects receiving 
placebo will be switched in a blinded manner to BMS-986165 6 mg QD at Week 16. Subjects who 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
37
are receiving BMS-986165 6 mg QD or apremilast 30 mg BID will continue the same treatment 
through Week 24.
4.1.2
Randomized Withdrawal and Maintenance Period (Week 24-52)
The Randomized Withdrawal and Maintenance Period will start at Week 24 and continue to 
Week 52. The subjects who had been in the placebo arm and switched to BMS-986165 6 mg QD 
at Week 16 will continue this treatment until Week 52.
4.1.2.1
Week 24
At Week 24, subjects originally randomized to BMS-986165 6 mg QD who do not achieve 
PASI 75 response will continue to receive BMS-986165 6 mg QD in a blinded manner. Subjects 
who achieve PASI 75 response will be re-randomized in a blinded manner to one of the following 
2 treatment groups in a 1:1 ratio:
x
BMS-986165 6 mg QD
x
Placebo
If the subjects who were re-randomized to placebo experience a relapse as defined below at any 
visit during this period, they will be switched back in a blinded manner to  BMS-986165 6 mg QD 
until the end of the maintenance period (Week 52). Relapse will be defined as at least a 50% loss 
of Week 24 PASI percent improvement from baseline.
Subjects originally randomized to apremilast who achieve PASI 75 response will be switched in a 
blinded manner to placebo. If the subject experiences a relapse at any visit during this period, the 
subject will be treated with BMS-986165 6 mg QD until the end of the maintenance period 
(Week 52). Subjects receiving apremilast who do not achieve PASI 75 response at Week 24 will 
be switched to BMS-986165 6 mg QD.
During the assessment at Week 24, a subject who has an sPGA ≥ 3 
 may be treated 
with restricted topicals/shampoos as described in Section 6.7.1 at the investigator’s discretion. 
These treatments may be only initiated at Week 24, and not at subsequent time points. A subject 
who is initiated on these treatments at Week 24 may use them as needed per the investigator’s 
judgment through Week 52.
4.1.2.2
Week 52 and Follow-up Period
The follow-up period is a 4-week window after the Week 52 visit, unless the subject rolls over into 
the long-term extension. All subjects (excluding those in the long-term extension) should be off 
treatment after the Week 52 visit. Subjects will be encouraged to report any serious adverse events
(SAEs) or AEs experienced during this time.
Subjects who discontinue study treatment early should remain in the study for protocol-specified 
procedures (please refer to Section 7.1 for more details).
Subjects completing 52 weeks of treatment will be offered the opportunity to roll over to a separate 
long-term extension study (≥2 years) where they will be treated with BMS-986165 6 mg QD.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
38
The study design schematic is presented in Figure 1.
Figure 1:
Study Design Schematic
*Upon relapse (at least a 50% loss of Week 24 PASI percent improvement from baseline), subjects will be switched 
to BMS-986165 6 mg QD. 
†Apremilast is titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing as described in Section 4.1.1.2
Abbreviations: BID = twice daily; PASI = Psoriasis Area and Severity Index; QD = once daily; R = randomize
The coprimary endpoints will be evaluated at Week 16. The duration of the study for each 
subject will be up to 52 weeks on treatment, and 4 additional weeks for safety follow-up.
4.1.3
Data Monitoring Committee and Other External Committees
4.1.3.1
Data Monitoring Committee
An external data monitoring committee (DMC) with multi-disciplinary representation will be 
established to evaluate on a periodic basis AEs, laboratory measurements, and safety assessments 
to ensure the ongoing safety of study subjects. An independent reporting statistician not involved 
in the conduct of the study will be designated by 
 to provide the DMC with essential safety 
data during the study.
The DMC responsibilities, authorities, and procedures will be documented and followed according 
to the DMC charter.
4.1.3.2
Infection Adjudication Committee
An independent Infection Adjudication Committee, composed of individuals with relevant 
expertise, will blindly review and adjudicate infection AEs, such as opportunistic infections, 
influenza, herpes zoster, and TB, reported in the study per criteria specified in a separate charter. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
39
Additional information about these infections may be collected on the case report form in order to 
characterize and understand them. The Adjudication Committee members will be blinded to the 
treatment assignment of subjects. The structure, responsibilities, and procedures of the 
Adjudication Committee will be outlined in a charter. The Adjudication Committee is distinct from 
the DMC and Adjudication Committee members will not be investigators on the study.
4.1.3.3
CV Adjudication Committee
An independent cardiovascular (CV) Adjudication Committee, composed of individuals with 
relevant expertise, will blindly review and adjudicate cardiovascular and cerebrovascular AEs such 
as, but not limited to, Major Adverse Cardiovascular Events (MACE) that include death, non-fatal 
myocardial infarction, non-fatal stroke; revascularization procedures; heart failure; dysrhythmias; 
heart blocks; and thrombotic events reported in the study per criteria specified in a separate charter. 
Additional information about cardiovascular and cerebrovascular AEs may be collected on the 
case report form in order to characterize and understand them. The Adjudication Committee 
members will be blinded to the treatment assignment of subjects. The structure, responsibilities, 
and procedures of the Adjudication Committee will be outlined in a charter. The Adjudication 
Committee is distinct from the DMC and Adjudication Committee members will not be 
investigators on the study.
4.1.3.4
Suicidal Ideation and Behavior Adjudication Committee
An independent Suicidal Ideation and Behavior Adjudication Committee, composed of individuals 
with relevant expertise, will blindly review and adjudicate suicidal ideation/behavior reported in 
the study per criteria specified in a separate charter. Additional information about suicidal 
ideation/behavior may be collected on the case report form. The Adjudication Committee members 
will be blinded to the treatment assignment of subjects. The structure, responsibilities, and 
procedures of the Adjudication Committee will be outlined in a charter. The Adjudication 
Committee is distinct from the DMC and Adjudication Committee members will not be 
investigators on the study.
4.2
Number of Subjects
Approximately 1000 qualified subjects will be randomized in a 2:1:1 ratio to BMS-986165 6 mg 
QD, apremilast 30 mg BID, and placebo, respectively. Sample size considerations are described 
in Section 9.1.
4.3
End of Study Definition
The duration of study participation for individual subjects is expected to be up to 60 weeks (420 
days), which includes screening (up to 4 weeks), treatment (52 weeks), and follow-up (up to 
4 weeks) periods.
The start of the trial is defined as first visit for first subject screened. The end of the trial is defined 
as the last visit or scheduled procedure shown in the Schedule of Activities (Section 1.3) for the 
last subject. Study completion is defined as the final date on which data were or are expected to be 
collected (Week 56 for collection of potential SAEs).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
40
4.4
Scientific Rationale for Study Design
This Phase 3 study will be conducted in a population of subjects with stable moderate-to-severe 
plaque psoriasis who are candidates for systemic psoriasis therapy. This study is designed to 
confirm the efficacy and safety of BMS-986165 compared with placebo and apremilast in 
achieving sPGA of 0/1 and PASI 75 at Week 16. The sPGA and PASI 75 are standard measures 
in clinical trials of demonstrating efficacy of systemic psoriasis treatments. This study will also 
examine the efficacy durability after re-randomized withdrawal at Week 24 in subjects who had 
achieved PASI 75 in the BMS-986165 treatment arm. A placebo arm is included in this study for 
a short duration of 16 weeks to provide a control for the natural fluctuation of psoriasis activity 
that may occur and to provide a safety standard for comparison. Subjects in the placebo arm will 
be switched to BMS-986165 at Week 16 to provide them psoriasis treatment after the endpoints 
are collected. Apremilast is included as the active control in this study as it is an approved, widely 
used, oral daily medication for psoriasis. Week 16 was chosen as it would allow enough time for 
BMS-986165 as well as apremilast to treat psoriasis. In addition, prior apremilast registrational 
trials had reported psoriasis-related outcomes at Week 16 as their primary endpoints. Randomized 
withdrawal at Week 24 through Week 52 is considered enough time to assess the efficacy 
maintenance and durability of BMS-986165 in subjects who had achieved a PASI 75 at Week 24.
5
STUDY POPULATION
Eligibility criteria for this study have been carefully considered to ensure 1) selection of 
appropriate subjects with psoriasis, 2) safety of the study subjects, and 3) the results of the study 
can be used for regulatory filing and other purposes. It is imperative that subjects fully meet all 
eligibility criteria.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
41
All screening and randomization evaluations must be completed and reviewed to confirm that 
potential subjects meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for screening 
failure, as applicable.
5.1
Inclusion Criteria
In order to be eligible to participate in this study, an individual must meet all of the following 
criteria:
1) Signed Written Informed Consent
a) Subjects must be willing to participate in the study and sign the informed consent form 
(ICF)
2) Type of Subject and Target Disease Characteristics
a) Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable 
psoriasis is defined as no morphology changes or significant flares of disease activity in 
the opinion of the investigator.
b) Deemed by the investigator to be a candidate for phototherapy or systemic therapy
c) ≥10% of BSA involvement at screening visit and Day 1
d) Psoriasis Area and Severity Index (PASI) score ≥12, and static Physician’s Global 
Assessment (sPGA) ≥3 at screening visit and Day 1
3) Age and Reproductive Status
a) Men and women aged ≥18 years at the time of screening visit
b) Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at 
screening visit, and a negative urine pregnancy test (minimum sensitivity 25 IU/L or 
equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start 
of study drug
c) Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the 
study period
d) Women of childbearing potential must agree to use correctly a highly effective method(s) 
of contraception for the duration of treatment (52 weeks) with study drug(s) BMS-986165 
plus 5 half-lives of study drug (3 days) plus 30 days (duration of ovulatory cycle) for a total 
of 33 days post-treatment completion (total of 33 days after last dose of study drug). 
WOCBP who are continuously not heterosexually active are exempt from contraceptive 
requirements, but must still undergo pregnancy testing as described in this protocol
e) Male subjects who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception (APPENDIX 4) for the duration of treatment with study 
treatment(s) plus 5 half-lives of the study treatment (3 days) for a total of 3 days 
post-treatment completion. In addition, male subjects must be willing to refrain from sperm 
donation during this time
Investigators shall counsel WOCBP, and male subjects who are sexually active with WOCBP, on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on the use of highly effective methods of contraception (APPENDIX 4),
which have a failure rate of < 1% when used consistently and correctly.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved   BMS Confidential
42
5.2
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this 
study:
1) Target Disease Exceptions
a) Has non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced 
psoriasis) at screening or Day 1
2) Infectious/Immune-related Exclusions
a) History or evidence of outpatient active infection and/or febrile illness within 7 days prior 
to Day 1 
b) History of serious bacterial, fungal, or viral infection requiring hospitalization and 
intravenous (IV) antimicrobial treatment within 60 days prior to Day 1
c) Any untreated bacterial infection within 60 days prior to Day 1
d) Any ongoing evidence of chronic, bacterial infection (eg, chronic pyelonephritis, chronic 
osteomyelitis, chronic bronchiectasis)
e) Any history of proven infection of a joint prosthesis in which the prosthesis was not 
removed or replaced, or received antibiotics for suspected infection of a joint prosthesis in 
which the prosthesis was not removed or replaced
f)
Received live vaccines within 60 days prior to Day 1, or plans to receive a live vaccine 
during the study, or within 60 days after completing study treatment
g) Presence of herpes zoster lesions at screening or Day 1
h) History of serious herpes zoster or serious herpes simplex infection which includes, but is 
not limited to, any episode of disseminated herpes simplex, multidermatomal herpes zoster, 
herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (recurrent is defined as 
2 episodes within 2 years)
i)
Evidence of, or test positive for, hepatitis B virus (HBV) at screening. Positive hepatitis B 
lab testing is defined as 1) Positive Hepatitis B Surface Ag (HBsAg+) OR 2) Presence of 
Hepatitis B Virus DNA OR 3) Positive anti-hepatitis B core antibody without concurrent 
positive hepatitis B surface antibody (HBcAb+ and HBsAb-)
j)
Evidence of, or test positive for, hepatitis C virus (HCV) at screening. A positive test for 
HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), AND 2) positive 
via a confirmatory test for HCV (for example, HCV polymerase chain reaction)
k) Positive for human immunodeficiency virus by antibody testing (HIV-1 and -2 Ab) at 
screening
l)
Any history of known or suspected congenital or acquired immunodeficiency state or 
condition that would compromise the subject’s immune status (eg, history of opportunistic 
infections [eg, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidioidomycosis], 
history of splenectomy, primary immunodeficiency)
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved   BMS Confidential
43
3) Any of the following TB criteria:
a) History of active TB prior to screening visit, regardless of completion of adequate 
treatment
b) Signs or symptoms of active TB (eg, fever, cough, night sweats, and weight loss) during 
screening as judged by the investigator
c) Any imaging of the chest (eg, chest x-ray, chest computed tomography [CT] scan) obtained 
during the screening period, or anytime within 6 months prior to screening with 
documentation, showing evidence of current active or history of active pulmonary TB
d) Latent TB infection (LTBI) defined as positive IFN gamma release assay (IGRA), by 
QuantiFERON-TB Gold testing at screening, in the absence of clinical manifestations
Note: Subject is eligible if (i) there are no current signs or symptoms of active TB AND 
(ii) subject has received adequate documented treatment for LTBI within 5 years of 
screening OR has initiated prophylactic treatment for LTBI per local guidelines and is 
rescreened after 1 month of treatment. To continue in the study, subject must agree to 
complete a locally-recommended course of treatment for LTBI. Use of rifampin, however, 
is not recommended as it can reduce efficacy of apremilast used as a comparator in this 
trial
Note: An IGRA test that is indeterminate must be retested for confirmation. If the second 
test is again indeterminate, the subject will be excluded from the study. If the retest is 
positive, the subject should be treated as having LTBI. If the retest is negative, subject may 
be eligible provided no other exclusion criteria for TB are met
4) Medical History and Concurrent Diseases
a) Any major surgery within 8 weeks prior to Day 1, or any planned surgery for the first 
52 weeks of the study
b) Has donated blood >500 mL within 4 weeks prior to Day 1, or plans to donate blood during 
the course of the study
c) Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1
d) Medical marijuana or prescription marijuana taken for medicinal reasons
e) Any major illness/condition or evidence of an unstable clinical condition (eg, renal, 
hepatic, hematologic, gastrointestinal (GI), endocrine, pulmonary, psychiatric, neurologic, 
immunologic, or local active infection/infectious illness) that, in the investigator’s 
judgment or after consultation with the medical monitor, will substantially increase the risk 
to the subject if he or she participates in the study
f)
Unstable cardiovascular disease, defined as a recent clinical cardiovascular event (eg, 
unstable angina, myocardial infarction, stroke, rapid atrial fibrillation) in the last 3 months 
prior to screening, or a cardiac hospitalization (eg, revascularization procedure, pacemaker 
implantation) within 3 months prior to screening
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved   BMS Confidential
44
g) Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) 
>160 mm Hg or diastolic BP >100 mm Hg
Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this 
limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If 
the repeat value is less than the criterion limits, the second value may be accepted
h) Class III or IV congestive heart failure by New York Heart Association Criteria
i)
Has cancer or history of cancer (solid organ or hematologic including myelodysplastic 
syndrome) or lymphoproliferative disease within the previous 5 years (other than resected 
cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has 
been treated with no evidence of recurrence)
j)
Any uncontrolled neuropsychiatric illness judged as clinically significant by the 
investigator during screening or at Day 1
OR
Any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by medical 
history or by electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) 
documentation, or by answering “yes” to Question 4 or 5 for suicidal ideation on the 
eC-SSRS at screening or at Day 1, or is clinically deemed to have a suicide risk by the 
investigator
k) Prior exposure to investigational product (ie, BMS-986165 or apremilast)
l)
If the subject has received biologics previously, the following exclusion criteria for 
washout will apply: 
i)
Antibodies to IL-12, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, 
ixekizumab, or guselkumab) within 6 months of Day 1
ii) TNF inhibitor(s) (eg, etanercept, adalimumab, infliximab, certolizumab) within 
2 months of Day 1
iii) Agents that modulate integrin pathways to impact lymphocyte trafficking (eg, 
natalizumab), or agents that modulate B cells or T cells (eg, alemtuzumab, abatacept, 
or visilizumab) within 3 months of Day 1
iv) Rituximab within 6 months of Day 1
m) Has received systemic non-biologic psoriasis medications and/or any systemic 
immunosuppressants therapy (including, but not limited to, methotrexate, azathioprine, 
cyclosporine, JAK inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, 
hydroxyurea, tacrolimus, oral or injectable corticosteroids, retinoids, 1,25-dihydroxy
vitamin D3 and analogues, psoralens, sulfasalazine, or fumaric acid derivatives) within 4 
weeks prior to Day 1
n) Has used leflunomide within 6 months prior to Day 1
o) Has used opioid analgesics within 4 weeks prior to Day 1
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved   BMS Confidential
45
p) Has received lithium, antimalarials, or intramuscular (IM) gold within 4 weeks of the first 
administration of any study medication
q) Has used any strong CYP450 inducers (eg, rifampin, phenobarbital, carbamazepine, 
phenytoin) within 4 weeks prior to Day 1
r)
Has received phototherapy (including either oral and topical PUVA light therapy, 
ultraviolet B [UVB] or self-treatment with tanning beds or therapeutic sunbathing) within 
4 weeks prior to Day 1
s) Has used topical medications/treatments that could affect psoriasis evaluation (including, 
but not limited to, high potency corticosteroids (WHO Classes I-V), >3% salicylic acid, 
urea, alpha- or beta-hydroxyl acids, anthralin, calcipotriene, topical vitamin D derivatives, 
retinoids, tazarotene, methoxsalen, trimethylpsoralens, pimecrolimus, and tacrolimus) 
within 2 weeks prior to Day 1
Note: Low potency topical steroids (WHO Class VI and VII) are permitted on the palms, 
soles, face, and intertriginous areas but should not be used within 24 hours prior to any 
study visit. Bland emollients (defined as emollients without urea or alpha or beta hydroxy 
acids or other ingredients which are pharmaceutically active) are allowed on all body 
regions but should not be used within 24 hours prior to any study visit
t)
Use of shampoos that contain corticosteroids, coal tar, >3% salicylic acid, or vitamin D3 
analogues within 2 weeks prior to Day 1
u) Has received an experimental antibody or experimental biologic therapy within the 
previous 6 months, OR received any other experimental therapy or new investigational 
agent within 30 days or 5 half-lives (whichever is longer) prior to Day 1 OR is currently 
enrolled in an investigational study
v) Any other sound medical, psychiatric and/or social reason as determined by the investigator
5) Physical and Laboratory Evaluations
a) At Screening
i)
Absolute WBC count <3000/mm3
ii)
Absolute lymphocyte count <500/mm3
iii)
Absolute neutrophil count <1000/mm3
iv)
Platelet count <100,000/mm3
v)
Hemoglobin <9 g/dL
vi)
ALT and/or AST >3 × upper limit of normal (ULN)
vii)
Total, unconjugated, and/or conjugated bilirubin >2 × ULN
viii) Thyroid-stimulating hormone (TSH) outside the normal reference range
AND
Free T4 (thyroxine) or T3 (triiodothyronine) outside the normal reference range
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved   BMS Confidential
46
b) ECG abnormalities that are considered clinically significant and would pose an 
unacceptable risk to the subject if participating in the study 
c) Renal impairment based on an estimated glomerular filtration rate (eGFR) <45 mL/min
d) Inability to be venipunctured and/or tolerate venous access
e) Any other significant laboratory abnormalities that, in the opinion of the investigator, might 
place the subject at unacceptable risk for participation in this study
6) Allergies and Adverse Drug Reactions
a) History of any significant drug allergy (such as anaphylaxis)
7) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a subject. Strict conditions apply and BMS approval is required).
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
c) Inability to comply with restrictions and prohibited activities/treatments as listed in the 
study protocol
d) Site personnel or their immediate family
e) Any contraindications listed in the country-specific label for apremilast
5.3
Lifestyle Restrictions
General skin care measures (with above restrictions for topical treatments) that are standard for 
patients with plaque psoriasis are permitted. Subjects should avoid excessive sun exposure and 
avoid risks that are known to provoke flare of psoriasis.
5.3.1
Meals and Dietary Restrictions
Study treatment may be taken without regard to meals; however, subjects are required to fast for a 
minimum of 10 hours before visits on which fasting lipid samples 
 
will be drawn. Details are provided in Section 8.5.
5.3.2
Caffeine, Alcohol, and Tobacco
No restrictions are required; however, extensive use of caffeine, alcohol, and tobacco should be 
avoided.
5.3.3
Activity
No restrictions are required; however, unusual physical exertion should be avoided during the 
study.
5.4
Screen Failures
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently randomized in the study for any reason. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure subjects, to meet the Consolidated 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
47
Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries 
from regulatory authorities. Minimal set of screen failure information includes date of consent, 
demography, screen failure details (ie, eligibility criteria that the subject did not meet), and any 
serious AEs during the screening period.
5.4.1
Retesting During Screening or Rescreening
For laboratory parameters that initially do not meet eligibility requirements, a single retest within 
the 28-day screening period is permitted before subject is declared a screen failure. This is an effort 
to find all possible well-qualified subjects. Consultation with the medical monitor may be needed 
to identify whether repeat testing of any particular parameter is clinically relevant.
The study permits the rescreening (after the end of the initial 28-day screening period) of a subject 
who discontinues the study as a pretreatment failure (ie, the subject fails to meet eligibility criteria 
and has not been treated). The subject must be reconsented and will be assigned a new 
identification number, and a full screening visit must be performed again. A subject can only be 
rescreened 1 time (ie, if the subject fails 1 rescreening attempt, no additional rescreening is 
allowed). Depending on the timing of rescreening, repeat chest imaging may not be required. 
Duration of existing treatments and required discontinuation periods shall be considered relative 
to the new screening visit and/or randomization.
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the subject’s most current clinical state.
6
TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or 
medical device intended to be administered to a study subject according to the study randomization 
or treatment allocation.
Study 
treatment 
includes 
both 
Investigational 
[Medicinal] 
Product 
(IP/IMP) 
and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following: 
BMS-986165, placebo, and apremilast.
An investigational product, also known as investigational medicinal product in some regions, is 
defined as a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as
non-investigational products. Table 5 shows the study treatments for Protocol IM011047.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
20 May 2020, Revised Protocol 09, Final Approved
BMS Confidential
48
Table 5:
Study Treatments for IM011047
Product Description / 
Class and Dosage Form
Potency
IP/Non-IMP
Blinded or Open 
Label
Packaging / 
Appearance
Storage Conditions
(per label)
BMS-986165 tablet
6 mg
IP
Blinded
Bottle
Store at 15 to 25°C; 
Store in a tightly closed 
container; Protect from 
light
Placebo tablet to match 
BMS-986165 6 mg
n/a
IP
Blinded
Bottle
Store at 15 to 25°C; 
Store in a tightly closed 
container; Protect from 
light
Apremilast tablet
10 mg*
IP
Blinded
Blister card
Store tablets below 
30°C (86°F). Store in 
original container
Placebo tablet to match 
apremilast 10 mg
n/a
IP
Blinded
Blister card
Store tablets below 
30°C (86°F). Store in 
original container
Apremilast tablet
20 mg†
IP
Blinded
Blister card
Store tablets below 
30°C (86°F). Store in 
original container
Placebo tablet to match 
apremilast 20 mg
n/a
IP
Blinded
Blister card
Store tablets below 
30°C (86°F). Store in 
original container
Apremilast tablet
30 mg‡
IP
Blinded
Bottle
Store tablets below 
30°C (86°F). Store in 
original container
Placebo tablet to match 
apremilast 30 mg
n/a
IP
Blinded
Bottle
Store tablets below 
30°C (86°F). Store in 
original container
IP = investigational product; IMP = investigational medicinal product; n/a = not applicable
*Used for titration Day 1 through Day 3 morning dose
†Used for titration Day 3 evening dose through Day 5 morning dose
‡From Day 5 evening dose onwards.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
49
6.1
Treatments Administered
Study treatment will be administered as described in Section 4.1.1.2. The selection and timing of 
dose for each subject is as follows:
Table 6:
Selection and Timing of Dose
Study Treatment
Unit dose 
strength(s)/Dosage 
level(s)
Dosage formulation
Frequency of Administration
Route of 
Administration
6 mg QD 
BMS-986165
6 mg
1 active tablet QD in the morning; 1 
placebo titration kit* then 2 apremilast 
placebo (1 tablet in the morning, 1 
tablet in the evening)
oral
30 mg BID 
apremilast
30 mg
1 active titration kit* then 1 active 
morning and evening and 1 
BMS-986165 placebo QD in the 
morning
oral
Placebo BID
n/a
1 placebo apremilast titration kit* then 
2 apremilast placebo (1 tablet in the 
morning, 1 tablet in the evening) and 1 
BMS-986165 placebo QD in the 
morning
oral
Abbreviations: BID = twice daily; n/a = not applicable; QD = once daily
*Titration kit described in Section 6.1.1.
6.1.1
Titration Kit for Active and Placebo Apremilast
Apremilast will be titrated over 5 days to a maintenance dose of 30 mg BID. To maintain the blind 
between subjects receiving apremilast and BMS-986165 during the titration period, active 
apremilast and matching apremilast placebo tablets will be provided. This will be supplied in an 
18-day titration kit as follows:
One 10 mg tablet in the morning on Day 1; two 10 mg tablets (one in the morning, one in the 
evening) on Day 2; one 10 mg tablet in the morning and one 20 mg tablet in the evening on Day 3; 
two 20 mg tablets (one tablet in the morning, one tablet in the evening) on Day 4; one 20 mg tablet 
in the morning and one 30 mg tablet in the evening on Day 5; one 30 mg tablet in the morning and 
one 30 mg tablet in the evening for each Day 6 through Day 18.
6.2
Method of Treatment Assignment
Before the study is initiated, each user (at investigative sites) will receive log-in information and 
directions on how to access the interactive response technology (IRT) system. At the time of the 
screening visit, immediately after informed consent is obtained and before any study-related 
procedures are performed, the investigative site will access the enrollment option of the IRT 
system for assignment of a subject number for all subjects, including subjects not subsequently 
randomized or treated. The subject number is assigned sequentially by the system and will be 
unique across all sites. All enrolled subjects will be assigned sequential subject numbers. The 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
50
subject number will not be used for any other subject. If a subject is rescreened, they will be given 
a new identification number.
At Week 0 (Day 1), subjects who meet all criteria for enrollment at Screening and Day 1 will be 
centrally randomized in a 2:1:1 ratio to BMS-986165 6 mg QD, placebo, or apremilast 30 mg BID 
as determined by a computer-generated randomization schedule using IRT. The randomization 
lists will be generated by the IRT vendor using a permuted block design within each combination 
of stratum level. The randomization in this study will be stratified by geographic region geographic 
region (US and rest of world), previous biologic use for psoriasis, psoriatic arthritis or other 
inflammatory disease (yes/no), and body weight (≥90 kg and <90 kg). As this is designed to be a 
global study across multiple countries, randomization in each country will be targeted to 
approximately 35% or less of the total sample size. This change is being implemented to achieve 
geographical representation across countries and to minimize the potential for any single country 
to have a disproportionate impact on the overall efficacy and/or safety profile.
After all inclusion/exclusion criteria have been met for a subject, the investigative site will access 
the IRT on Day 1 for the purposes of randomizing a subject. A treatment group will be assigned 
by IRT based on the above-described randomization schedule and each subject will be assigned a 
unique randomization number. In addition, a unique kit number will be assigned to the subject 
corresponding to the treatment assignment.
At the Week 0 and Week 2 visits, a kit with a 2-week supply of study treatment is provided. At all 
subsequent visits, kits will contain adequate study treatment for a 4-week supply. At subsequent 
visits, when new treatment kits are to be dispensed, the investigative site will access the IRT to 
obtain the kit number to assign to the subject. Study treatment will be dispensed at study visits as 
shown in the Schedule of Activities (Section 1.3).
At Week 16, subjects receiving placebo will be switched in a blinded manner to BMS-986165
6 mg QD.
At Week 24, subjects originally randomized to BMS-986165 6 mg QD who do not achieve 
PASI 75 will continue to receive BMS-986165 6 mg QD in a blinded manner. Subjects who 
achieve PASI 75 response will be re-randomized in a blinded manner to either BMS-986165 6 mg 
QD or placebo. Subjects re-randomized to placebo who experience a relapse at a subsequent visit 
will be switched back onto BMS-986165 6 mg QD in a blinded manner. The investigative site and 
other study personnel will not be provided with the PASI 75 scores at these visits.
At Week 24, subjects originally randomized to apremilast 30 mg BID who do not achieve PASI 75 
response will be switched in a blinded manner to BMS-986165 6 mg QD while subjects who 
achieve PASI 75 response at Week 24 will be switched in a blinded manner to placebo. If a relapse 
occurs at a subsequent visit, they will be switched in a blinded manner to BMS-986165 6 mg QD. 
The investigative site and other study personnel will not be provided with the PASI 75 scores at 
these visits.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
51
6.2.1
Method of Study Treatment Assignment at Week 24 and Subsequent 
Visits Impacted by COVID-19-related Issues
At Week 24, when COVID-19-related issues result in the subject visit being missed or conducted 
remotely, the study treatment assigned by the IRT system will not be determined by the PASI 75 
response, because PASI assessments will not be done.  The study treatment assigned by the IRT 
system will be defaulted to BMS-986165 6 mg QD for the duration of the study.
For all subsequent visits post Week 24, when COVID-19-related issues result in the subject visit 
being missed or conducted remotely, the study treatment assigned by the IRT system will not be 
determined by the PASI relapse response, because PASI assessments will not be done. Study 
treatment assignment will be done as per the following:
o
Missed visits: the study treatment assigned by the IRT system will be the study 
treatment assigned at the previous visit  
o
Visits conducted remotely: the study treatment assigned by the IRT system will be 
defaulted to BMS-986165 6 mg QD for the duration of the study
6.3
Blinding
6.3.1
Maintaining the Blind
Blinded treatment assignments will be managed using IRT. 
All tablets are identical in appearance and will be supplied in blister cards or bottles with each 
daily dose made up of the appropriate combination of active and/or placebo tablets to provide the 
correct treatment, as shown in Table 5. Investigative site staff, Sponsor and designee personnel, 
and subjects and their families will remain blinded to treatment assignments.
 
 
 
 
6.3.2
Circumstances for Unblinding
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subject in which knowledge of the 
investigational product is critical to the subject's management, the blind for that subject may be 
broken by the investigator. The subject’s safety takes priority over any other considerations in 
determining if a treatment assignment should be unblinded.
Before breaking the blind of an individual subject's treatment, the investigator should determine 
that the unblinded information is necessary, ie, that it will alter the subject's immediate 
management. In many cases, particularly when the emergency is clearly not related to the 
investigational product, the problem may be properly managed by assuming that the subject is 
receiving active product. It is highly desirable that the decision to unblind treatment assignment 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
52
be discussed with the medical monitor, but the investigator always has ultimate authority for the 
decision to unblind. The principal investigator should only call in for emergency unblinding 
AFTER the decision to discontinue the subject has been made.
In case of an emergency, the investigator has unrestricted access to randomization information via 
IRT and is capable of breaking the blind through the IRT system without prior approval from the 
sponsor. After the unblinding, the investigator shall notify the medical monitor and/or study 
director. The method of unblinding for emergency purposes is described in the IRT manual. 
Subject and unblinded treatment information and the reason for the blind being broken must be 
recorded on the appropriate study status page of the electronic case report form (eCRF). After 
unblinding via IRT, the investigator shall notify the medical monitor.
In cases of accidental unblinding, contact the medical monitor and ensure every attempt is made 
to preserve the blind. Any request to unblind a subject for non-emergency purposes must be 
discussed with the medical monitor prior to unblinding.
6.4
Dosage Modification
There is no provision for dose modification of study treatment. If a subject interrupts treatment 
due to an AE, study treatment can be restarted in consultation with the medical monitor.
6.5
Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment 
should not be dispensed and BMS should be contacted immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
x
Guidance and information for final disposition of unused study treatment are provided in 
APPENDIX 2.
x
6.5.1
Retained Samples for Bioavailability/Bioequivalence
Not applicable.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
53
6.6
Treatment Compliance
Study treatment compliance will be periodically monitored using standard drug accountability 
procedures (comparing the number of tablets returned to number dispensed, considering the 
expected regimen and any reported missed doses). Drug accountability will be reviewed by the 
investigative site staff at each visit to confirm treatment compliance. Site staff will discuss any 
discrepancies with the subject and remind the subject of the importance of compliance with the 
assigned regimen. A real-time monitoring platform may be used.
6.7
Concomitant Therapy
6.7.1
Prohibited and/or Restricted Treatments
Prohibited and/or restricted medications during the study are described below. Medications taken 
within 4 weeks prior to study drug administration must be recorded on the CRF.
1) Exposure to any investigational drug or placebo outside of the current study
2) Any concurrent use of strong CYP450 inducers according to the US package insert for 
apremilast as it may reduce apremilast efficacy. Examples include rifampin, phenobarbital, 
carbamazepine, and phenytoin, unless it is considered necessary for the subject’s welfare 
and/or treatment of an AE/SAE.
3) Use of any medications/therapy that would aggravate psoriasis. These include agents such as 
lithium, antimalarials (quinacrine, chloroquine, and hydroxychloroquine), propranolol, 
indomethacin, and quinidine unless it is considered necessary for the subject’s welfare and/or 
treatment of an AE/SAE.
4) Use of opioid analgesics unless it is considered necessary for the subject’s welfare and/or 
treatment of an AE/SAE.
5) Phototherapy; use of tanning booths or therapeutic sunbathing.
6) Any use of biologic medications (eg, adalimumab, etanercept, infliximab, ustekinumab).
7) Any use of oral psoriasis medications (eg, methotrexate, cyclosporine, retinoids, fumaric acid 
derivatives) for any indication.
8) Any use of oral or injectable corticosteroids (prednisone, methylprednisolone, etc.), unless it 
is considered necessary for the subject’s welfare and/or treatment of an AE/SAE.
Note: otic, ophthalmic, nasal, or inhaled corticosteroids within recommended doses and with 
no systemic effects are permitted.
9) Any topical medications/treatments, which are used for any indication, that could affect 
psoriasis evaluation (including, but not limited to, high potency corticosteroids (WHO Classes 
I-V), >3% salicylic acid, urea, alpha- or beta-hydroxyl acids, anthralin, calcipotriene, vitamin 
D derivatives, retinoids, tazarotene, methoxsalen, trimethylpsoralens, pimecrolimus, and 
tacrolimus).
Exception: The following topical treatments may be initiated only at Week 24 per 
investigator’s discretion in subjects who have 
 (See Section 4.1.2.1):
x
High potency corticosteroids (WHO Classes I-V), >3% salicylic acid, urea, alpha- or
beta-hydroxyl acids, anthralin, calcipotriene, vitamin D derivatives, retinoids, tazarotene.
Note: Low potency topical steroids (WHO Classes VI and VII) are permitted on the palms, 
soles, face, and intertriginous areas but should not be used within 24 hours prior to any study 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
54
visit. Bland emollients (defined as emollients without urea or alpha or beta hydroxy acids or
other ingredients which are pharmaceutically active) are allowed on all body regions but should 
not be used within 24 hours prior to any study visit.
10) Any medicated shampoos that contain corticosteroids, coal tar, >3% salicylic acid, or vitamin 
D3 analogues.
Exception: The above shampoos may be initiated only at Week 24 per investigator’s discretion 
in subjects who have 
 (See Section 4.1.2.1):
11) Live vaccination
No concomitant medications (prescription, over-the-counter, or herbal) are to be administered 
during study unless they are prescribed for treatment of specific clinical events. Any concomitant 
therapies must be recorded on the CRF.
The investigator should contact and confirm agreement with the medical monitor prior to the 
administration of any concomitant medications.
6.7.2
Permitted Concomitant Medications
Stable doses of concomitant medication for chronic medical conditions, except for psoriasis, are 
permitted as long as neither the medication nor the medical condition meet exclusion criteria as 
detailed in Section 5.2. Dose adjustments of these medications should be avoided during the study 
unless clinically indicated. If a dose adjustment of these medications should occur, they must be 
recorded on the Concomitant medications eCRF or the Procedures and Significant non-drug
therapies eCRF. The investigator should instruct the subject to notify the study site about any new 
treatments he/she takes after the start of the study treatment. All medications and significant 
non-drug therapies (including physical therapy and blood transfusions) administered after the 
subject starts study treatment must be listed on the Concomitant medications eCRF or the 
Procedures and Significant non-drug therapies eCRF.
Note: Low potency topical steroids (WHO Classes VI and VII) are permitted on the palms, soles, 
face, and intertriginous areas but should not be used within 24 hours prior to any study visit. Bland 
emollients (defined as emollients without urea or alpha or beta-hydroxy acids or other ingredients 
which are pharmaceutically active) are allowed on all body regions but should not be used within 
24 hours prior to any study visit.
6.7.3
Rescue Medications
At Week 24, a subject who has an sPGA 
 may be treated with restricted topicals or 
shampoos, respectively, at the investigator’s discretion (see Section 6.7.1). These treatments may 
be only initiated at Week 24, and not at subsequent time points. A subject who is initiated on these 
treatments at Week 24 may use them as needed per the investigator’s judgment through Week 52.
6.8
Treatment After the End of the Study
At the end of the study, the investigator should ensure that subjects continue to receive appropriate 
standard of care to treat the condition under study. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
55
In addition, for subjects who continue to demonstrate clinical benefit, BMS may continue to 
provide study treatment via a rollover extension study requiring approval by responsible health 
authority and ethics committee, or through another mechanism at the discretion of BMS. 
BMS reserves the right to terminate access to BMS supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) the development of BMS-986165 is 
terminated for other reasons, including, but not limited to, lack of efficacy and/or not meeting the 
study objectives; c) the subject can obtain medication from a government-sponsored or private 
health program. In all cases, BMS will follow local regulations.
7
DISCONTINUATION CRITERIA
7.1
Discontinuation from Study Treatment
Subjects MUST discontinue IP (and non-IP at the discretion of the investigator) for any of the 
following reasons:
x
Subject requests to stop study treatment. Subjects who discontinue study treatment early 
should remain in the study for protocol-specified procedures. The only exception to this is 
when a subject specifically withdraws consent for any further contact with him/her or
persons previously authorized by subject to provide this information.
x
Any clinically significant AE, laboratory abnormality, or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the
best interest of the subject. If treatment is discontinued due to an AE, the AE eCRF must
be completed to show that the AE caused discontinuation
x
eGFR <45 mL/min on repeat assessment within 7 days
x
Abnormal liver tests suggestive of drug-induced liver injury (DILI), as defined in 
Section 8.2.8 or if the investigator believes that it is in the best interest of the subject
x
Subject reports suicidal ideation, suicidal behavior, or suicide attempts at any time after 
randomization, or documents suicidal ideation by answering “Yes” to Question 4 or 5 on 
the eC-SSRS, or documents suicidal behavior on the eC-SSRS at any time during the study. 
The subject should then be immediately referred to a mental health professional for 
evaluation of suicide risk
x
The subject develops a malignancy, with the exception of a subject who develops 
non-melanoma skin cancer who may continue in the study at the discretion of the 
investigator 
x
Pregnancy, positive pregnancy test, or subject expresses an interest in becoming pregnant 
(refer to Section 8.2.6)
x
Subject develops active TB during the study or prematurely discontinues treatment for 
LTBI, or subject is noncompliant with LTBI therapy (refer to Section 8.4.4)
x
Termination of the study or program by BMS
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
56
x
Unblinding of a subject’s treatment assignment for any reason (emergency or 
nonemergency)
x
Inability or failure to comply with protocol requirements in the opinion of the investigator
x
Loss of ability to freely provide consent through imprisonment or involuntary incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness
Refer to the Schedule of Activities (Section 1.3) for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations that can be completed.
All subjects who discontinue BMS-986165 should comply with protocol-specified follow-up 
procedures as outlined in Section 1.3. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness). Replacement of subjects is not permitted.
If study treatment is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate eCRF page.
7.1.1
Temporary Discontinuation of Study Medication
Temporary study treatment discontinuation is only allowed if the subject develops an AE which, 
in the opinion of the investigator, indicates that it is in the subject’s best interest that the study 
treatment be placed on hold. Study treatment in this situation should be stopped until the AE is 
medically treated and has resolved per investigator judgment.
Any temporary study treatment discontinuation as well as restart must be documented on the 
corresponding eCRF.
7.1.2
Post-Study Treatment Follow-Up
Post-treatment follow-up is of critical importance and is essential to preserving subject safety and 
the integrity of the study. Subjects who discontinue study treatment must continue to be followed 
for collection of outcomes and/or survival follow-up data as required and in line with Section 4
until death or the conclusion of the study.
Subjects who discontinue study treatment should be encouraged to undergo all study-related visits 
for the full treatment period in order to support the final efficacy and safety analysis.
7.2
Discontinuation from the Study
Subjects who request to discontinue study treatment will remain in the study and must continue to 
be followed for protocol-specified follow-up procedures specified in Section 1.3. The only 
exception to this is when a subject specifically withdraws consent for any further contact with 
him/her or persons previously authorized by subject to provide this information. 
x
Subjects should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
57
x
The withdrawal of consent should be explained in detail in the medical records by the 
investigator and entered on the appropriate CRF page.
x
In the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law.
x
If the subject withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.
7.3
Lost to Follow-up
x
All reasonable efforts must be made to locate subjects to determine and report their ongoing
status. This includes follow-up with persons authorized by the subject.
x
Lost to follow-up is defined by the inability to reach the subject after a minimum of three
documented phone calls, faxes, or emails, as well as lack of response by subject to one 
registered mail letter. All attempts should be documented in the subject’s medical records.
x
If it is determined that the subject has died, the site will use permissible local methods to obtain 
date and cause of death.
x
If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the subject’s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary to complete the follow-up portion of the 
study.
x
The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.
x
If after all attempts, the subject remains lost to follow-up, then the last known alive date as 
determined by the investigator should be reported and documented in the subject’s medical 
records.
8
STUDY ASSESSMENTS AND PROCEDURES
x
Study procedures and timing are summarized in the Schedule of Activities (Section 1.3) and 
described in Section 4.1.
x
Protocol waivers or exemptions are not allowed.
x
All significant safety concerns must be discussed with the medical monitor immediately upon 
occurrence or awareness to determine if the subject should continue or discontinue treatment.
x
Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.
x
All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria before randomization. Randomization should not occur until at least 
8 days after the screening visit to allow collection of PSSD data during screening in order to 
calculate a baseline PSSD score. The investigator will maintain a screening log to record details 
of all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable.
x
Procedures conducted as part of the subject’s routine clinical management (eg, blood count) 
and obtained before signing of informed consent may be utilized for screening or baseline 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
58
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
x
For several assessments, appropriate training will be provided to investigators and designated 
personnel at sites. Only those individuals trained and certified to perform these assessments 
will be performing them during the study.
8.1
Efficacy Assessments
Every effort must be made to ensure that the same evaluator(s) complete the assessment for each 
subject. If the evaluator(s) is/are unable to complete the evaluation, then a qualified individual with 
overlapping experience may perform the evaluation. Documentation of who performed the 
evaluation is to be recorded in source documents. Assessments are to be performed at 
approximately the same time of day throughout the duration of the study. 
Baseline assessments must be performed per protocol. Procedures not specified in the protocol that 
are part of standard care may be performed if they do not interfere with study procedures; any data 
arising from such procedures are not to be reported in the eCRF.
8.1.1
Investigator-administered Assessments
8.1.1.1
static Physician’s Global Assessment (sPGA)
The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, 
scale, and induration.24 The sPGA measure determines psoriasis severity at a single point in time 
(without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), 
moderate (3), or severe (4). sPGA assessments should be performed by a trained physician (eg, 
dermatologist) or appropriately trained investigator who is experienced in the assessment of 
psoriasis patients. Every effort should be made to ensure that the physician or designee who 
performed the sPGA evaluations for a subject at randomization performs the sPGA for that subject 
at all subsequent visits (see APPENDIX 5).
8.1.1.2
Psoriasis Area and Severity Index (PASI)
The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions 
(each graded on a 0 -4 scale), weighted by the area of involvement (head, arms, trunk to groin, and 
legs to top of buttocks).25 PASI produces a numeric score that can range from 0 to 72, with higher 
PASI scores denoting more severe disease activity. PASI can also be used to assess response to 
treatment. The PASI 50 is the proportion of subjects who experience at least a 50% improvement 
in PASI score as compared with the baseline value. The PASI 75, PASI 90, and PASI 100 are 
defined similarly. BMS will host a training session prior to initiation of the study to demonstrate 
proper PASI scoring. PASI assessments should be performed by a trained physician 
(dermatologist) or appropriately trained investigator who is experienced in the assessment of 
psoriasis patients (see APPENDIX 6).
8.1.1.3
Body Surface Area (BSA)
Measurement of psoriasis body surface area involvement is estimated using the handprint method 
with the size of a subject’s handprint (including fingers and thumb) representing 1% of body 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
59
surface area involved.26,27,28 The total BSA = 100% with breakdown by body region as follows: 
head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including 
axillae  and groin = 30% (30 handprints), lower extremities including buttocks = 40%
(40 handprints). BSA assessments should be performed by a dermatologist or appropriately trained 
investigator who is experienced in the assessment of psoriasis patients.
8.1.1.4
scalp specific Physician’s Global Assessment (ss-PGA)
For this assessment in subjects with scalp involvement,29 scalp lesions are evaluated in terms of 
clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA 
scale:
0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe 
disease.
The ss-PGA should be performed by a dermatologist or appropriately trained investigator who is 
experienced in the assessment of psoriasis patients. An example of the ss-PGA is provided in 
APPENDIX 7.
8.1.1.6
Physician’s Global Assessment-Fingernails (PGA-F)
In this assessment,31 the overall condition of the fingernails is rated on a 5-point scale:
0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
The PGA-F will be performed only in subjects with psoriatic fingernail involvement to assess 
severity and subsequent improvement. An example is provided in APPENDIX 9. The PGA-F
should be performed by a dermatologist or appropriately trained investigator who is experienced 
in the assessment of psoriasis patients.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
60
8.1.1.8
Palmoplantar PGA (pp-PGA)
This measure will be used for subjects with palmoplantar (including the finger and toe surfaces) 
involvement at baseline.33 The pp-PGA uses a 5-point (0-4) scale:  0 = clear; 1 = almost clear; 2 = 
mild; 3 = moderate; and 4 = severe (see APPENDIX 11). The pp-PGA should be performed by a 
dermatologist or appropriately trained investigator who is experienced in the assessment of 
psoriasis patients.
8.1.2
Subject-reported Assessments
8.1.2.1
Psoriasis Symptoms and Signs Diary (PSSD)
The PSSD is an 11-item subject-reported instrument that assesses severity of symptoms and 
subject-observed signs commonly associated in plaque psoriasis.35,36 It has been shown to be 
reliable and valid in measuring symptoms and signs of subjects with moderate-to-severe plaque 
psoriasis in the clinic and has strong psychometric properties in assessing treatment effects in 
clinical trials.37 The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin 
tightness) and 6 subject-observed signs (skin dryness, cracking, scaling, shedding or flaking, 
redness, bleeding) using 0 to10 numerical ratings. The severity of each item is rated on an 11-point 
numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Two versions of the PSSD 
were developed, one with a 24-hour recall period (PSSD-24h) and one with a 7-day recall period. 
The PSSD-24h will be administered daily in this trial to avoid recall bias with a longer recall period 
(see APPENDIX 13).
8.1.2.2
Dermatology Life Quality Index (DLQI)
The DLQI38 is a subject-reported quality of life index which consists of 10 questions concerning 
symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment 
during the last week. Each question is scored on a scale of 0 to 3 by a tick box: 0 - “not at all,” 1 –
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
61
“a little,” 2 – “a lot,” or 3 – “very much.” The scores are summed, giving a range from 0 (no 
impairment of life quality) to 30 (maximum impairment) (see APPENDIX 14).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
62
8.1.2.8
Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire
The psoriatic arthritis screening and evaluation (PASE) questionnaire will be administered at 
screening in subjects with peripheral joint complaints. The PASE questionnaire is a 
self-administered tool that is used to screen for psoriatic arthritis among subjects who have 
psoriasis. The PASE questionnaire consists of 15 questions subdivided into 7 questions focusing 
on symptoms of psoriatic arthritis, and 8 questions focusing on the impact of psoriatic arthritis on 
function. Each question is scored on a 1 to 5 scale, with a maximum score of 75. A score of 47 or 
above has been shown to distinguish between psoriatic arthritis and non-psoriatic arthritis.44 This 
questionnaire is only intended to be a screening tool for psoriatic arthritis and does not replace a 
comprehensive musculoskeletal exam performed by a rheumatologist. The PASE questionnaire 
should take 6 to 10 minutes to complete and is only done at screening (see APPENDIX 20).
8.2
Adverse Events
The definitions of an AE and SAE can be found in APPENDIX 3.
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or 
the subject's legally authorized representative). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the subject to 
discontinue before completing the study.
Contacts for SAE reporting are specified in APPENDIX 3.
8.2.1
Adverse Events of Interest
Adverse events of interest (AEIs) are AEs for a particular product or class of products that a 
Sponsor may wish to monitor carefully. Adverse events of interest may be serious or non-serious. 
Such events may require further investigation  to better characterize and understand them. In the 
BMS-986165 clinical development program, certain skin-related AEs (eg, acne), infection AEs, 
and CK elevation have been identified as potential AEIs; however, there has been no definitive 
assessment on the causal relationship between these events and treatment with BMS-986165. 
Additionally, given a potential association between treatment for autoimmune diseases and 
increased risk for cancer, malignancy has been identified as a potential AEI. Therefore, additional 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
63
information about certain skin-related AEs, infection AEs, CK elevation, and malignancy may be 
collected on the case report form in order to better characterize and understand them.
8.2.2
Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information should begin at initiation of study treatment until
discharge from the study (ie, final study visit for a given subject), at the timepoints specified in the 
Schedule of Activities (Section 1.3).
The Reference Safety Information in Sections 5.6.1 and 5.6.2 of the IB should be used to determine 
expectedness of SAEs for expedited reporting. Following the subject’s written consent to 
participate in the study, all SAEs, whether related or not related to study drug, must be collected, 
including those thought to be associated with protocol-specified procedures.
All SAEs must be collected from the date of subject’s written consent until 30 days after the final 
dose of the study drug or subject’s participation in the study if the last scheduled visit occurs at a 
later time. Monitoring for SAEs will occur at every study visit. 
x
The investigator must report any SAE that occurs after these time periods and that is believed 
to be related to study drug or protocol-specified procedure. Medical occurrences that begin 
before the start of study treatment but after obtaining informed consent will be recorded on the 
appropriate section of the CRF.
x
All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in APPENDIX 3.
x
The investigator will submit any updated SAE data to the sponsor within 24 hours of this being 
available.
Investigators are not obligated to actively seek AEs or SAEs in former study subjects. However, 
if the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the study treatment 
or study participation, the investigator must promptly notify the sponsor.
The method of evaluating and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in APPENDIX 3.
8.2.3
Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
8.2.4
Follow-up of AEs and SAEs
x
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see APPENDIX 3).
x
Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate.
x
All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF. Completion of supplemental CRFs may be requested for AEs and/or laboratory 
abnormalities that are reported/identified during the course of the study.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
64
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up (as defined 
in Section 7.3).
Further information on follow-up procedures is given in APPENDIX 3.
8.2.5
Regulatory Reporting Requirements for SAEs
x
Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities toward the safety of subjects and the safety of a product 
under clinical investigation are met.
x
An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the Investigator Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
Sponsor or designee will be reporting AEs to regulatory authorities and ethics committees 
according to local applicable laws including European Directive 2001/20/EC and Food and Drug 
Administration (FDA) Code of Federal Regulations (CFR) 21 CFR Parts 312 and 320. A 
Suspected, Unexpected Serious Adverse Reaction (SUSAR) is a subset of SAEs and will be 
reported to the appropriate regulatory authorities and investigators following local and global 
guidelines and requirements.
8.2.6
Pregnancy
In the event a subject becomes pregnant during the trial, the study treatment must be discontinued 
immediately. If the subject becomes pregnant while on treatment or within 3 days of discontinuing 
study treatment, the investigator must immediately notify 
 Drug Safety of this event and 
complete and forward a Pregnancy Surveillance Form to 
 Drug Safety within 24 hours of 
awareness of the event and in accordance with SAE reporting procedures described in APPENDIX 
3. The investigator must also notify the medical monitor or designee of this event within 24 hours 
of awareness of pregnancy. 
The pregnant subject will need to be followed up until the conclusion of the pregnancy for 
pregnancy outcomes. The safety data of the subject will continue to be collected under the same 
rules as instructed in Section 7.1.
Any pregnancy that occurs in a female partner of a male study subject should be reported to 
 
Drug Safety. In order for Sponsor or designee to collect any pregnancy surveillance information 
from the female partner, the female partner must sign an informed consent form for disclosure of 
this information. Information on this pregnancy will be collected on the Pregnancy Surveillance 
Form.
8.2.7
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
65
x
Any laboratory test result that is clinically significant or meets the definition of an SAE 
x
Any laboratory test result abnormality that required the subject to have study treatment 
discontinued or interrupted
x
Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value).
8.2.8
Potential Drug-Induced Liver Injury (DILI)
All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs (see 
Section 8.2 and APPENDIX 3 for reporting details). Wherever possible, timely confirmation of 
initial liver-related laboratory abnormalities should occur prior to the reporting of a potential DILI 
event.
Potential drug-induced liver injury is defined as: 
1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation > 3 times ULN
AND
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
3) No other immediately apparent possible causes of liver function test elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic.
8.2.9
Other Safety Considerations
Any significant worsening of a pre-existing medical condition noted during interim or final PE, 
ECG, x-ray filming, any other potential safety assessment required or not required by protocol 
should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
8.3
Overdose
For this study, taking more than 2 days’ worth of study treatment within a 24-hour time period will 
be considered an overdose.
In the event of an overdose the investigator should:
1) Contact the medical monitor immediately
2) Closely monitor the subject for AEs/SAEs and laboratory abnormalities
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the subject.
8.4
Safety
Planned time points for all safety assessments are listed in the Schedule of Activities (Section 1.3).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
66
8.4.1
Physical Examinations
A complete physical examination will include general appearance, vital signs, eyes, ears, nose, 
mouth, throat, neck, respiratory, cardiovascular, respiratory, GI/abdomen, lymphatic, 
musculoskeletal, skin, and psychiatric and neurologic exams. A targeted physical examination will 
include any organ system associated with an AE or a laboratory abnormality.
8.4.2
Vital signs
Refer to Schedule of Activities (Section 1.3).
8.4.3
Electrocardiograms
A 12-lead electrocardiogram will be performed at the visits indicated in the Schedule of Activities. 
The subject will remain supine for 5 to 10 minutes prior to the ECG and must have their lab work 
done after the tracing so that the ECG results remain as accurate as possible. The ECG results will 
be read by the primary study investigator or a designee.
8.4.4
Tuberculosis Screening and Chest Imaging
Chest imaging results and PE are part of the process to assess a subject’s eligibility, as outlined in 
Section 1.3 and as defined in exclusion criterion 3.c (Section 5.2). Chest imaging (eg, chest x-ray, 
chest CT scan) at the screening visit is required if not already performed and documented within 
6 months of obtaining written informed consent. A subject must not have active signs or symptoms 
of TB, as judged by the investigator, to be eligible for the study.
In addition to a complete PE and medical history to evaluate exposure to TB, all subjects will have 
a screening test, an IGRA (eg, QuantiFERON®-TB Gold) performed centrally. If unable to obtain 
central laboratory results, an IGRA test could be obtained locally, after consultation with the 
 
medical monitor. A subject with an indeterminate IGRA test result must be retested for 
confirmation. If the second result is again indeterminate, the subject will be excluded from the 
study. If the second result is positive, the subject should be considered as having LTBI provided 
there are no signs or symptoms of active TB. If the second result is negative, the subject may be 
eligible provided no other exclusion criterion for TB is met.
8.4.5
Clinical Safety Laboratory Assessments
x
Investigators must document their review of each laboratory safety report.
x
Hematology
Hemoglobin (Hgb)
Hematocrit (Hct)
White Blood Cell Count, including differential
Platelet Count
Chemistry
AST
ALT
Total Bilirubin
Total Protein
Albumin
Sodium
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
67
Direct Bilirubin (if total bilirubin > ULN)
Alkaline Phosphatase
Lactate Dehydrogenase (LDH)
Creatinine
Blood Urea Nitrogen (BUN)
Uric Acid 
Glucose (fasting at some visits)
Potassium
Chloride
Calcium
Phosphorus
Creatine Kinase (CK)*
Estimated Glomerular Filtration Rate (eGFR)
Urinalysis
Protein
Glucose
Blood
Leukocyte Esterase
Specific Gravity
pH
Microscopic Examination (reflex if abnormal)
Lipid Panel
Cholesterol (total)
High Density Lipoprotein (HDL)
Low Density Lipoprotein (LDL)
Triglycerides
Infectious Serologies
Hepatitis C Antibody with reflex to Hepatitis C RNA if positive
Hepatitis B Surface Antigen (HBsAg)
Hepatitis B Surface Antibody (HBsAb)
Hepatitis B Core Antibody (HBcAb)
Hepatitis B DNA Viral Load (HBV DNA)
HIV-1 and -2 antibody 
Other Analyses
Pregnancy test (WOCBP only: serum hCG test at screening, followed by urine hCG test every 
4 weeks)
Follicle-stimulating Hormone (FSH) (to confirm menopausal status [see APPENDIX 4], at 
screening) 
Hemoglobin A1C 
Thyroid-Stimulating Hormone (TSH)
x
If TSH above normal reference range, test free T4; if TSH below normal range, test 
free T4 & T3
High-Sensitivity C Reactive Protein (hs-CRP)
Serum Immunoglobulins (IgM, IgG, IgA, IgE)
*If CK > 2.5 × ULN, then reflex testing (ie, CK-MB, Troponin I) will be required.
8.4.5.1
Estimated Glomerular Filtration Rate (eGFR)
Glomerular filtration rate will be estimated using the Modification of Diet in Renal Disease 
(MDRD) equation at screening and during the study at select visits.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
68
The MDRD equation is as follows:45
eGFR = 175 × standardized SCr−1.154 × age−0.203 × 1.212 [if black] or 0.742 [if female]
Note: GFR is expressed as mL/min/1.73 m2 of body surface area and SCr (serum creatinine) is expressed in mg/dL.
Subjects with an eGFR <45mL/min will be excluded from participation
8.4.6
Depression Monitoring
Depression will be monitored by administration of the Eight-item Patient Health Questionnaire 
(PHQ-8) at screening and during visits as outlined in Section 1.3.
8.4.6.1
Eight-item Patient Health Questionnaire (PHQ-8)
The PHQ-8 is established as a valid diagnostic and severity measure for depressive disorders in 
large clinical studies.46 Each of the 8 questions is based on a 2-week recall and scored on a scale 
of 0 to 3 by a tick box as: Not at All, Several Days, More than Half the Days, and Nearly Every 
Day. A score of ≥ 10 is suggestive of moderate depressive symptoms (see APPENDIX 21).47 If a 
subject scores ≥ 15 on the PHQ-8 during the study, the investigator will review the situation and 
refer the subject to a mental health professional if deemed necessary.
8.4.7
Suicidal Ideation and Behavior (SIB) Monitoring
Subjects in this clinical trial will be monitored for suicidal ideation and behavior by the eC-SSRS 
(Section 8.4.7.1) at the visits outlined in the Schedule of Activities (Section 1.3). Subjects who 
answer “yes” to Questions 4 or 5 which indicates a suicidal ideation severity level of 4 or 5 or 
document suicidal behavior or suicidal attempts on the eC-SSRS will have their treatments 
discontinued and be immediately referred to a mental health professional for further evaluation. In 
addition, family members or caregivers of the subjects will be instructed to immediately report any 
suicidal ideation, suicidal behavior, or suicide attempt to the investigator.
8.4.7.1
electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)
The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a computer-automated, 
patient-reported version of the C-SSRS instrument that defines 11 categories of suicidal ideation 
and behavior events.48,49,50 The categories are as follows:
x
Suicidal ideation
1. Passive
2. Active: Nonspecific (no method, intent, or plan)
3. Active: Method, but no intent or plan
4. Active: Method and intent, but no plan
5. Active: Method, intent, and plan
x
Suicidal behavior
1. Completed suicide
2. Suicide attempt
3. Interrupted attempt
4. Aborted attempt
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
69
5. Preparatory actions toward imminent suicidal behaviors
x
Self-injurious behavior, no suicidal intent
APPENDIX 22 provides definitions of these categories.51
8.4.8
Imaging Safety Assessment
Not applicable.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
70
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
71
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
72
8.7
Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Economics parameters will not be 
evaluated in this study.
9
STATISTICAL CONSIDERATIONS
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
73
9.2
Populations for Analyses
For purposes of analysis, the following analysis sets will be used in this trial:
Enrolled Population: All subjects who sign informed consent.
Full Analysis Set (FAS): All subjects who were randomized to receive assigned study treatment.
Following the intent-to-treat principle, subjects will be analyzed according to the treatment group
assigned at randomization. The FAS will be the primary efficacy analysis population.
Per Protocol Set (PPS): A subset of the FAS who are compliant with study treatment and who 
do not have any relevant protocol deviations that may impact the coprimary efficacy endpoint 
assessments (Section 9.6.3). The PPS will be analyzed for the coprimary endpoint comparisons
according to the treatment assigned at randomization.
Randomized Withdrawal Population:
Defined as all Week 24 responder subjects who are 
re-randomized and received at least one dose of study treatment during the randomized withdrawal 
and maintenance period. Subjects will be analyzed according to the treatment assigned at Week 24.
As-treated Population:  All randomized subjects who take at least one dose of study treatment. 
Subjects will be analyzed according to treatment received. The As-treated population will be for 
safety analyses.
9.3
Endpoints 
9.3.1
Primary Endpoints
The coprimary efficacy endpoints for BMS-986165 compared to placebo at Week 16 are defined 
as:
x
sPGA 0/1 response assessed as a proportion of subjects with a sPGA score of 0 or 1
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
74
x
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement 
from baseline in the PASI score
9.3.2
Secondary Endpoints
9.3.2.1
Key Secondary Endpoints for Comparisons to Placebo
The key secondary endpoints for BMS-986165 compared to placebo at Week 16 are defined as:
x
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement 
from baseline in the PASI score
x
PASI 100 response assessed as a proportion of subjects who achieve a 100% improvement 
from baseline in the PASI score
x
sPGA 0 response assessed as a proportion of subjects with a sPGA score of 0
x
Change from baseline in PSSD symptom score
x
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score 
of 0 among subjects with a baseline PSSD symptom score ≥ 1
x
ss-PGA 0/1 assessed as a proportion of subjects with a ss-PGA score 0 or 1 among subjects 
with a baseline ss-PGA score ≥ 3
x
DLQI 0/1 assessed as a proportion of subjects with a DLQI score of 0 or 1 among subjects 
with a baseline DLQI score ≥ 2
x
PGA-F 0/1 assessed as a proportion of subjects with a PGA-F score of 0 or 1 among 
subjects with a baseline PGA-F score ≥ 3
x
pp-PGA 0/1 assessed as a proportion of subjects with a pp-PGA score of 0 or 1 among 
subjects with a baseline pp-PGA score ≥ 3
An additional key secondary endpoint to assess the maintenance and durability of efficacy of 
BMS-986165 during the randomized withdrawal period through Week 52 among Week 24 
PASI 75 responders compared with re-randomized placebo is defined as:
x
Time to relapse until Week 52
9.3.2.2
Key Secondary Endpoints for Comparisons to Apremilast
The key secondary endpoints for BMS-986165 compared to apremilast at Week 16 are defined as:
x
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement 
from baseline in the PASI score
x
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement 
from baseline in the PASI score
x
PASI 100 response assessed as a proportion of subjects who achieve a 100% improvement 
from baseline in the PASI score
x
sPGA 0/1 response assessed as a proportion of subjects with a sPGA score of 0 or 1
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
75
x
sPGA 0 response assessed as a proportion of subjects with a sPGA score of 0
x
Change from baseline in PSSD symptom score
x
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score 
of 0 among subjects with a baseline PSSD symptom score ≥ 1
x
ss-PGA 0/1 assessed as a proportion of subjects with a ss-PGA score 0 or 1 among subjects 
with a baseline ss-PGA score ≥ 3
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
76
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
77
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
78
9.4
Efficacy Analyses
Categorical data will be summarized as frequency counts and percentages. Continuous data will 
be summarized using n, mean, standard deviation, median, minimum, and maximum unless 
otherwise specified. Efficacy variables will be summarized for all visits in which the variable is 
assessed. Complete details of the planned analyses will be documented in the statistical analysis 
plan and finalized before database lock.
During the active-controlled comparator period data will be presented for the following treatments:
x
BMS-986165 6 mg QD
x
Apremilast 30 mg BID
x
Placebo
For the randomized withdrawal and maintenance period data will be presented for the following 
treatments for assessment of maintenance and durability of re-randomized Week 24 PASI 75 
responders originally randomized to BMS-986165 6 mg QD:
x
BMS-986165 6 mg QD
x
Placebo
For other summaries of the randomized withdrawal and maintenance period data will be presented 
for the following treatments:
x
All BMS-986165 6 mg QD (all subjects exposed to BMS-986165 6 mg QD; includes 
subjects on placebo during the randomized withdrawal and maintenance period that 
switched)
x
BMS-986165 6 mg QD (responders/nonresponders)
x
BMS-986165 6 mg QD→Placebo
x
Placebo-BMS-986165 6 mg QD (starting from Week 16 rather than Week 24)
x
Apremilast 30 mg BID→Placebo
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
79
x
Apremilast 30 mg BID→BMS-986165 6 mg QD
9.4.1
Coprimary Endpoint Analyses
The analysis model for the coprimary efficacy endpoints, sPGA 0/1 and PASI 75 (responder / non-
responder) at Week 16, will use stratified Cochran-Mantel-Haenszel (CMH) tests stratified by 
geographic region (US and rest of world), previous biologic use for psoriasis, psoriatic arthritis or 
other inflammatory disease (yes/no), and body weight (≥90 kg and <90 kg) to compare the 
response rates of BMS-986165 6 mg QD to placebo using the Week 16 data of the FAS. If expected 
cell counts are not sufficient for each strata level, then strata levels will be combined for the
analysis. The odds ratio (ratio of odds in BMS-986165 6 mg QD group to the /odds in placebo 
group) and the corresponding 2-sided 95% confidence interval (CI) will be provided. Estimates of 
proportions and their 2-sided 95% CIs will be provided.
9.4.1.1
Imputation Methods for Coprimary Endpoints
Non-responder imputation (NRI) will be used for coprimary efficacy endpoints for subjects who 
discontinue study or treatment of study prior to Week 16, start a protocol prohibited 
medication/therapy that could improve psoriasis during the first 16 weeks of treatment, or who 
have otherwise missing endpoint data at the specified timepoint. NRI will the primary method of 
imputation for the coprimary efficacy endpoints.
9.4.1.2
Sensitivity Analyses for the Coprimary Endpoints
The following imputation methods will be used in sensitivity analyses of the coprimary efficacy 
endpoints:
x
Last observation carried forward (LOCF) for subjects with missing values at Week 16
x
For subjects with missing values at Week 16, LOCF will be used for placebo subjects. NRI 
will be used for BMS-986165 6 mg QD subjects. This will include subjects who 
discontinue early, start a protocol prohibited medication/therapy prior to Week 16 that 
could improve psoriasis, or who have otherwise missing endpoint data at Week 16
9.4.1.3
Supportive Analyses for the Coprimary Endpoints
The coprimary efficacy endpoints will be analyzed using the Week 16 data of the PPS using the 
analysis described in Section 9.4.1 and the imputation methods described in Section 9.4.1.1.
Additionally, the coprimary efficacy endpoints for the FAS will be analyzed with a logistic 
regression model with treatment, geographic region, prior biologic treatment use, and body weight 
strata. Proportions and 2-sided 95% confidence intervals will be provided.
9.4.1.4
Subgroup Analyses for the Coprimary Endpoints
Subgroup analyses will be conducted for the coprimary efficacy endpoints for the FAS using the 
analysis described in Section 9.4.1 and the imputation methods described in Section 9.4.1.2.
Subgroups to be evaluated may include the following:
x
Gender
x
Age categories (< 65; ≥65)
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
80
x
Race
x
Body weight categories (< 90 kg; ≥90 kg)
x
Prior biologic use (yes/no)
x
Prior systemic treatment of psoriasis (yes/no)
x
Geographic region (per stratification factor; US or rest of world)
9.4.2
Secondary Endpoint Analyses 
The analysis model for the binary secondary endpoints will use stratified CMH tests stratified by 
geographic region (US and rest of world), prior biologic treatment use (yes/no), and body weight 
(≥90 kg and <90 kg) to compare the response rates of BMS-986165 6 mg QD to placebo or 
apremilast for the FAS. If expected cell counts are not sufficient for each strata level, then strata 
levels will be combined for the analysis. The odds ratio (ratio of odds in BMS-986165 6 mg QD 
group to the /odds in placebo group or active comparator group) and the corresponding 2-sided 
95% CI will be provided.
The analysis model for continuous secondary endpoints will use analysis of covariance 
(ANCOVA) with treatment, geographic region (US and rest of world), prior biologic treatment 
use (yes/no), and body weight (≥90 kg and <90 kg) as fixed effects. The baseline value will be
added into the model as a covariate. Treatment differences based on least-squares (LS) means and 
the corresponding 2-sided 95% CIs will be provided for the difference between BMS-986165 6 mg 
QD and placebo or active comparator depending on the endpoint being assessed.
9.4.2.1
Imputation Methods for Secondary Endpoints
NRI will be applied to the analyses of binary secondary efficacy endpoints for subjects who 
discontinue early, start a protocol prohibited medication/therapy that could improve psoriasis, or 
who have otherwise missing endpoint data at the specified timepoint. 
For continuous secondary efficacy endpoints, baseline observation carried forward (BOCF) will 
be used for subjects who discontinue study treatment due to:
x
Lack of efficacy
x
Adverse events
Additionally, BOCF will be used for subjects who start a protocol prohibited medication/therapy 
that could improve psoriasis. LOCF will be used for all other missing data.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
81
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
82
9.4.4
Time-to-Relapse Endpoint
The Kaplan-Meier product limit method will be used to estimate the distribution curves for 
time-to-relapse during the Randomized Withdrawal and Maintenance Period. Relapse is defined 
as the first loss of 50% or greater of the PASI percent improvement at Week 24 any time during 
the Randomized Withdrawal and Maintenance Period. Treatment comparisons of subjects re-
randomized at Week 24 to BMS-986165 6 mg QD or placebo will be performed using the log-
rank test stratified by geographic region (US and rest of world), prior biologic treatment use 
(yes/no), and body weight (≥90 kg and <90 kg).
9.5
Safety Analyses
Safety data will be analyzed for AEs, SAEs, laboratory analytes, vital signs, ECGs, and suicidality 
and depression. Safety will be summarized using the As-treated population for the active 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
83
comparator-controlled period, randomized withdrawal period, and overall. Categorical data will 
be summarized as frequency counts and percentages. Continuous data will be summarized using 
n, mean, standard deviation, median, minimum, and maximum unless otherwise specified.
During the active comparator-controlled period, data will be presented for the following 
treatments:
x
BMS-986165 6 mg QD
x
Apremilast 30 mg BID
x
Placebo
For the randomized withdrawal and maintenance period data will be presented for the following 
treatments for assessment of maintenance and durability of re-randomized Week 24 PASI 75 
responders originally randomized to BMS-986165 6 mg QD:
x
BMS-986165 6 mg QD
x
Placebo
For other summaries of the randomized withdrawal and maintenance period data will be presented 
for the following treatments:
x
All BMS-986165 6 mg QD (all subjects exposed to BMS-986165 6 mg QD; includes 
subjects on placebo during the randomized withdrawal and maintenance period that 
switched)
x
BMS-986165 6 mg QD (responders/nonresponders)
x
BMS-986165 6 mg QD-Placebo
x
Placebo-BMS-986165 6 mg QD (starting from Week 16 rather than Week 24)
x
Apremilast 30 mg BID-Placebo
x
Apremilast 30 mg BID-BMS-986165 6 mg QD
9.5.1
Adverse Events
Treatment-emergent adverse events (TEAEs), SAEs, deaths, AEs leading to study treatment 
discontinuation, AEs by maximum severity, and AEs by relationship will be summarized by the 
MedDRA system organ class and preferred term. All TEAEs as well as AEIs, and each AE 
adjudicated category (ie, infections, cardiovascular, and suicidal ideation/behavior) will also be 
summarized by preferred term sorted by decreasing frequency. 
9.5.2
Vital Signs and ECGs
Vital signs and ECGS will be summarized as raw, change from baseline, and change from 
maximum postbaseline value. Incidence of abnormal ECG findings will also be summarized.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
84
9.5.3
Clinical Laboratory Tests
Laboratory analytes will be summarized as raw, change from baseline, and change from maximum 
postbaseline value. Incidence of abnormal, high, or low values will be summarized.
9.5.4
Suicidality and Depression Assessments
Suicidality and depression will be assessed using eC-SSRS and PHQ-8. Data will be summarized, 
as applicable.
9.6
Other Analyses
9.6.1
Demographics and Baseline Data
Demographics and baseline data will be summarized by treatment for each applicable analysis 
population. Categorical data will be summarized as frequency counts and percentages. Continuous 
data will be summarized using n, mean, standard deviation, median, minimum, and maximum 
unless otherwise specified.
9.6.2
Prior and Concomitant Medications
Prior and concomitant medications, categorized by medication group and subgroup according to 
the World Health Organization (WHO) Drug Dictionary, will be summarized by treatment for the 
As-treated population. Medications with an end date prior to the first dose of study drug will be
considered prior medications.
9.6.3
Relevant Protocol Deviations
Relevant protocol deviations are deviations that can have an impact on the primary efficacy 
endpoints. The impact of relevant protocol deviations on the primary efficacy results will be 
assessed by excluding subjects from the FAS to define the PPS in supportive analyses of the 
primary efficacy endpoints. Relevant protocol deviations to be considered regarding exclusion of 
subjects from the FAS will include the following:
x
Subject randomized but did not take any study treatment
x
Subject failed to meet any study inclusion criteria but was randomized to receive study 
treatment
x
Subject met a study exclusion criterion which may have an impact on the coprimary 
efficacy endpoints but was randomized to receive study treatment
x
Subject non-compliant with study treatment within the first 16 weeks of treatment; defined 
as <80% compliant with study treatment 
x
Subject took prohibited concomitant medication prior to Week 16
x
Subject received treatment different to intended treatment at any visit prior to Week 16
All subjects with relevant protocol deviations will be identified prior to database lock. Relevant 
protocol deviations will be summarized by treatment group and deviation category for the FAS
population.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
85
9.7
Interim Analyses
No interim analysis is currently planned.
9.8
Statistical Impacts Due to COVID-19
9.8.1
Impact on Efficacy Endpoints 
There are no COVID-19-related impacts to the Week 16 efficacy endpoints as all subjects 
remaining in the trial completed the Week 16 visit prior to COVID-19 site restrictions. Efficacy 
endpoints involving Week 24 and later visits may be impacted by COVID-19 in the form of 
missing data and/or a treatment assignment defaulting to BMS-986165.
Censoring rules will be applied to the PASI 75 time-to-relapse endpoint for re-randomized subjects 
due to the following COVID-19-related issues post Week 24:
x
Subject study treatment assignment was defaulted to BMS-986165 because they had a 
remote safety monitoring visit due to COVID-19 and efficacy assessments were not 
performed. The subject will be censored at the time of the remote visit if relapse had not 
been observed already;
x
Subject has missing visit(s) (ie, efficacy assessments not performed) after Week 24 and 
assuming relapse was not observed prior to missed visit(s):
o
If the subject returns at a later visit and is found to have relapsed, midpoint 
imputation will be used to determine time-to-relapse (ie, midpoint of the censoring 
interval).
o
If the subject returns at a later visit and has not relapsed, then the subject will 
continue to be evaluated for relapse.
o
If the subject is discontinued from study treatment, then the subject will be 
censored at the time of study treatment discontinuation.
Sensitivity analyses for time-to-relapse may be performed with additional details provided in the 
statistical analysis plan prior to database lock.
Data handling due to COVID-19-related issues for other efficacy endpoints 
 will 
be described in the statistical analysis plan prior to database lock.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
86
9.8.2
Impact on Safety Variables
No modifications are planned for the analysis of safety data due to COVID-19-related issues. There 
will not be any additional safety data handling considerations for missing data or treatment 
interruptions due to COVID-19.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
87
10
REFERENCES
1
Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic 
review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85.
2
Kupetsky EA, Keller M. Psoriasis vulgaris: an evidence-based guide for primary care. J Am 
Board Fam Med 2013;26(6):787-801.
3
World Health Organization. Global Report on psoriasis. WHO 2016.
4
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis 2005;64(Suppl II):ii18-ii23.
5
Queiro R, Tejón P, Alonso S, Coto P. Age at disease onset: a key factor for understanding 
psoriatic disease. Rheumatology (Oxford) 2014;53(7):1178-85.
6
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe 
psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan;303(1):1-10.
7
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much 
disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7
8
Nestle FO, Kaplan DH, Barker J. Mechanisms of Disease: Psoriasis. N Engl J Med 
2009;361:496-509.
9
Mehta NN, Afzar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe 
psoriasis are at increased risk of cardiovascular mortality: cohort study using the General 
Practice Research Database. European Heart J 2010;31:1000–1006.
10 Novartis. Rheumatrex® (methotrexate). United States Prescribing Information. 2016.
11 Novartis. Neoral® (cyclosporine). United States Prescribing Information. 2009.
12 Celgene. Otezla® (apremilast). United States Prescribing Information. 2017.
13 Abbvie. Humira® (adalimumab). United States Prescribing Information. 2017.
14 Janssen Biotech. Remicade® (infliximab). United States Prescribing Information. 2013.
15 Janssen Biotech. Stelara® (ustekinumab). United States Prescribing Information. 2016.
16 Novartis. Cosentyx® (sekukinumab). United States Prescribing Information. 2015.
17 Eli Lilly. Taltz® (ixekizumab). United States Prescribing Information. 2017.
18 Valeant. Siliq® (brodalumab). United States Prescribing Information. 2017.
19 Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, Treatment 
Trends, and Treatment Dissatisfaction Among Subjects with Psoriasis and Psoriatic Arthritis 
in the United States. Findings from the National Psoriasis Foundation Surveys, 2003-
2011. JAMA Dermatol 2013;149(10):1180–1185.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
88
20 Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the 
immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-56.
21 Tokarski JS, Zupa-Fernandez A, Tredup JA, et al.. Tyrosine Kinase 2-Mediated Signal 
Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of its 
Pseudokinase Domain. J Biol Chem 2015;290:11061-11074.
22 Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain 
underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad 
Sci U S A. 2003;100:11594-11599.
 
 
 
24 Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 
2005;64:ii65-ii68.
25 Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 
1978;157(4):238-44.
26 Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns. 1996;22:230-1.
27 Thomas CL, Finlay AY. The 'handprint' approximates to 1% of the total body surface area 
whereas the 'palm minus the fingers' does not. Br J Dermatol. 2007;157(5):1080-1.
28 Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch 
Dermatol. 1992;128:1129–30.
29 Kragballe K, Menter A, Lebwohl M, et al. Long-term management of scalp psoriasis: 
perspectives from the international psoriasis council. J Dermatol Treat. 2013;24:188-192.
 
 
31 Tan EST, Chong W-S, Liang Tey H. Nail psoriasis: a review. Am J Clin Dermatol. 
2012;13:375-388.
 
 
33 Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, 
in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-
005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis 
(ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 
2016;75:99-105.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
89
 
 
35 Feldman SR. Development of a patient-reported outcome questionnaire for use in adults with 
moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. Journal of 
Dermatology & Dermatologic Surgery. 2016;20:19–26.
36 Mathias SD. Measurement properties of a patient-reported outcome measure assessing
psoriasis severity: The psoriasis symptoms and signs diary. Journal of Dermatological 
Treatment. 2016;27(4):322-327.
37 Armstrong A, Puig L, Langley R, et al. Validation of psychometric properties and development 
of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase 
III 
clinical 
trial. 
Journal 
of 
Dermatological 
Treatment. 
2017: 
1-31.
DOI: 
10.1080/09546634.2017.1364694.
38 Finlay, AY, Khan, GK: Dermatology Life Quality Index (DLQI): A simple practical measure 
for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
 
 
 
 
 
44 Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. J Am Acad Dermatol 
2007;57(4):581-7
45 Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized 
serum creatinine values in the modification of diet in renal disease study equation for 
estimating glomerular filtration rate. Ann Intern Med 2006;145(4):247–54
46 Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the 
general population. J Affect Disord. 2009;114(1-3):163-173.
47 Dhingra SS, Kroenke K, Zack MM, Strine TW, Balluz LS. PHQ-8 Days: a measurement option 
for DSM-5 Major Depressive Disorder (MDD) severity. Population Health Metrics. 2011;9:11. 
doi:10.1186/1478-7954-9-11.
48 The Federal Register. Guidance for Industry- Suicidal ideation and behavior: prospective 
assessment 
of 
occurrence 
in 
clinical 
trials. 
(06-Aug-2012). 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved  BMS Confidential
90
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidanc
es/UCM225130.pdf. Accessed 22-Mar-2018.
49 Greist JH, Mundt JC, Gwaltney CJ, Jefferson JW, Posner K. Predictive value of baseline 
electronic Columbia–Suicide Severity Rating Scale (eC–SSRS) assessments for identifying 
risk of prospective reports of suicidal behavior during research participation. Innov Clin 
Neurosci. 2014;11(9–10):23–31.
50 Mundt JC, Greist JH, Jefferson JW, Federico M, Mann JJ, Posner K. Prediction of suicidal 
behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the 
electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 2013;74(9):887-893.
51 Posner, K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm 
of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric 
Suicidal Risk Analysis of Antidepressants. Am J Psychiatry. 2007;164:1035-1043.
52 Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate 
pain in millimetres? Pain. 1997;72(1-2):95-7.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
91
11
APPENDICES
APPENDIX 1 
ABBREVIATIONS AND TRADEMARKS .............................................92 
APPENDIX 2 
STUDY GOVERNANCE CONSIDERATIONS......................................96 
APPENDIX 3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING .............................104 
APPENDIX 4 
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS 
AND METHODS OF CONTRACEPTION............................................108 
APPENDIX 5 
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF 
PSORIASIS (sPGA) ................................................................................112 
APPENDIX 6 
PSORIASIS AREA AND SEVERITY INDEX (PASI)..........................113 
APPENDIX 7 
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA) ..................................................................................................114 
 
APPENDIX 9 
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS  
(PGA-F) ...................................................................................................117 
 
APPENDIX 11 
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA).......................................................................120 
APPENDIX 13 
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD) .....................122 
APPENDIX 14 
DERMATOLOGY LIFE QUALITY INDEX (DLQI)............................123 
APPENDIX 20 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE....................................................................135 
APPENDIX 21 
EIGHT ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8)........136 
APPENDIX 22 
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS.........................................................................................137 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
92
APPENDIX 1
ABBREVIATIONS AND TRADEMARKS
Term
Definition
 
 
AE
adverse event
AEI
adverse event of interest
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
Anti-HCV
hepatitis C virus antibody
AST
aspartate aminotransferase
 
BID
twice daily
BMS
Bristol-Myers Squibb
BSA
body surface area
BUN
blood urea nitrogen
CFR
Code of Federal Regulations
CI
confidence interval
Cmax
maximum plasma concentration
CMH
Cochran-Mantel-Haenszel 
CK
creatine kinase
CT
computed tomography
 
CYP450
cytochrome P450
DILI
drug-induced liver injury
DLQI
Dermatology Life Quality Index
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
93
Term
Definition
DMC
Data Monitoring Committee
DNA
deoxyribonucleic acid
ECG
electrocardiogram
eCRF
electronic case report form
eC-SSRS
electronic Columbia-Suicide Severity Rating 
Scale
eGFR
Estimated Glomerular Filtration Rate
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GI
gastrointestinal
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus 
hCG
human chorionic gonadotropin
Hct
hematocrit
HCV
hepatitis C virus
HDL
high density lipoprotein
Hgb
hemoglobin
HIV
human immunodeficiency virus
hs-CRP
high-sensitivity C-reactive protein
IB
Investigator Brochure
ICF
informed consent form
IEC
Independent Ethics Committee
IFN
interferon
IFNJ
interferon gamma
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
94
Term
Definition
IGRA
interferon gamma release assay
IL
interleukin
IM
intramuscular
IMP
investigational medicinal product
IP
investigational product 
IRT
interactive response technology
ITT
intent-to-treat
IV
intravenous
JAK
Janus kinase
LDH
lactate dehydrogenase
LDL
low density lipoprotein
LTBI
latent tuberculosis infection
MACE
Major Adverse Cardiovascular Events
MedDRA
Medical Dictionary for Regulatory Activities
NRI
non-responder imputation
PASE
psoriatic arthritis screening and evaluation
PASI
Psoriasis Area and Severity Index
PD
pharmacodynamics
PE
physical examination
PHQ-8
Eight-Item Patient Health Questionnaire
PK
pharmacokinetics
 
pp-PGA
palmoplantar Physician’s Global Assessment
PsA
psoriatic arthritis
PSSD
Psoriasis Symptoms and Signs Diary
QD
once daily
QOD
every other day
PGA-F
Physician Global Assessment- Fingernails
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
95
Term
Definition
PUVA
Psoralens with ultraviolet A
RNA
ribonucleic acid 
SAE
serious adverse event
SIB
Suicidal Ideation and Behavior
sPGA
static Physician Global Assessment
ss-PGA
scalp specific Physician’s Global Assessment
STAT
signal transducer and activator of 
transcription
TB
tuberculosis
T4
thyroxine
T3
triiodothyronine
 
TSH
thyroid-stimulating hormone
TNF
tumor necrosis factor 
TYK2
tyrosine kinase 2
ULN
upper limit of normal
UVB
ultraviolet B
WOCBP
women of childbearing potential
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
96
APPENDIX 2
STUDY GOVERNANCE CONSIDERATIONS
Regulatory and Ethical Considerations
Good Clinical Practice
This study will be conducted in accordance with:
x
Good Clinical Practice (GCP), 
x
as defined by the International Council for Harmonisation (ICH)
x
in accordance with the ethical principles underlying European Union Directive 2001/20/EC
x
United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) 
x
applicable local requirements.
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive approval/favorable opinion by Institutional Review 
Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in connection with the study or the 
protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity 
of the subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
Institutional Review Board/Independent Ethics Committee
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The investigator 
or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates. 
The investigator, Sponsor, or designee should provide the IRB/IEC with reports, updates, and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
Compliance with the Protocol and Protocol Revisions
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
97
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s) the deviation or change will be submitted, as soon 
as possible to:
x
IRB/IEC
x
Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
Financial Disclosure
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
Informed Consent Process
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the subject volunteers to participate. 
Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample 
informed consent form which will include all elements required by ICH, GCP, and applicable 
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Investigators must:
x
Provide a copy of the consent form and written information about the study in the language in 
which the subject is most proficient prior to clinical study participation. The language must be 
non-technical and easily understood. 
x
Allow time necessary for subject or subject's legally acceptable representative to inquire about 
the details of the study.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
98
x
Obtain an informed consent signed and personally dated by the subject or the subject's legally 
acceptable representative and by the person who conducted the informed consent discussion. 
x
Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior to the beginning of the study, 
and after any revisions are completed for new information.
If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his or her 
informed consent during the study, consent must additionally be obtained from the subject.
Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legally acceptable representative or legal guardian, 
of all pertinent aspects of the study and of any new information relevant to the subject's willingness 
to continue participation in the study. This communication should be documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records.
For minors, according to local legislation, one or both parents or a legally acceptable representative 
must be informed of the study procedures and must sign the informed consent form approved for 
the study prior to clinical study participation. The explicit wish of a minor, who is capable of 
forming an opinion and assessing this information to refuse participation in, or to be withdrawn 
from, the clinical study at any time should be considered by the investigator. 
Minors who are judged to be of an age of reason must also give their written assent.
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with his or her 
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The explicit wish of a subject who is unable to give his or 
her written consent, but who is capable of forming an opinion and assessing information to refuse 
participation in, or to be withdrawn from, the clinical study at any time should be considered by 
the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
Source Documents
The investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
99
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
Study Treatment Records
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:
x
amount received and placed in storage area
x
amount currently in storage area
x
label identification number or batch 
number
x
amount dispensed to and returned by each 
subject, 
including 
unique 
subject 
identifiers
x
amount transferred to another area/site for 
dispensing or storage
x
nonstudy disposition (eg, lost, wasted) 
x
amount destroyed at study site, if 
applicable
x
amount returned to BMS
x
retain 
samples 
for 
bioavailability/bioequivalence, 
if 
applicable 
x
dates and initials of person responsible for 
Investigational 
Product 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
100
If
Then
dispensing/accountability, 
as 
per 
the 
Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced from 
the sites stock or commercial supply, or a 
specialty pharmacy)
The 
investigator 
or 
designee 
accepts 
responsibility for documenting traceability and 
study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.   
These records should include:
x
label identification number or batch 
number 
x
amount dispensed to and returned by each 
subject, 
including 
unique 
subject 
identifiers
x
dates and initials of person responsible for 
Investigational 
Product 
dispensing/accountability, 
as 
per 
the 
Delegation of Authority Form.
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and paper Pregnancy Surveillance form, respectively. If 
electronic SAE form is not available, a paper SAE form can be used.
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
101
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task. For electronic CRFs, review and approval/signature is completed electronically through the 
electronic data capture tool. The investigator must retain a copy of the CRFs including records of 
the changes and corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the electronic data capture tool using the unique user account 
provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals
Monitoring
Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of study records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents.
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee. 
Records Retention
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
Return of Study Treatment
For this study, study treatments (those supplied by BMS, a vendor or sourced by the investigator) 
such as partially used study treatment containers, vials and syringes may be destroyed on site. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
102
If
Then
Study treatments supplied by BMS (including 
its vendors
Any unused study treatments supplied by BMS 
can only be destroyed after being inspected and 
reconciled by the responsible Study Monitor 
unless study treatments containers must be 
immediately destroyed as required for safety, 
or to meet local regulations (eg, cytotoxics or 
biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or 
commercial 
supply, 
or 
a 
specialty 
pharmacy)
It 
is 
the 
investigator’s 
or 
designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
x
On-site disposal practices must not expose humans to risks from the drug.
x
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
x
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
x
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
x
Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non- study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
103
Clinical Study Report and Publications
A Signatory Investigator must be selected to sign the CSR.
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
x
External Principal Investigator designated at protocol development
x
National Coordinating Investigator 
x
Study Steering Committee chair or their designee
x
Subject recruitment (eg, among the top quartile of enrollers)
x
Involvement in trial design
x
Regional representation (eg, among top quartile of enrollers from a specified region or country)
x
Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing study site or investigator participation in the 
study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTA.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
104
APPENDIX 3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING
Adverse Events
Adverse Event Definition:
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study drug, whether or not 
considered related to the study drug.
Events Meeting the AE Definition
x
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. Note that 
abnormal lab tests or other safety assessments should only be reported as AEs if the 
final diagnosis is not available. Once the final diagnosis is known, the reported term 
should be updated to be the diagnosis.
x
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
x
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
x
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
x
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose as a verbatim term (as reported by 
the investigator), should not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae and should specify "intentional overdose" as the 
verbatim term.
Events NOT Meeting the AE Definition
x
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads 
to the procedure is the AE.
x
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
105
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met.
Serious Adverse Events
Serious Adverse Event Definition: Any untoward medical occurrence that, at any dose:
Results in death
Is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see note 
below)
Note: The following hospitalizations are not considered SAEs in BMS clinical studies: 
x
a visit to the emergency room or other hospital department < 24 hours, that does not 
result in admission (unless considered an important medical or life-threatening event)
x
elective surgery, planned prior to signing consent
x
admissions as per protocol for a planned medical/surgical procedure
x
routine health assessment requiring admission for baseline/trending of health status 
(eg, routine colonoscopy)
x
medical/surgical admission other than to remedy ill health and planned prior to entry 
into the study. Appropriate documentation is required in these cases.
x
admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (eg, lack of housing, economic 
inadequacy, caregiver respite, family circumstances, administrative reason)
x
admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols)
Results in persistent or significant disability or permanent damage
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above). Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization. Potential drug-induced liver injury (DILI) is also considered an important 
medical event (see Section 8.2.8 for the definition of potential DILI). 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
106
Pregnancy and potential DILI must follow the same transmission timing and processes to BMS as 
used for SAEs (see Section 8.2.6 for reporting pregnancies).
Evaluating AEs and SAEs
Follow-up of AEs and SAEs
Assessment of Intensity
The intensity of AEs is determined by a physician and will use the following levels:
x
Mild: An event that is easily tolerated by the subject, causing minimal discomfort, 
and not interfering with everyday activities.
x
Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.
x
Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utilized for 
rating the intensity of an even; and both AEs and SAEs can be assessed as severe.
Assessment of Causality
x
The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE. A “reasonable possibility of a relationship” 
conveys that there are facts, evidences, and/or arguments to suggest a causal 
relationship rather than a relationship cannot be ruled out.  
x
The investigator will use clinical judgment to determine the relationship.
x
Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.
x
The investigator will also consult the Investigator Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
x
For each AE/SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality.
x
There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor. However, it is very 
important that the investigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to Sponsor.
x
The investigator may change his/her opinion of causality in light of follow-up
information and send a SAE follow-up report with the updated causality 
assessment.
x
The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
107
If only limited information is initially available, follow-up reports are required. Note: 
Follow-up SAE reports must include the same investigator term(s) initially reported. 
If an ongoing SAE changes in its intensity or relationship to study drug or if new 
information becomes available, the SAE report must be updated and submitted within 
24 hours to BMS (or designee) using the same procedure used for transmitting the initial 
SAE report.
All SAEs must be followed to resolution or stabilization.
Reporting of SAEs to Sponsor or Designee
SAEs, whether related or not related to study drug, and pregnancies must be reported to 
 Drug Safety within 24 hours of awareness of the event.
SAEs must be recorded on the SAE Report Form. For studies capturing SAEs through 
electronic data capture (EDC), electronic submission is the required method for reporting. 
In the event the electronic system is unavailable for transmission, paper forms must be used 
and submitted immediately. When paper forms are used, the original paper forms are to 
remain on site.
Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
SAE Fax Number: 
Americas: 
Europe/East Asia Pacific:
SAE Telephone Contact - For questions on SAE/pregnancy reporting, please call:
Americas: 
Europe/East Asia Pacific: 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
108
APPENDIX 4
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
x
Premenarchal
x
Premenopausal female with 1 of the following:

Documented hysterectomy

Documented bilateral salpingectomy

Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the subject’s medical records, 
medical examination, or medical history interview.
x
Postmenopausal female

A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 45 
years in the absence of other biological or physiological causes. In addition, females under 
the age of 55 years must have a serum follicle-stimulating hormone (FSH) level > 
40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their judgment 
in checking serum FSH levels. 
x
1 week minimum for vaginal hormonal products (rings, creams, gels)
x
4 week minimum for transdermal products
x
8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the woman can be considered 
postmenopausal.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
109
CONTRACEPTION GUIDANCE FOR FEMALE SUBJECTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 3 days after the end of study treatment, 
plus 30 days.
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
x
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulationb

oral 

intravaginal 

transdermal 
x
Progestogen-only hormonal contraception associated with inhibition of ovulationb

oral 

injectable 
Highly Effective Methods That Are User Independent
x
Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation b
x
Intrauterine device (IUD)c
x
Intrauterine hormone-releasing system (IUS)c
x
Bilateral tubal occlusion
x
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used. 
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
110
x
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the subject.
x
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
x
WOCBP subjects who choose complete abstinence must continue to have pregnancy tests, 
as specified in Section 5.1.
x
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP subjects chooses to forego complete abstinence 
NOTES: 
a  Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
subjects participating in clinical studies. 
b  Hormonal contraception may be susceptible to interaction with the study treatment, which may 
reduce the efficacy of the contraceptive method. Hormonal contraception is permissible only 
when there is sufficient evidence that the IMP and other study medications will not alter 
hormonal exposures such that contraception would be ineffective or result in increased 
exposures that could be potentially hazardous. In this case, alternative methods of 
contraception should be utilized. 
c  Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of 
contraception in the absence of definitive drug interaction studies when hormone exposures 
from intrauterine devices do not alter contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year when used consistently and correctly.
x
Male or female condom with or without spermicide. Male and female condoms cannot be 
used simultaneously
x
Diaphragm with spermicide
x
Cervical cap with spermicide
x
Vaginal Sponge with spermicide
x
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
111
Unacceptable Methods of Contraception
x
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
x
Withdrawal(coitus interruptus).
x
Spermicide only
x
Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE SUBJECTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL
Male subjects with female partners of childbearing potential are eligible to participate if they agree 
to the following during the treatment and until the end of relevant systemic exposure.
x
Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.
x
Male subjects are required to use a condom for study duration and until the end of relevant 
systemic exposure defined as 3 days after the end of treatment in the male subject.
x
Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 3 days after the end of 
treatment in the male subject.
x
Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 3 days after the end of treatment. 
x
Refrain from donating sperm for the duration of the study treatment and for 3 days after the 
end of treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 8.2.6 and APPENDIX 3.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
112
APPENDIX 5
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF PSORIASIS 
(sPGA)
The static PGA is used to determine the subject’s psoriasis lesions overall at a given time point. 
Overall lesions will be graded for erythema, induration, and scaling based on the scales below. 
The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA 
score.
Characteristics
Score
Rating Score
Erythema (E)
(averaged over the whole body)
0 = No evidence of erythema, but post inflammatory 
hyper/hypopigmentation changes may be present
1 = Faint erythema
2 = Light red coloration
3 = Moderate red coloration 
4 = Bright red coloration
Induration (I)
(averaged over the whole body)
0 = No evidence of plaque elevation
1 = Minimal plaque elevation, barely palpable, = 0.25 mm
2 = Mild plaque elevation, slight but definite 
elevation, indistinct edge, = 0.5 mm
3 = Moderate plaque elevation, elevated with distinct edges, 
= 0.75 mm
4 = Severe plaque elevation, hard/sharp 
borders, ≥ 1 mm
Scaling (S)
(averaged over the whole body)
0 = No evidence of scaling
1 = Minimal; occasional fine scaling
2 = Mild; fine scale dominates
3 = Moderate; coarse scale predominates
4 = Severe; thick scale predominates
E + I + S = / 3 = (Total Average)
Physician’s Static Global Assessment based upon above Total Average 
0 = Clear, except for residual discoloration 
1 = Almost clear -majority of lesions have individual scores for E + I + S / 3 that averages 1
2 = Mild -majority of lesions have individual scores for E + I + S / 3 that averages 2 
3 = Moderate -majority of lesions have individual scores for E + I + S / 3 that averages 3 
4 = Severe -majority of lesions have individual scores for E + I + S / 3 that averages 4 
Note: Scores should be rounded to the nearest whole number. If total ≤ 1.49, score = 1; if 
total ≥ 1.50, score = 2.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
113
APPENDIX 6
PSORIASIS AREA AND SEVERITY INDEX (PASI)
Psoriasis Area and Severity Index (PASI); a quantitative rating scale for measuring the severity of 
psoriatic lesions based on area coverage and plaque appearance. Please complete all sections of 
the table below.
Plaque Characteristic
Rating score
Body region (and weighting factor)
Head
Upper Extremities
Trunk
Lower Extremities
Erythema (Redness)
0 = None
1 = Slight
2 = Moderate
3 = Severe
4 = Very severe
Infiltration (Thickness)
Desquamation (Scaling)
Add together each of the 3 scores for each of the body regions to give 4 separate sub totals.
Sub Totals A1 =
A2 =
A3 =
A4 =
Multiply each subtotal by amount of body surface area represented by that region, ie, A1 x 0.1 for head, A2 x 0.2 for upper 
extremities, A3 x 0.3 for trunk, A4 x 0.4 for lower extremities to give a value B1, B2, B3 and B4 for each body region respectively
A1 x 0.1 = B1
A2 x 0.2 = B2
A3 x 0.3 = B3
A4 x 0.4 = B4
B1 =
B2 =
B3 =
B4 =
Degree of involvement 
as % for each body 
region affected; (score 
each region with score 
between 0-6)
0 = None
1 = 1-9 %
2 = 10-29%
3 = 30-49%
4 = 50 -69%
5 = 70-89%
6 = 90-100%
For each body region multiply sub total B1, B2, B3 and B4 by the score (0-6) of the % of body region involved to give 4 subtotals 
C1, C2, C3 and C4
B1 x score = C1
B2 x score = C2
B3 x score = C3
B4 x score = C4
C1 =
C2 =
C3 =
C4 =
The patient’s PASI score is the sum of C1 + C2 + C3 + C4
PASI=
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
114
APPENDIX 7
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA)
Please rate overall scalp psoriasis severity by selecting the overall score based on the following 
rating scale:
Score
Category
Description
0
Absence of 
Disease
No evidence of redness, no evidence of thickness, and no 
evidence of scaliness on the scalp
1
Very Mild Disease
The overall clinical picture consists of flat lesions with barely 
perceptible erythema, with or without a trace of overlying fine 
scale
2
Mild Disease
The overall clinical picture consists of lesions with mild 
erythema, slight, but definite, thickness, and a thin scale layer
3
Moderate Disease
The overall clinical picture consists of lesions with moderate 
erythema, a moderate thickness, and a moderate scaled layer
4
Severe Disease
The overall clinical picture consists of lesions with bright 
erythema, severe thickness, and a severe, coarse thick scale 
layer
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
115
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
116
APPENDIX 9
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS 
(PGA-F)
For this assessment in subjects with psoriasis fingernail involvement, the overall condition of the 
fingernails is rated by the investigator on a 0-4 (5-point) scale. The overall score assigned is based 
on the higher of the nail bed/nail matrix score:
Nail Bed Signs
Nail Matrix Signs
Clear
0
Onycholysis- consistent with a normal nail
AND
Hyperkeratosis- none
AND
Splinter Hemorrhages-consistent with non-psoriatic splinter 
hemorrhages
AND
Nail Bed Erythema- none
No nonpsoriatic nail plate 
irregularities including 
pitting, crumbling, Beau’s 
lines, senile onychorrhexis, 
and nonpsoriatic leukonychia
Minimal
1
Onycholysis- < 10% involved on all nails
OR
Hyperkeratosis- present, but barely detectable elevation of 
nail plate
OR
Nail Bed Erythema- faint
AND
Splinter Hemorrhages- consistent with non-psoriatic splinter 
hemorrhages
No more than 5 pits or 
psoriatic leukonychia on any 
nail
AND
No crumbling
Mild
2
Onycholysis- > 10% on five or more nails
OR
Hyperkeratosis- present with mild elevation of nail plate
OR
Splinter Hemorrhages- present on four or fewer nails
OR
Nail Bed Erythema- mild
Five or more nails with mild 
pitting (eg, >10 pits/nail) or 
psoriatic leukonychia
AND
No crumbling
Moderate
3
Onycholysis- >30% on at least one nail
OR
Hyperkeratosis- present with moderate elevation of nail plate
OR
Splinter Hemorrhages- scattered and present on five or more 
nails
OR
Nail Bed Erythema- moderate
Five or more nails with 
moderate pitting (eg, >25 
pits/nail)
AND
≤25% crumbling on any nails
Severe
4
Onycholysis- > 50% on at least one nail
OR
Hyperkeratosis- present with severe elevation of nail plate
OR
Splinter Hemorrhages- numerous and present on five or more 
nails
OR
Nail Bed Erythema- severe
Five or more nails with 
severe pitting (> 50 pits/nail)
OR
>25% crumbling on any nail
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
117
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
118
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
119
APPENDIX 11
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA)
Palmoplantar (including finger and toe surfaces) psoriasis lesions are evaluated by the investigator 
based on overall severity, then scored on the following 5-point scale:
Score
Category
Description
0
Clear
No signs of plaque psoriasis
1
Almost 
Clear
Just perceptible erythema and just perceptible scaling
2
Mild
Light pink erythema, with minimal scaling with or without pustules
3
Moderate
Dull red, clearly distinguishable erythema with diffuse scaling, some 
thickening of the skin, with or without fissures, with or without pustule 
formation
4
Severe
Deep, dark red erythema with obvious and diffuse scaling and 
thickening as well as numerous fissures with or without pustule 
formation
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
120
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
121
APPENDIX 13
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD)
Please answer each question to the best of your ability. There are no right or wrong answers. Please 
pay close attention to the time period of interest. These questions ask you to think about the past 
24 hours. Please complete the diary at the same time every day.
Individuals with psoriasis may experience a range of symptoms. Please indicate how severe each 
of the following skin symptoms was in the past 24 hours. Please select only one number for  each 
item on the 0 to 10 scale (0=Absent and 10= Worst imaginable).
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
122
APPENDIX 14
DERMATOLOGY LIFE QUALITY INDEX (DLQI)
Hospital No:
Date:
Score:
Name:
Diagnosis:
Address:
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE 
LAST WEEK. Please tick one box for each question.
Please check you have answered EVERY question. Thank you
1.
Over the last week, how itchy, sore, painful or stinging has your skin been?
Very much 
A lot
A little 
Not at all
2.
Over the last week, how embarrassed or self-conscious have you been because 
of your skin?
Very much 
A lot
A little 
Not at all
3.
Over the last week, how much has your skin interfered with you going shopping 
or looking after your home or garden?
Very much 
A lot
A little 
Not at all
Not relevant
4.
Over the last week, how much has your skin influenced the clothes you wear?
Very much 
A lot
A little 
Not at all
Not relevant
5.
Over the last week, how much has your skin affected any social or leisure activities? Very much 
A lot
A little 
Not at all
Not relevant
6.
Over the last week, how much has your skin made it difficult for you to do any sport? Very much 
A lot
A little 
Not at all
Not relevant
7.
Over the last week, has your skin prevented you from working or studying?
yes 
no
Not relevant
If “No”, over the last week how much has your skin been a problem at work or
studying?
A lot 
A little
Not at all
8.
Over the last week, how much has your skin created problems with your partner 
or any of your close friends or relatives?
Very much 
A lot
A little 
Not at all
Not relevant
9.
Over the last week, how much has your skin caused any sexual difficulties?
Very much 
A lot
A little 
Not at all
Not relevant
10. Over the last week, how much of a problem has the treatment for your skin been, 
for example by making your home messy, or by taking up time?
Very much 
A lot
A little 
Not at all
Not relevant
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
123
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
124
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
125
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
126
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
127
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
128
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
129
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
130
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
131
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
132
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
133
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
134
APPENDIX 20
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE
Please circle or mark ONLY ONE of the five choices on the following 15 questions. The answers to these 
questions will help us better understand your symptoms. This should take about 5-6 minutes to complete. 
Thank you for your time.
Symptoms sub-scale
Strongly 
Disagree
Disagree
Neutral
Agree
Strongly 
Agree
1.
I feel tired for most of the day
1
2
3
4
5
2.
My joints hurt
1
2
3
4
5
3.
My back hurts
1
2
3
4
5
4.
My joints become swollen
1
2
3
4
5
5.
My joints feel ‘hot’
1
2
3
4
5
6.
Occasionally, an entire finger or toe 
becomes swollen, making it look like a 
‘sausage’
1
2
3
4
5
7.
I have noticed that the pain in my joints 
moves from one joint to another, eg, my wrist 
will hurt for a few days then my knee will hurt 
and so on.
1
2
3
4
5
SYMPTOM SCORE (Max 35)
Add scores for questions 1-7 and write in box A
A.
Function sub-scale
Strongly 
Disagree
Disagree
Neutral
Agree
Strongly 
Agree
8.
I feel that my joint problems have affected 
my ability to work
1
2
3
4
5
9.
My joint problems have affected my ability 
to care for myself, eg, getting dressed or 
brushing my teeth
1
2
3
4
5
10. I have had trouble wearing rings on my 
fingers or my watch
1
2
3
4
5
11. I have had trouble getting into or out of a 
car
1
2
3
4
5
12. I am unable to be as active as I used to 
be
1
2
3
4
5
13. I feel stiff for more than 2 hours after 
waking up in the morning
1
2
3
4
5
14. The morning is the worst time of day for 
me
1
2
3
4
5
15. It takes me a few minutes to get moving to 
the best of my ability, any time of the day
1
2
3
4
5
FUNCTION SCORE (Max 40)
Add scores for questions 8-15 and write in box B
B.
TOTAL PASE SCORE (Max 75)
Add scores in boxes A and B and write in box C
C.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
135
APPENDIX 21
EIGHT ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8)
The eight-item Patient Health Questionnaire depression scale is established as a valid self-
administered diagnostic and severity measure for depressive disorders. It consists of 8 different 
questions, with an answer scale from 0-3. The overall score is determined by adding up each of 
the individual answers from each question. 
Scoring interpretation is as follows: 0-4 no significant depressive symptoms, 5-9 mild depressive 
symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, 
and 20-24 severe depressive symptoms
Over the last 2 weeks, how often have you
been bothered by any of the following
problems?
Not at all
Several 
Days
More than 
half the 
days
Nearly 
every day
1. Little interest or pleasure in doing things
0
1
2
3
2. Feeling down, depressed, or hopeless
0
1
2
3
3. Trouble falling or staying asleep, or 
sleeping too much
0
1
2
3
4. Feeling tired or having little energy
0
1
2
3
5. Poor appetite or over eating
0
1
2
3
6. Feeling bad about yourself, or that you 
are a failure, or have let yourself or your 
family down
0
1
2
3
7. Trouble concentrating on things, such as 
reading the newspaper, or watching 
television
0
1
2
3
8. Moving or speaking so slowly that other 
people could have noticed? Or the 
opposite, being so fidgety or restless that 
you have been moving around a lot more 
than usual
0
1
2
3
Total Score:
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
136
APPENDIX 22
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS
Suicidal Ideation
Passive suicidal ideation: wish to be dead
Patient has thoughts about a wish to be dead or not alive anymore, or wish to fall asleep 
and not wake up.
Active suicidal ideation: nonspecific (no method, intent, or plan)
General nonspecific thoughts of wanting to end one’s life or commit suicide (eg, “I’ve 
thought about killing myself”) without general thoughts of ways to kill oneself/associated 
methods, intent, or plan during the assessment period.
Active suicidal ideation: method, but no intent or plan
Patient has thoughts of suicide and has thought of at least one method during the assessment 
period. This situation is different than a specific plan with time, place, or method details 
worked out (eg, thought of method to kill self but not a specific plan). Includes person who 
would say, “I thought about taking an overdose but I never made a specific plan as to when, 
where, or how I would actually do it . . . and I would never go through with it.”
Active suicidal ideation: method and intent, but no plan
Active suicidal thoughts of killing oneself, and patient reports having some intent to act on 
such thoughts, as opposed to “I have the thoughts but I definitely will not do anything about 
them.”
Active suicidal ideation:  method, intent, and plan
Thoughts of killing oneself with details of plan fully or partially worked out and patient 
has some intent to carry it out (ie, some degree of intent is implicit in the concept of plan).
Suicidal Behavior
Completed suicide
A self-injurious behavior that resulted in fatality and was associated with at least some 
intent to die as a result of the act. Evidence that the individual intended to kill him- or 
herself, at least to some degree, can be explicit or inferred from the behavior or 
circumstance.
Suicide attempt
A potentially self-injurious behavior, associated with at least some intent to die as a result 
of the act. Evidence that the individual intended to kill him- or herself, at least to some 
degree, can be explicit or inferred from the behavior or circumstance. A suicide attempt 
may or may not result in actual injury.
Approved
2.0
v
Approved
2.0
v


Clinical Protocol
IM011047
BMS-986165
TYK2 Inhibitor
21 May 2020, Revised Protocol 09, Final Approved BMS Confidential
137
Interrupted suicide attempt
When the person is interrupted (by an outside circumstance) from starting a potentially 
self-injurious act (if not for that, actual attempt would have occurred).
Aborted suicide attempt
When person begins to take steps toward making a suicide attempt, but stops before 
actually engaging in any self-destructive behavior. Examples are similar to interrupted 
attempts, except that the individual stops before being stopped by something else.
Preparatory acts toward imminent suicidal behaviors
This category can include anything beyond a verbalization or thought, but it stops short of 
a suicide attempt, an interrupted suicide attempt, or an aborted suicide attempt. This might 
include behaviors related to assembling a specific method (eg, buying pills, purchasing a 
gun) or preparing for one’s death by suicide (eg, giving things away, writing a suicide 
note).
Self-Injurious Behavior Without Suicidal Intent
Self-injurious behavior associated with no intent to die. The behavior is intended purely for other 
reasons, either to relieve distress (often referred to as self-mutilation (eg, superficial cuts or 
scratches, hitting or banging, or burns)) or to effect change in others or the environment.
Approved
2.0
v
Approved
2.0
v

SAP_001.pdf: 
Official Title of Study: 
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study 
with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in 
Subjects with Moderate-to-Severe Plaque Psoriasis 
 
NCT Number: NCT03611751 
Document Date (Date in which document was last revised): May 21, 2020 


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 1 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Statistical Analysis Plan 
Sponsor: 
Bristol-Myers Squibb 
Protocol No: 
IM011047 
Version Date: 
21-May-2020
Version No.: 
7.0 
Title: 
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-
controlled Phase 3 Study with Randomized Withdrawal and Retreatment to 
Evaluate the Efficacy to Evaluate the Efficacy and Safety of BMS-986165 in 
Subjects with Moderate-to-Severe Plaque Psoriasis 
SAP No. 
2.0 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 2 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approvals 
 Author 
 Title: 
Signature /Date: 
 Approvals 
 
Title: 
Signature /Date: 
BMS Approvals 
 
Signature /Date 
 
Signature /Date: 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 3 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Table of Contents 
Approvals ...................................................................................................................................................... 2
Table of Contents .......................................................................................................................................... 3
Abbreviations ................................................................................................................................................ 6
 Purpose ................................................................................................................................................... 8
 Study Description .................................................................................................................................... 8
2.1 Study Design ................................................................................................................................................................... 8 
 
2.3 Treatment Assignment and Randomization .................................................................................................. 10 
2.4 Unblinding Information .......................................................................................................................................... 11 
2.5 Changes in Statistical Considerations from the Protocol .......................................................................... 11 
 Objectives ............................................................................................................................................. 12
3.1 Primary Objective ..................................................................................................................................................... 12 
3.2 Secondary 
 Objectives ............................................................................................................... 12 
 Outcomes .............................................................................................................................................. 13
4.1 Efficacy ........................................................................................................................................................................... 13 
4.1.1 Primary Endpoint(s)........................................................................................................................................ 13 
4.1.2 Secondary Endpoint(s) ................................................................................................................................... 13 
4.1.2.1 Key Secondary Endpoints for Comparisons to Placebo ........................................................... 13 
4.1.2.2 Key Secondary Endpoints for Comparisons to Apremilast ..................................................... 13 
 
 
 
 
4.2 Safety .............................................................................................................................................................................. 17 
 
 
 Populations for Analyses ...................................................................................................................... 19
5.1 Relevant Protocol Deviations ............................................................................................................................... 20 
 Statistical Analyses ............................................................................................................................... 20
6.1 Efficacy Analyses ....................................................................................................................................................... 21 
6.1.1 Primary Endpoints ........................................................................................................................................... 21 
6.1.1.1 Primary Analysis ...................................................................................................................................... 21 
6.1.1.2 Sensitivity Analyses ................................................................................................................................. 22 
6.1.1.3 Supportive Analyses ................................................................................................................................ 23 
6.1.2 Key Secondary Endpoints .............................................................................................................................. 23 
6.1.2.1 Binary Endpoints ...................................................................................................................................... 23 
6.1.2.2 Continuous Endpoints ............................................................................................................................ 23 
6.1.2.3 Time-to-Relapse Endpoint.................................................................................................................... 24 
 
6.1.4 Subgroup Analyses ........................................................................................................................................... 26 
 
6.2 Safety .............................................................................................................................................................................. 28 
6.2.1 Adverse Events .................................................................................................................................................. 28 
6.2.1.1 Adverse Events of Interest (AEI) and Other Important AEs .................................................. 29 
6.2.1.2 Serious Adverse Events ......................................................................................................................... 29 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 4 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.2.1.3 Adverse Events Leading to Discontinuation of Study Treatment or Study Treatment 
Interruption ............................................................................................................................................................... 29 
6.2.2 Deaths .................................................................................................................................................................... 29 
6.2.3 Clinical Laboratory Data ................................................................................................................................ 29 
6.2.4 Vital Signs and Physical Findings ............................................................................................................... 29 
6.2.5 ECGs ........................................................................................................................................................................ 30 
6.2.6 Other Safety Data .............................................................................................................................................. 30 
6.2.6.1 PHQ-8 ............................................................................................................................................................ 30 
6.2.6.2 eC-SSRS ......................................................................................................................................................... 30 
6.3 General Methodology ............................................................................................................................................... 30 
6.3.1 Subject Populations and Disposition ........................................................................................................ 30 
6.3.2 Demographic and Baseline Characteristics ........................................................................................... 31 
6.3.3 Prior and Concomitant Medications ......................................................................................................... 31 
6.3.3.1 Psoriasis, Psoriatic Arthritis and Other Inflammatory Disease Related Systemic 
Medications ............................................................................................................................................................... 32 
6.3.3.2 Concomitant High Potency Corticosteroid Use ............................................................................ 32 
6.3.4 Exposure ............................................................................................................................................................... 32 
6.3.4.1 Duration of Treatment ........................................................................................................................... 32 
6.3.4.2 Summary of Dosing ................................................................................................................................. 33 
6.3.4.3 Compliance.................................................................................................................................................. 33 
 
 
6.6 Statistical Impacts Due to COVID-19 ................................................................................................................. 34 
6.6.1 Impact on Efficacy Endpoints ...................................................................................................................... 34 
6.6.2 Impact on Safety Endpoints .......................................................................................................................... 35 
 Sequence of Planned Analyses ............................................................................................................ 35
7.1 Interim Analyses ........................................................................................................................................................ 35 
7.2 Final Analyses and Reporting............................................................................................................................... 36 
 Conventions .......................................................................................................................................... 36
8.1 General Definitions ................................................................................................................................................... 36 
8.2 Calculation of Key Measures ................................................................................................................................. 37 
8.2.1 Investigator-Administered Assessments ................................................................................................ 38 
8.2.1.1 static Physician’s Global assessment (sPGA) ................................................................................ 38 
8.2.1.2 Psoriasis Area and Severity Index (PASI) ...................................................................................... 38 
8.2.1.3 Body Surface Area (BSA) ....................................................................................................................... 39 
8.2.1.4 scalp specific Physician’s Global Assessment (ss-PGA) ............................................................ 39 
 
8.2.1.6 Physician’s Global Assessment-Fingernails (PGA-F) ................................................................. 39 
 
8.2.1.8 Palmoplantar PGA (pp-PGA)................................................................................................................ 40 
 
8.2.2 Subject-Reported Assessments ................................................................................................................... 41 
8.2.2.1 Psoriasis Symptoms and Signs Diary (PSSD) ................................................................................ 41 
8.2.2.2 Dermatology Life Quality Index (DLQI) .......................................................................................... 41 
 
 
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 5 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
8.2.2.8 Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire ................................. 43 
8.2.2.9 Eight-Item Patient Health Questionnaire (PHQ-8) ..................................................................... 43 
8.2.2.10 electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) ............................................ 43 
8.3 Missing, Unknown, or Partial Dates ................................................................................................................... 44 
8.4 Study Periods .............................................................................................................................................................. 45 
8.5 Day Ranges for Analysis Visits ............................................................................................................................. 45 
 References ............................................................................................................................................ 46
 Document History ................................................................................................................................ 47
Appendix 1 Planned Analyses .................................................................................................................... 81
Appendix 2 Summary of Efficacy Assessments.......................................................................................... 83
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 6 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Abbreviations 
Glossary of Abbreviations: 
AE 
Adverse event 
AEI 
Adverse event of interest 
ANCOVA 
Analysis of covariance 
 
 
ATC 
Anatomic Therapeutic Classification 
BID 
Twice daily 
BSA 
Body surface area 
CI 
Confidence interval
CK 
Creatine kinase 
CMH 
Cochran-Mantel-Haenszel 
CRF 
Case Report Form 
CSP 
Clinical Safety Program 
CSR 
Clinical Study Report 
CTCAE 
Controlled Terminology Criteria for Adverse Events
DLQI 
Dermatology Life Quality Index 
DMC 
Data Monitoring Committee 
EAIR 
Exposure-adjusted incidence rate 
ECG 
Electrocardiogram 
eC-SSRS 
Electronic Columbia-Suicide Severity Rating Scale 
 
 
FAS 
Full analysis set 
 
 
IL 
Interleukin 
IRS 
Independent Reporting Statistician 
IRT 
Interactive Response Technology 
ITT 
Intention-to-treat 
LOCF 
Last observation carried forward 
LS 
Least-squares 
MAR 
Missing at random 
MedDRA 
Medical Dictionary for Regulatory Activities 
mBOCF 
Modified baseline observation carried forward 
MI 
Multiple imputation 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 7 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Glossary of Abbreviations: 
 
 
 
 
NRI 
Nonresponder imputation 
PASE 
Psoriatic arthritis screening and evaluation 
PASI 
Psoriasis Area and Severity Index 
 
 
PDGD 
Protocol deviation guidance document 
PGA-F 
Physician Global Assessment-Fingernails 
PHQ-8 
Eight-Item Patient Health Questionnaire 
 
 
PP 
Per-protocol 
 
 
pp-PGA 
Palmoplantar Physician’s Global Assessment 
PPS 
Per-protocol set 
PSSD 
Psoriasis Symptoms and Signs Diary 
 
 
QD 
Once daily 
QoL 
Quality of Life 
QTcB 
QT interval corrected using Bazett’s formula 
QTcF 
QT interval corrected using Fridericia’s formula 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
 
 
sPGA 
static Physician Global Assessment 
ss-PGA 
Scalp specific Physician’s Global Assessment 
TEAE 
Treatment-emergent adverse event 
TFLs 
Tables, figures, and listings 
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 8 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 Purpose 
The statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and 
analyses of data collected under BMS Protocol IM011047. 
The SAP outlines the following: 
x 
Study design 
x 
Study objectives 
x 
Endpoints and assessments 
x 
Analysis sets 
x 
Statistical methodology 
x 
Conventions and definitions 
The SAP should be read in conjunction with the study protocol and case report form (CRF) according to 
the version on Page 1 of this document. Any further changes to the protocol or CRF may necessitate 
updates to the SAP. Changes following approval of the first version of the SAP will be tracked in the SAP 
Change Log and a final version of the updated SAP will be approved prior to final database lock. 
 Study Description 
2.1 Study Design 
This is a 52-week, multi-center, randomized, double-blind, double-dummy, placebo- and active comparator-
controlled study with randomized withdrawal and retreatment to evaluate the safety and efficacy of BMS-
986165 vs placebo and apremilast. A total of 1000 qualified subjects with moderate-to-severe plaque 
psoriasis will be enrolled.  
Following a screening period of up to 4 weeks, qualified subjects who have completed the screening 
procedures and have met the inclusion/exclusion criteria will be randomized in a blinded manner in a 2:1:1 
ratio via interactive response technology (IRT) to one of the following 3 treatment groups: 
  
x 
BMS-986165 6 mg once daily (QD) 
x 
Placebo  
x 
Apremilast titrated to 30 mg twice daily (BID) as follows: 
o 
Day 1: 10 mg tablet in the morning 
o 
Day 2: 10 mg tablet in the morning and evening 
o 
Day 3: 10 mg tablet in the morning and 20 mg tablet in the evening 
o 
Day 4: 20 mg tablet in the morning and the evening 
o 
Day 5: 20 mg tablet in the morning and 30 mg tablet in the evening 
o 
Day 6 and thereafter: 30 mg tablet in the morning and the evening 
 
Dummy tablets (placebo for the BMS-986165 6 mg tablet, placebo for apremilast 30 mg tablet BID, and 
placebo for apremilast 10 mg, 20 mg, 30 mg during titration) will be administered to the subjects to maintain 
blinding in a double-dummy fashion.  
Week 16 
The coprimary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity 
Index (PASI) 75 will be assessed at Week 16. Subjects receiving placebo will be switched in a blinded 
manner to BMS-986165 6 mg QD at Week 16. Subjects who are randomized to BMS-986165 6 mg QD or 
apremilast will continue on this treatment regimen in a blinded manner. 
Week 24 
The randomized withdrawal and maintenance period will start at Week 24 and continue to Week 52. At 
Week 24, subjects originally randomized to BMS-986165 6 mg QD who do not achieve PASI 75 response 
will continue to receive BMS-986165 6 mg QD in a blinded manner. Subjects who achieve PASI 75 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 9 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
response will be re-randomized in a blinded manner to one of the following 2 treatment groups in a 1:1 
ratio: 
x 
BMS-986165 6 mg QD 
x 
Placebo 
 
If the subjects who were re-randomized to placebo experience a relapse as defined below at any visit during 
this period, they will be switched back in a blinded manner to BMS-986165 6 mg QD until the end of the 
maintenance period (Week 52). Relapse will be defined as at least a 50% loss of Week 24 PASI percent 
improvement from baseline. 
 
Subjects originally randomized to apremilast who achieve PASI 75 response will be switched in a blinded 
manner to placebo. If the subject experiences a relapse at any visit during this period, the subject will be 
treated with BMS-986165 6 mg QD until the end of the maintenance period (Week 52). Subjects receiving 
apremilast who do not achieve PASI 75 response at Week 24 will be switched to BMS-986165 6 mg 
QD.During the Week 24 assessment, a subject who has an sPGA 3 or ss-PGA3 may be treated with 
restricted topicals/shampoos as described in the protocol (Section 6.7.1). These treatments may only be 
initiated at Week 24, and not at subsequent time points. A subject who is provided these treatments at 
Week 24 may use them as needed per the investigator’s judgement through Week 52. 
The duration of study participation is approximately 60 weeks and will be divided into the following periods: 
Screening (up to 4 weeks), Treatment (52 weeks), and Follow-up (4 weeks). A schedule of assessments 
can be found in the protocol. A study design schematic is provided in Figure 1. 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 10 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Figure 1: Study Design Schematic 
 
2.3 Treatment Assignment and Randomization 
At Week 0 (Day 1), subjects who have met all criteria for enrollment will be centrally randomized by a 
computer-generated randomization schedule in a 2:1:1 ratio to the following treatments: 
 
x 
BMS-986165 6 mg QD 
x 
Placebo 
x 
Apremilast 30 mg BID (titrated) 
 
The randomization lists were generated by the IRT vendor using a permuted block design within each 
stratum combination level. Randomization will be stratified by geographic region (U.S. and Rest of World), 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 11 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
previous biologic use (for psoriasis, psoriatic arthritis, or other inflammatory disease only; yes/no), and body 
weight (90 kg and <90 kg).  
 
A treatment group will be assigned by IRT based on the above-described randomization schedule and each 
subject will be assigned a unique randomization number. In addition, a kit (container) number will be 
assigned to the subject by the IRT each time study treatment is dispensed. Dummy tablets (placebo to the 
BMS-986165 6 mg tablet and placebo to apremilast) will be administered to the subjects to maintain 
blinding. 
At Week 16, subjects receiving placebo will be switched in a blinded manner to BMS-986165 6 mg QD.  
At Week 24, subjects originally randomized to BMS-986165 6 mg QD who do not achieve PASI 75 will 
continue to receive BMS-986165 6 mg QD in a blinded manner. Subjects who achieve PASI 75 response 
will be re-randomized in a blinded manner in a 1:1 ratio to the following treatments: 
x 
BMS-986165 6 mg QD 
x 
Placebo 
Subjects re-randomized to placebo who experience a relapse at a subsequent visit will be switched back 
onto BMS-986165 6 mg QD in a blinded manner. The investigative site and other study personnel will not 
have knowledge of the PASI 75 scores at these visits and will therefore remain blinded. 
At Week 24, subjects originally randomized to apremilast who do not achieve a PASI 75 response will be 
switched in a blinded manner to BMS-986165 6 mg QD. Subjects originally randomized to apremilast who 
achieve PASI 75 response at Week 24 will be switched \ in a blinded manner in a 1:1 ratio to the following 
treatments: 
x 
Apremilast  30 mg BID 
x 
Placebo 
 The investigative site and other study personnel will not have knowledge of the PASI 75 score at this visit 
and will therefore remain blinded. 
Subjects re-randomized to placebo from apremilast treatment who experience a relapse as defined above 
at a subsequent visit will be switched to BMS-986165 6 mg QD in a blinded manner. The investigative site 
and other study personnel will not have knowledge of the PASI 75 scores at these visits and will therefore 
remain blinded. 
2.4 Unblinding Information 
The Data Monitoring Committee (DMC) provides oversight of safety considerations throughout the study. 
A separate unblinded team, comprised of an unblinded Independent Reporting Statistician (IRS) and 
unblinded programmer(s), will produce output for the DMC using masked treatments. Treatment decodes 
may only be requested by the DMC Chair and will be provided by the IRS. Data summaries and listings will 
be transmitted via a secure portal by the IRS to only the DMC members. Additional details regarding the 
DMC process and unblinding are provided in the DMC charter. 
 
 
  
2.5 Changes in Statistical Considerations from the Protocol 
The following is a list of the important changes in the SAP from the Statistical Considerations section in the 
protocol: 
x 
The hierarchical testing order for the key secondary endpoints has been updated and two separate 
hierarchies have been provided, one for US submission and one for ex-US submission (see Tables 
1 and 2 in Sec. 6.1.3).  The update to the hierarchies are due to emerging information from clinical 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 12 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
trials conducted with other agents recently approved for the treatment of psoriasis.  The hierarchies 
presented in the document supersede the one that is in the protocol. 
x 
Key secondary endpoints were added for the comparison of BMS-986165 to apremilast for sPGA 
0/1, PASI 75, and PASI 90 at Week 24. 
x 
Imputation methods were updated to remove the prohibited medication/therapy criteria for binary 
and continuous endpoints. 
x 
The Full Analysis Set was changed from “all subjects who were randomized to receive assigned 
study treatment” in the protocol to “all subjects who are randomized”. 
x 
The list of relevant protocol deviations provided in the protocol was updated for determination of 
the Per Protocol population. 
x 
Logistic regression analyses for binary endpoints were removed as these are similar to the CMH 
analyses. 
 Objectives 
3.1 Primary Objective 
x 
Assess whether BMS-986165 is superior to placebo at Week 16 in the treatment of subjects with 
moderate-to-severe plaque psoriasis 
3.2 Secondary 
 Objectives 
x 
Assess whether BMS-986165 is superior to apremilast at Week 16 
x 
Assess whether BMS-986165 is superior to apremilast at Week 24 
x 
Assess whether BMS-986165 is superior to placebo over the first 16 weeks of treatment 
x 
Assess whether BMS-986165 is superior to placebo in scalp psoriasis through Week 16 in those 
subjects who have baseline scalp severity Physician’s Global Assessment (ss-PGA) score 3 
x 
Assess whether BMS-986165 is superior to apremilast in scalp psoriasis through Week 16 in those 
subjects who have baseline ss-PGA score 3 
x 
Assess whether BMS-986165 is superior to placebo in nail psoriasis through Week 16 in those 
subjects who have baseline Physician’s Global Assessment-Fingernail (PGA-F) psoriasis score 3 
x 
 
 
x 
Assess whether BMS-986165 is superior to placebo in palmoplantar psoriasis through Week 16 in 
those subjects who have baseline palmoplantar Physician’s Global Assessment (pp-PGA) score 
3 
x 
Evaluate improvement in patient-reported outcomes for BMS-986165 compared with placebo 
through Week 16 
x 
Evaluate improvement in patient-reported outcomes for BMS-986165 compared with apremilast 
through Week 24 
x 
Evaluate maintenance and durability of efficacy of BMS-986165 during the randomized withdrawal 
period through Week 52 among Week 24 PASI 75 responders continuing on treatment compared 
with those re-randomized to placebo 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 13 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 Outcomes 
The description of assessments for efficacy and safety can be found in Section 8 of the protocol. The 
calculation of key measures are provided in Section 8.2 of the SAP. 
4.1 Efficacy 
4.1.1 Primary Endpoint(s) 
The coprimary endpoints for BMS-986165 compared to placebo at Week 16 are defined as: 
x 
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 with at least 
a 2-point improvement from baseline 
x 
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement from 
baseline in the PASI score 
4.1.2 Secondary Endpoint(s) 
4.1.2.1 Key Secondary Endpoints for Comparisons to Placebo 
The key secondary efficacy endpoints for BMS-986165 compared to placebo at Week 16 are defined as: 
x 
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement from 
baseline in PASI score 
x 
sPGA 0 response assessed as a proportion of subjects with an sPGA score of 0 
x 
Scalp specific Physician’s Global Assessment (ss-PGA) 0/1 assessed as a proportion of subjects 
with a ss-PGA score of 0 or 1 with at least a 2-point improvement from baseline among subjects 
with a baseline ss-PGA score 3 
x 
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score of 0 
among subjects with a baseline PSSD symptom score 1 
x 
PASI 100 response assessed as a proportion of subjects who achieve a 100% improvement from 
baseline in PASI score 
x 
Physician Global Assessment-Fingernails (PGA-F) 0/1 assessed as a proportion of subjects with a 
PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among subjects with a 
baseline PGA-F score 3 
x 
DLQI 0/1 assessed as a proportion of subjects with a DLQI score of 0 or 1 among subjects with a 
baseline DLQI score 2 (Ex-US submission only) 
An additional key secondary endpoint to assess the maintenance and durability of efficacy of BMS-986165 
during the randomized withdrawal period through Week 52 among Week 24 PASI 75 responders compared 
with re-randomized placebo is defined as: 
x 
Time-to-relapse (where relapse is defined as  50% loss of Week 24 PASI percent improvement 
from baseline) until Week 52 for Week 24 BMS-986165 PASI 75 responders (Ex-US submission 
only) 
4.1.2.2 Key Secondary Endpoints for Comparisons to Apremilast 
The key secondary endpoints for BMS-986165 compared to apremilast at Week 16 are defined as: 
x 
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 with at least 
a 2-point improvement from baseline 
x 
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement from 
baseline in the PASI score 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 14 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement from 
baseline in the PASI score 
x 
Change from baseline in PSSD symptom score 
x 
ss-PGA 0/1 assessed as a proportion of subjects with a ss-PGA score of 0 or 1 with at least a 2-
point improvement from baseline among subjects with a baseline ss-PGA score 3 
x 
sPGA 0 response assessed as a proportion of subjects with an sPGA score of 0 
x 
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score of 0 
among subjects with a baseline PSSD symptom score 1 
The key secondary endpoints for BMS-986165 compared to apremilast at Week 24 are defined as: 
x 
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 with at least 
a 2-point improvement from baseline at Week 24 
x 
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement from 
baseline in the PASI score at Week 24 
x 
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement from 
baseline in the PASI score at Week 24 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 15 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 16 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 17 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 
 
4.2 Safety 
The safety outcomes include the following: 
x 
Adverse events (AEs) 
o 
Treatment-emergent adverse events (TEAEs) – defined as: 
 
AEs which occur after the first dose of study treatment through 30 days after the 
final dose of the study treatment or subject’s participation in the study if the last 
scheduled visit occurs at a later time.   
o 
Treatment-emergent adverse events of interest (AEIs) for the following events: 
 
Skin-related AEs 
 
Infection AEs, including influenza 
 
CK elevation (evaluated as lab toxicity grade 2 or higher) 
 
Malignancy 
o 
SAEs 
o 
Deaths 
x 
Clinical laboratory parameters 
o 
Absolute and change from baseline values 
o 
Laboratory abnormalities (as determined by Controlled Terminology Criteria for Adverse 
Events [CTCAE v5.0] grading) presented as the worst postbaseline toxicity group 
o 
Shifts from baseline 
o 
Potential drug induced liver injury (DILI) is defined as a subject who meets the following 
criteria: 
 
1) ALT or AST elevation >3 times ULN 
AND 
 
2) Total bilirubin >2 times ULN, without initial findings of cholestasis (elevated 
serum alkaline phosphatase) 
AND 

3) No other immediately apparent possible causes of liver function test elevation 
and hyperbilirubinemia, including, but not limited to, viral hepatitis, preexisting 
chronic or acute liver disease, or the administration of other drug(s) known to be 
hepatotoxic.季季
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 18 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
o ALT or AST elevation >5 times ULN季
x 
Vital signs 
o 
Absolute and change from baseline values 
o 
Marked abnormalities defined by the below categories: 
 
Heart rate: 
x 
Value > 100 and change from baseline > 30 
x 
Value < 55 and change from baseline < -15 
 
Systolic blood pressure: 
x 
Value > 140 and change from baseline > 20 
x 
Value < 90 and change from baseline < -20 
 
Diastolic blood pressure: 
x 
Value > 90 and change from baseline > 10 
x 
Value < 55 and change from baseline < -10 
x 
Electrocardiograms (ECGs) 
o 
Absolute and change from baseline values 
o 
Marked abnormalities defined by the below categories: 
 
QT interval corrected using Fridericia’s formula (QTcF): 
x 
450 -< 480 msec 
x 
480 -< 500 msec 
x 
500 msec 
x 
FKDQJHIURPEDVHOLQHPVHF 
x 
Change from baseline > 60 msec 
x 
0DOHVPVHF450 msec 
x 
)HPDOHVPVHFPVHF 
 
PR interval PVHF 
 
QRS interval PVHF 
In cases where the QT interval is corrected using Bazett’s (QTcB) formula is captured instead of QTcF, 
then QTcB will be converted to QTcF for analyses. 
x 
Eight-Item Patient Health Questionnaire (PHQ-8) total score 
o 
Absolute and change from baseline values 
o 
Shifts from baseline scores  
x 
Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) 
o 
Suicidal ideation and suicidal behavior responses by visit  
o 
Shifts from baseline to postbaseline value for suicidal ideation and suicidal behavior 
o 
Worst postbaseline value for suicidal ideation and behavior 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 19 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 Populations for Analyses 
The following analysis sets will be used in the summary and analysis of study data: 
x 
Enrolled population: All subjects who sign informed consent. 
x 
Full Analysis Set (FAS): All subjects who are randomized. Following the intent-to-treat (ITT) 
principle, subjects will be analyzed according to the treatment group assigned at randomization. 
The FAS will be the primary efficacy analysis population. 
x 
Per Protocol Set (PPS): A subset of the FAS who are compliant with study treatment and who do 
not have any relevant protocol deviations that may impact the coprimary efficacy endpoint 
assessments. The PPS will be analyzed according to the treatment assigned at randomization. The 
PPS will be a supportive efficacy analysis population and only the co-primary endpoints will be 
analyzed using this set. 
x 
As-treated population: All randomized subjects who take at least one dose of study treatment. 
Subjects will be analyzed according to treatment received. 
x 
 
 
 
x 
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 20 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
5.1 Relevant Protocol Deviations 
Relevant protocol deviations are deviations that can have an impact on the primary efficacy endpoints. The 
impact of relevant protocol deviations on the primary efficacy results will be assessed by excluding subjects 
from the FAS to define the PPS in supportive analyses of the primary efficacy endpoints. Relevant protocol 
deviations to be considered regarding exclusion of subjects from the FAS will include the following: 
x 
Randomized but did not take any study treatment 
x 
No postbaseline PASI or sPGA 
x 
Baseline BSA involvement < 10% 
x 
Baseline PASI score < 12 
x 
Baseline sPGA < 3 
x 
Did not have non-plaque psoriasis at baseline
x 
Poor compliance to study medication within the first 16 weeks of treatment, <75% compliant with 
study treatment 
x 
Failure to adhere to prohibited concomitant medication restrictions as described below: 
o 
Investigational drug or placebo taken outside of the study any time between Day 1 and the 
Week 16 assessment 
o 
Phototherapy within 4 weeks prior to the Week 16 assessment 
o 
Biologic medications (eg, adalimumab, etanercept, infliximab, ustekinumab) any time 
between Day 1 and the Week 16 assessment  
o 
Oral psoriasis medications any time between Day 1 and the Week 16 assessment 
o 
Oral corticosteroids (unless for the treatment of an adverse event) within 4 weeks prior to 
the Week 16 assessment 
o 
Topical medications/treatments that could affect psoriasis evaluations within 2 weeks prior 
to the Week 16 assessment 
o 
Medicated shampoos within 2 weeks prior to the Week 16 assessment 
 
x 
Subject received treatment that was different than intended treatment at any visit prior to Week 16. 
 
All subjects with relevant protocol deviations will be identified prior to database lock and unblinding of 
treatment assignment with the exception of subjects where actual treatment received is different than 
randomized treatment which will be determined after treatment unblinding. Relevant protocol deviations will 
be summarized by treatment group and deviation category for the FAS population. 
 Statistical Analyses 
Descriptive summaries and analyses will be presented for data captured throughout the study using the 
following treatment groups.  
During the first 16 weeks of treatment, summaries will be provided for the following treatment groups: 
x 
BMS-986165 6 mg QD 
x 
Apremilast  
x 
Placebo 
During the first 24 weeks of treatment, summaries will be provided for the following treatment groups: 
x 
BMS-986165 6 mg QD (subjects continuously taking BMS-986165 6 mg QD) 
x 
Apremilast 
Summaries of all subjects exposed to BMS-986165 6 mg QD will also be provided as applicable. Adverse 
events will be summarized using exposure-adjusted incidence rates (EAIR) for these summaries. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 21 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Additionally, certain data for BMS-986165 Week 24 PASI 75 responders who have been re-randomized will 
be summarized by re-randomized treatment. Additional summary may be defined later. 
6.1 Efficacy Analyses
All efficacy analyses will be performed using the FAS, unless otherwise specified. 
Tests of significance of BMS-986165 6 mg QD vs. placebo for the coprimary endpoints will be two-sided 
with a significance level of 0.05. Both coprimary endpoints need to demonstrate statistical significance to 
result in a successful study.  
The key secondary endpoints will be tested with a two-sided significance level of 0.025 to compare BMS-
986165 6mg QD vs. placebo and vs. apremilast. A hierarchical testing approach will be used for testing of 
key secondary endpoints (see Section 6.1.3). Two-sided 95% confidence intervals (CIs) will be provided 
for all efficacy estimates. 
 
Coprimary and key secondary efficacy endpoints will be displayed graphically by treatment group and visit, 
as applicable. All efficacy endpoints will be summarized descriptively. 
The stratified levels are provided below: 
 
US/PRIOR USE/< 90 KG 
 
US/PRIOR USE/>=90 KG  
 
US/NAÏVE/<90 KG  
 
US/NAÏVE/>=90 KG  
 
ROW/PRIOR USE/< 90 KG 
 
ROW/PRIOR USE/>=90 KG  
 
ROW/NAÏVE/<90 KG  
 
ROW/NAÏVE/>=90 KG 
6.1.1 Primary Endpoints 
6.1.1.1 Primary Analysis 
Analysis Model 
A stratified Cochran-Mantel-Haenszel (CMH) test will be used to compare the sPGA 0/1 response rates at 
Week 16 between BMS-986165 6 mg QD and placebo using the stratification factors from IRT specified 
in Section 6.1. The odds ratio (ratio of odds in BMS-986165 6 mg QD group to the odds in the placebo 
group) and the corresponding 2-sided 95% CIs and p-values will be reported. Additionally, treatment 
differences in proportions and the 95% CI for the treatment difference will be provided. The common 
treatment difference in proportion with the confidence interval, common odds ratio with the confidence 
interval and p-value will be estimated by the Mantel-Haenszel method consistently.  
 
A similar analysis will be performed to compare the PASI 75 response rates at Week 16 between BMS-
986165 6mg QD and placebo. 
Imputation Methodology 
Non-responder imputation (NRI) will be used for coprimary efficacy endpoints for subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x 
Have missing Week 16 endpoint data for any reason 
NRI will be used as the primary method of imputation for the coprimary efficacy endpoints. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 22 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.1.1.2 Sensitivity Analyses 
As a method to assess the sensitivity of the primary imputation method for the coprimary endpoints, 
further imputation methods will be used to impute Week 16 data in subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x 
Have missing Week 16 endpoint data for any reason 
The coprimary endpoints will be analyzed using the primary analysis method for each sensitivity 
imputation method described below: 
Last Observation Carried Forward (LOCF) 
The last observed post-baseline value will be carried forward and used as the Week 16 value. Subjects 
without a post-baseline will be considered a nonresponder. 
LOCF and NRI 
Subjects randomized to the placebo group will have the endpoint value imputed using LOCF (post-
baseline). If a placebo subject does not have a post-baseline values, they will be considered a 
nonresponder. Subjects randomized to BMS-986165 6 mg QD will have their endpoint value imputed 
using the NRI methodology.  
Tipping Point Analysis 
Tipping point analysis will further be used to assess the robustness of the primary study results. Different 
number of events between treatment groups will be assessed until the study conclusion is changed. Each 
imputed value is initially imputed as a responder. The imputed values in the placebo group will remain as 
responders while the BMS-986165 imputed values are replaced as a nonresponders one at a time, 
therefore changing the number of events between groups. Once all imputed values in the BMS-986165 
group have been replaced with nonresponders values, the data will reset to where the BMS-986165 group 
imputed values are all responders and one by one the imputed values in the placebo group are replaced 
with a nonresponder until all placebo are nonresponders and all BMS-986165 are responders. Furthermore, 
every pair of imputations between the placebo and BMS-986165 groups will be assessed similarly, creating 
a matrix of possible patterns.  
At each iteration, the statistical analysis is assessed, and the direction of the analysis is recorded. A 
graph will be provided to identify at what point to which the difference in events cause a direction shift in 
study results. The tipping point analyses will be based on a two-sample chi-square test approach rather 
than a stratified CMH test approach for simplicity of the analysis. 
Figure 1: Example of Tipping Point Analysis Direction Boundary 
“ Responders”  in 
missing Placebo Group 
 
4 
 
 
 
 
 
3 
 
 
 
 
 
2 
 
 
 
 
 
1 
 
 
 
 
 
0 
 
 
 
 
 
 
0 
1 
2 
3 
4 
“Responders” in missing BMS-986165 Group 
Figure 1 represents an example of the tipping-point analysis for all subjects with missing primary efficacy 
endpoint (responder/non-responder) in BMS-986165 group (N=5) and placebo group (n=5). Gray cells 
represent pairs where the statistical analysis resulted in non-significance. Green cells represent pairs 
where the statistical analysis resulted in significant difference between groups. The tipping-point 
boundary is where the green cells become gray. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 23 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Multiple Imputation 
Multiple imputation (MI) will be used for sensitivity analyses for each of the coprimary efficacy endpoints, 
PASI 75 response at Week 16 and sPGA 0/1 response at Week 16. Multiple imputation of missing data 
for PASI 75 response and sPGA 0/1 response will be performed by fully conditional specification (FCS) 
using PROC MI in SAS with the FCS option. The FCS MI specifies the multivariate imputation model on a 
variable-by-variable basis by a set of conditional densities. For each missing value at Week X, the FCS 
MI will generate values from a conditional distribution for the missing data given the other data prior to 
Week X. The FCS MI model will include treatment group and stratification factors for randomization. A 
total of 1000 imputed (complete) datasets will be generated for the MI analysis. The same test procedure 
used for the main analysis (CMH test), will be used to analyze the responder endpoint from each imputed 
dataset. SAS PROC MIANALYZE will be used to pool the results from the CMH tests and generate an 
overall result by Rubin’s rules (1987). 
6.1.1.3 Supportive Analyses
Per Protocol Population Analysis
The coprimary endpoints will be analyzed using the PPS using the primary analysis methodology and 
primary imputation method.  
6.1.2 Key Secondary Endpoints 
6.1.2.1 Binary Endpoints 
Analysis Model 
CMH tests will be used to compare response rates between either BMS-986165 6mg QD and placebo or 
apremilast using the stratification factors from IRT specified in Section 6.1. The odds ratio (ratio of odds in 
BMS-986165 6 mg QD group to the odds in the placebo or apremilast group) and the corresponding 2-
sided 95% CIs and p-values will be reported. Additionally, treatment differences in proportions and the 95% 
CI for the treatment difference will be provided. 
Imputation Methodology for Week 16 Endpoints 
NRI will be used for key secondary efficacy endpoints for subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x 
Have missing Week 16 endpoint data for any reason 
Imputation Methodology for Week 24 Endpoints (for comparison of BMS-986165 6 mg QD to apremilast) 
NRI will be used for key secondary efficacy endpoints for subjects who: 
x 
Discontinue treatment or study prior to Week 24 
x 
Have missing Week 24 endpoint data for any reason 
6.1.2.2 Continuous Endpoints 
Analysis Model 
Analysis of covariance (ANCOVA) models will be used to compare the change between BMS-986165 6 mg 
QD and placebo or between BMS-986165 6 mg QD and apremilast at Week 16. Treatment group will be 
included in the model as well as the stratification factors from IRT specified in Section 6.1 and will be 
considered as fixed effects. The baseline value will be added into the model as a covariate. The adjusted 
least-squares (LS) means as well as the treatment differences based on LS means and the corresponding 
2-sided 95% CIs will be provided for the difference between BMS-986165 6 mg QD and placebo or 
apremilast. 
Imputation Methodology for Week 16 Endpoints 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 24 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
For continuous key secondary endpoints, a modified baseline observation carried forward (mBOCF) 
approach will be used for missing data. The baseline observation will be carried forward for subjects who 
discontinue study treatment prior to Week 16 due to: 
x 
Lack of efficacy 
x 
AEs 
Subjects who discontinue study treatment prior to Week 16 for other reasons or who have a missing Week 
16 value will have the last valid observation carried forward (including the baseline value as applicable).  
6.1.2.3 Time-to-Relapse Endpoint 
PASI 75 response will be assessed at each visit between Week 24 and Week 52. Subjects who experience 
a relapse as defined above at any visit between Week 24 and Week 52 will be considered as having an 
‘event’. Subjects who discontinue study (or treatment) during this time, have missing data, and subjects 
that do not have relapse by Week 52 will be censored and the date they experienced the above criteria, will 
be used as their ‘event’ date. 
The Kaplan-Meier product limit method will be used to estimate the survival curves for time-to-relapse 
during the randomized withdrawal period. Treatment comparisons between BMS-986165 6 mg QD and 
placebo for subjects re-randomized during the randomized withdrawal period will be performed using the 
log-rank test stratified using the stratification factors from IRT specified in Section 6.1. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 25 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 26 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.1.4 Subgroup Analyses 
Subgroup analyses will be performed on the coprimary endpoints using the FAS. The primary imputation 
method will be applied for these analyses. The CMH test using the stratification factors from IRT will be the 
analysis method used. The following subgroups will be considered: 
x 
Geographic region (U.S., Rest of World) 
x 
Country 
x 
Sex (male, female) 
x 
$JHJURXS\\) 
x 
Body weight (<90 kg, 90 kg) – from case report form 
x 
Race 
x 
Prior biologic use for psoriasis, psoriatic arthritis and other inflammatory diseases only (yes, no) – 
from case report form 
x 
Prior systemic treatment use (yes/no) 
x 
Prior phototherapy use (yes/no) 
x 
sPGA (3, 4) 
x 
PASI score (20, >20) 
x 
BSA involvement (10-20, >20)  
x 
Duration of disease (< 10 y,  10 y) 
x 
Age at disease onset (<18, 18-39, 40) 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 27 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 28 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.2 Safety 
Summaries of safety data will be presented by period and treatment group, as applicable, for the As-treated 
population.  
6.2.1 Adverse Events
Adverse events will be presented for the number and percentage of subjects and the number of events. 
Treatment-emergent will be provided in listings. Summary tables will be reported in decreasing frequency 
based on the BMS-986165 column. Counting for frequency analysis will be by subject and not by AEs, and 
subjects are only counted once for recurring AEs within each system organ class (SOC) or preferred term 
(PT); however, the number of total AEs per subject, including multiple occurrences of individual AEs, will 
also be presented. For summaries of severity, AEs will be reported only at their maximum severity in each 
subject. Subjects with multiple AEs within a particular SOC or PT will be counted under the category of their 
most severe event within that SOC or PT. 
AE (including deaths) dates will be imputed according to algorithms detailed in Section 8.0. The imputed 
date of AE onset will be used to assess whether AEs should be considered as treatment-emergent and 
included in the safety summaries. The original, partial dates will be included in data listings. No imputation 
will be performed on missing AE seriousness, severity, or relationship; they will be reported as missing. 
AEs will be included in a period if the start date of the AE is after the first dispensation date within a period. 
An overall summary for the following categories will be presented: 
x 
Deaths 
x 
SAEs 
x 
Related SAEs 
x 
AEs 
x 
Related AEs 
x 
Discontinued treatment due to AEs 
 
The following summaries will also be provided for the following: 
x 
TEAEs by SOC and PT 
x 
Treatment-related TEAEs by SOC and PT 
x 
TEAEs by PT UHSRUWHGLQRIVXEMHFWV 
x 
TEAEs by PT UHSRUWHGLQ 1% of subjects 
x 
Treatment-related TEAEs by PT UHSRUWHGLQRIVXbjects 
x 
TEAEs categorized by severity by SOC and PT 
x 
Exposure-adjusted incidence rate (EAIR) for TEAEs by SOC and PT – EAIR is defined in Section 
8.1 of the SAP. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 29 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.2.1.1 Adverse Events of Interest (AEI) and Other Important AEs 
Summaries for treatment-emergent AEIs events will be provided by PT for each AEI category: 
x 
Skin-related events 
x 
Infection events 
x 
Malignancy events 
Creatine kinase (CK) elevation for CK elevation > 2.5 upper limit of normal will be summarized as CTCAE 
grade 2 or higher in the clinical laboratory summaries. 
Additional information collected for some events as part of the clinical safety program and adjudicated 
events will also be summarized.  
6.2.1.2 Serious Adverse Events 
Summaries for treatment-emergent SAEs will be provided for the following: 
x 
Treatment-emergent SAEs by SOC and PT 
6.2.1.3 Adverse Events Leading to Discontinuation of Study Treatment or Study 
Treatment Interruption 
Summaries for TEAEs leading to discontinuation of study treatment will be provided for the following: 
x 
TEAEs by SOC and PT 
Summaries for TEAEs leading to study treatment interruption will be provided for the following: 
x 
TEAEs by SOC and PT 
6.2.2 Deaths 
All adverse events with an outcome of death will be listed. 
6.2.3 Clinical Laboratory Data 
Laboratory parameters will be summarized using the International System (SI) of Units and US conventional 
units. Data will be summarized by time point, as applicable. The following summaries will be provided for 
each parameter: 
x 
Absolute and change from baseline values for continuous parameters 
x 
Number and percentage of subjects for the following: 
o 
Maximum postbaseline CTCAE grade for each applicable laboratory parameter through 
Week 16 
o 
Shifts from baseline based on maximum postbaseline CTCAE grade through Week 16 
x 
Drug-induced Liver Injury (DILI) and Hy’s Law summaries 
6.2.4 Vital Signs and Physical Findings 
Vital signs, including weight, will be summarized by time point, as applicable. The following summaries will 
be provided for each parameter: 
x 
Absolute and change from baseline values 
x 
Number and percentage of subjects for the following: 
o 
Marked abnormality for each abnormality category as defined in Section 4.2 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 30 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.2.5 ECGs 
ECG parameters will be summarized by time point, as applicable. The following summaries will be provided 
for each parameter: 
x 
Absolute and change from baseline values 
x 
Number and percentage of subjects for the following: 
o 
Marked abnormality for each abnormality category as defined in Section 4.2 
6.2.6 Other Safety Data 
6.2.6.1 PHQ-8 
PHQ-8 total score will be summarized by time point, as applicable. The following summaries will be 
provided: 
x 
Absolute and change from baseline values 
x 
Number and percentage of subjects: 
o 
Shifts from none, mild, moderate, moderately severe and severe scores at baseline and 
at each time point 
6.2.6.2 eC-SSRS 
Suicidal ideation and behavior individual item responses will be summarized by time point, as applicable. 
The following summaries will be provided: 
x 
Number and percentage of subjects with positive responses on suicidal ideation and/or suicidal 
behavior questions for each question and overall all questions within suicidal ideation and suicidal 
behavior 
x 
Shifts from baseline based on maximum postbaseline response through Week 16 
x 
Worst postbaseline value for suicidal ideation and behavior through Week 16 
6.3 General Methodology 
The following standards/ methods will be used: 
x 
Statistical package(s) planned to be used 
o 
All analyses will use SAS version 9.4 or higher. 
x 
Standard summary statistics for continuous and categorical variables: 
o 
Unless otherwise noted, categorical variables will be summarized using counts and 
percentages. Percentages will be rounded to one decimal place, except 100% will be 
displayed without any decimal places and percentages will not be displayed for zero 
counts.  
o 
Continuous variables will be summarized using the number of observations (n), mean, 
standard deviation (SD), median, minimum and maximum. The median, minimum and 
maximum values will be displayed to the same level of precision as the raw data, the mean 
to a further decimal place and the SD to two additional decimal places. 
o 
Variables will be summarized by period, treatment group, and time point, as applicable. 
6.3.1 Subject Populations and Disposition 
The number of subjects enrolled/screened and the number and percentage of subjects randomized, treated, 
and in each analysis population will be presented. The number and percentage of subjects randomized in 
each region, country, and site will be presented. 
Additionally, the following summaries will be provided for the FAS by treatment group and overall: 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 31 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
Number and percentage of subjects who completed 16 weeks of treatment  
x 
Number and percentage of subjects who discontinued treatment prior to Week 16 and reason for 
treatment discontinuation 
x 
Number and percentage of subject who completed 24 weeks of treatment, who discontinued 
treatment prior to Week 24 and post Week 16, and those who discontinued at any time prior to 
week 24 and reason for treatment discontinuation. Denominator will be the number of subjects in 
the FAS. 
x 
Number and percentages of subjects who completed 52 weeks of treatment, who discontinued 
treatment prior to Week 52 and post Week 24, and who discontinued treatment at any time and 
reason for treatment discontinuation. Denominator will be the number of subjects in the FAS. 
6.3.2 Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized by treatment group for the FAS. 
Demographic characteristics include the following: 
x 
Sex 
x 
Race 
x 
Ethnicity 
x 
Age (in \HDUVDWWLPHRIVLJQLQJLQIRUPHGFRQVHQWDQGDJHFDWHJRU\YV  
x 
Weight (in kg, at baseline) and weight category (90 kg, <90 kg) 
x 
Body mass index (BMI in kg/m2, at baseline) 
x 
Geographic region (U.S., Rest of World) 
x 
Prior biologic use for psoriasis, psoriatic arthritis and other inflammatory diseases only (yes, no) 
x 
Reason for discontinuation of prior biologic use 
x 
Prior systemic treatment use (yes/no) 
x 
Prior phototherapy use (yes/no) 
x 
Stratification factors obtained from IRT: geographic region by prior biologic use and by body weight 
x 
Stratification factors obtained from database: geographic region by prior biologic use and by body 
weight 
x 
sPGA (3, 4) 
x 
PASI score (20, >20) 
x 
BSA involvement (10-20, >20)  
x 
Duration of disease (< 10 y,  10 y) 
x 
Age at disease onset (<18, 18-39, 40) 
 
Additional demographics or baseline data may be added to summary tables. 
 
General medical history and medical history related to psoriasis will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA). General medical history data will be summarized for each SOC and 
PT by treatment group and overall for the FAS. Separate tables will be provided for psoriasis medical 
history. 
6.3.3 Prior and Concomitant Medications 
Prior and concomitant medications will be coded according to World Health Organization-Drug Dictionary 
WHO-DD (version at the time of DBL) and will be summarized by Anatomic Therapeutic Classification 
(ATC) and preferred term (PT) by treatment group for the As-treated population. The number and 
percentage of subjects using at least one medication and each medication will be displayed by treatment 
group. Subjects taking more than one medication within the same ATC or PT will be counted once.  
Summaries will be provided for prior medications and medications that started prior to first treatment and 
were ongoing after first treatment start date as well concomitant medications. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 32 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Medication dates will be imputed according to algorithms detailed in Section 8.0. The imputed dates will be 
used to assess whether medications should be included in the summaries as prior or concomitant, however 
the original, partial dates will be included in data listings. 
6.3.3.1 Psoriasis, Psoriatic Arthritis and Other Inflammatory Disease Related Systemic 
Medications 
Prior medications and medications that started prior to first treatment and were ongoing after first treatment 
start date for systemic biologic and non-biologic medications will be summarized as described above for 
the number and percentage of subjects using each reported medication. 
6.3.3.2 Concomitant High Potency Corticosteroid Use 
The number and percentage of subjects using at least one high potency topical corticosteroid at Week 24 
will be summarized by treatment group. Additionally, corticosteroids will be summarized by ATC and PT. 
6.3.4 Exposure  
6.3.4.1 Duration of Treatment 
Duration by Group 
Overall duration of each treatment, in days, will be calculated for each subject in each treatment group. 
Subjects are dispensed study treatment at each visit, starting with Day 1 (Week 0) and at each subsequent 
visit. The date of first dose of study treatment is the Week 0 
 dosing date and is recorded on the eCRF. 
If this date is missing, then the earliest drug dispensation date will be used. The last dose date is recorded 
on the end of treatment page in the eCRF. If this date is missing, then the latest date from the 
 
page or drug accountability return date will be used. 
Duration of treatment will be summarized descriptively by randomized treatment group. 
BMS-986165: 
Subjects randomized to BMS-986165 continuing on BMS-986165 either if PASI 75 responder at Week 24 
or subjects randomized to BMS-986165 and are Week 24 PASI 75 nonresponders will have their duration 
of treatment derived as: 
x 
Date of last dose – date of first dose +1 
Subjects randomized to BMS-986165 and re-randomized to placebo at Week 24 will have their duration 
of treatment derived as: 
x 
BMS-986165 (Wk 0 through Wk 24) = Date of last dose of BMS-986165 prior to first placebo dose 
date – date of first dose +1 
x 
Placebo (Wk 24 through final week on placebo) = Date of last dose of placebo - date of first dose 
of placebo + 1 
x 
BMS-986165 (First dose after relapse on placebo or switched to BMS-986165 due to COVID-19  
through Wk 52) = Date of last dose of BMS-986165 – first BMS-986165 dose date after relapse + 
1; only calculated for subjects that relapse or are switched to BMS-986165 due to COVID-19 
x 
Total BMS-986165 = Sum BMS-986165 exposure over entire treatment period  
Placebo: 
For subjects randomized to placebo, duration is defined as: 
x 
Placebo = Date of last dose of placebo – date of first dose +1 
x 
BMS-986165 = Date of last dose of BMS-986165 – date of first dose of BMS-986165 +1 
Apremilast: 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 33 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
For subjects randomized to apremilast, duration is defined as: 
x 
Apremilast (Wk 0 through Wk 24) = Date of last dose of apremilast – date of first dose +1 
x 
Placebo (PASI 75 nonresponders) = Date of last dose of placebo – date of first dose of placebo + 
1 
x 
BMS-986165 (switched from apremilast or switched from placebo to BMS-986165 after relapse or 
due to COVID-19) = Date of last dose of BMS-986165  date of first dose date of BMS-986165 + 
1 
Duration by Period 
Overall duration (in days) of each treatment received within each study period will be calculated. Duration 
within each period is defined for each treatment group as: 
x 
Duration of the resumed BMS-986165 6 mg QD treatment 
x 
For subjects on BMS-986165 who are treated with placebo following Week 24 re-randomization 
and resume BMS-986165 treatment prior to Week 52, the duration of the resumed BMS-986165 
treatment will be calculated from the first IP dispense date of the resumed BMS-986165 to either 
Week 52 IP dispense date or the date of the last dose of IP in the study for subjects who 
discontinue in the period after resuming BMS-986165. 
x 
Duration of the re-randomized placebo treatment 
For all subjects (including those initially on BMS-986165 or apremilast) who are treated with 
placebo following Week 24 re-randomization, the duration of the re-randomized placebo 
treatment will be calculated from the IP dispense date at Week 24 to either the first IP dispense 
date of the BMS-986165 treatment in the period; or Week 52 IP dispense date for subjects who 
have not resumed BMS-986165 or apremilast in the period or the date of the last dose of IP in the 
study for subjects who discontinue in the period.  
6.3.4.2 Summary of Dosing 
The number of doses taken for each subject for each period will be determined using the eCRF drug 
accountability data and is defined as: 
ܦ݋ݏ݁ݏܶܽ݇݁݊ǣ ሺ݊ݑܾ݉݁ݎ݋݂ݐܾ݈ܽ݁ݐݏ݀݅ݏ݌݁݊ݏ݁݀െ݊ݑܾ݉݁ݎ݋݂ݐܾ݈ܽ݁ݐݏݎ݁ݐݑݎ݊݁݀ሻ 
 
The number of doses taken will be summarized descriptively by treatment group within each period and 
overall.  
6.3.4.3 Compliance 
Treatment compliance will be determined from data captured on the Drug Accountability eCRF.  
  
ܰݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݀݋ݏ݁ݏǣ ሺ݀ܽݐ݁݋݂݊݁ݔݐݒ݅ݏ݅ݐെ݀ܽݐ݁݋݂ܿݑݎݎ݁݊ݐݒ݅ݏ݅ݐሻݔ͵ 
Treatment compliance will be derived for each period. Compliance is defined as: 
൬ܰݑܾ݉݁ݎ݋݂݀݋ݏ݁ݏݐܽ݇݁݊
ܰݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݀݋ݏ݁ݏ൰ݔͳͲͲ 
Period compliance will be calculated by summing over all visits within the period using descriptive statistics 
by treatment group. The number and percentage of subjects with <75%, 75% to 100%, and >100% 
compliance will be provided by treatment group for each period. If a subject does not return the container, 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 34 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
then this dispensation event will be excluded in the calculation for the total number of doses taken, total 
number of expected doses, and total compliance. 
6.6 Statistical Impacts Due to COVID-19 
6.6.1 Impact on Efficacy Endpoints
There are no COVID-19-related impacts to the Week 16 efficacy endpoints as all subjects remaining in the 
trial completed the Week 16 visit prior to COVID-19 site restrictions. Efficacy endpoints involving Week 24 
and later visits may be impacted by COVID-19 in the form of missing data and/or a treatment assignment 
defaulting to BMS-986165. 
Censoring rules will be applied to the PASI 75 time-to-relapse endpoint for re-randomized subjects due to 
the following COVID-19-related issues post Week 24: 
x 
Subject study treatment assignment was defaulted to BMS-986165 because they had a remote 
safety monitoring visit and efficacy assessments were not performed. The subjects will be censored 
at the time of the remote visit if relapse had not been observed already; 
x 
Subject has missing visits (ie, efficacy assessments not performed) after Week 24 and assuming 
relapse was not observed prior to missing visits: 
o 
If the subject returns at a later visit and is found to have relapsed, midpoint imputation will 
be used to determine time-to-relapse (ie, midpoint of the censoring interval). 
o 
If the subject returns at a later visit and has not relapsed, then the subject will continue to 
be evaluated for relapse. 
o 
If the subject is discontinued from the study treatment, then the subject will be censored at 
the time of study treatment discontinuation. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 35 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Similar data handling rules will be applied to the following time-to-event endpoints: 
x 
Time to first loss of PASI 75 among subjects that are PASI 75 responders at Week 24 
x 
Time to first loss of sPGA 0/1 among subjects that are sPGA 0/1 responders at Week 24 where 
loss of sPGA 0/1 is defined as an sPGA score  2 
x 
Time to rebound as defined above among subjects re-randomized to placebo 
x 
Time-to-relapse for Week 24 PASI 75 apremilast responders switched to placebo 
Additional efficacy endpoints involving later visits may be impacted by COVID-19 in the form of missing 
data and/or a treatment assignment defaulting to BMS-986165. If a subject has missing data or is switched 
to BMS-986165 from a different treatment due to COVID-19 during the Week 24 through Week 52 period, 
the subject will be excluded from the analysis.  
Additional efficacy endpoints that may be impacted include the following: 
x 
 
x 
 
 
 
x 
Disease relapse assessed as the proportion of subjects who have  50% loss of Week 24 PASI 
percent improvement from baseline 
x 
 
 
 
 
 
6.6.2 Impact on Safety Endpoints 
No modifications will be made for the analysis of safety data due to COVID-19-related issues. There will 
not be any additional safety data handling considerations for missing data or treatment interruptions due to 
COVID-19. 
 Sequence of Planned Analyses 
7.1 Interim Analyses 
No interim analysis is planned for this study. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 36 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
7.2 Final Analyses and Reporting
All final, planned analyses identified in this statistical analysis plan will be performed only after the last 
subject has completed the study and the database has been locked. The randomization codes for all 
subjects will not be unblinded until after the database has been locked.  
Analyses of the palmoplantar pp-PGA 0/1 endpoint are provided for descriptive purposes within the 
individual CSR due to small sample sizes. A pooled analysis of data from IM011046 and IM011047 will be 
conducted for the submission.   
 Conventions 
8.1 General Definitions 
The following data definitions and handling conventions will be used for general analysis: 
Term 
Definition 
Study Day 
Study day is calculated as: 
assessment date – date of first dose + 1 
Baseline 
Unless otherwise stated, Baseline is defined as the measurement 
at the randomization visit (Week 0). If the measurement at the 
randomization visit is missing, then a prior measurement during the 
screening period may be used as baseline. Baseline assessments 
must be performed per protocol and standard of care assessments 
may not be used for baseline. 
Baseline for each PSSD question will be calculated as the average 
value over the 7 days prior to the randomization visit.  In the event 
of missing values in the 7 days prior to the randomization visit, daily 
scores from at least 4 days out of the 7 days can be used to 
calculate the average score. If > 3 daily scores in the last 7 days 
are missing for a particular question, then the baseline value for 
that question will be missing.  If any questions are missing baseline 
after using the described rule, then the baseline value for the 
subscore using that question and the baseline value for the total 
score will be missing. 
Change from Baseline 
Change from baseline is defined as (value at post-baseline visit – 
value at baseline). 
Change in the maximum post-
baseline value or change in the 
worst post-baseline value 
Change from baseline in the maximum post-baseline value or 
grade is defined as highest observed value post-baseline. The 
change is calculated using this value as the post-baseline value.  
Change from baseline in the worst post-baseline value is defined 
as worst observed value post-baseline. The change is calculated 
using this value as the post-baseline value. 
Concomitant and Prior Medication 
Prior medications are defined as medications with a stop date prior 
to the first dose of study treatment. Concomitant medications are 
defined as any medications ongoing at the start of study treatment 
or with a start date on or after the first dose date. 
End of Study (EOS) Date 
The EOS date is the date recorded on the eCRF that a randomized 
subject either discontinued or completed the study. If the subject is 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 37 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
lost to follow-up, the EOS date will be the date of the last visit 
assessment obtained. 
Exposure-adjusted incidence rate 
(EAIR)   
EAIR = 100* 365.25*(total number of subjects with the AE)/total 
exposure time for the selected AE under each treatment that a 
subject is exposed. Where total exposure time for each AE within a 
treatment is calculated as follows: 
x 
If a subject has at least 1 event while on a particular 
treatment, then the exposure time for that subject and AE on 
that treatment is: 
o 
First AE onset date – treatment start date (of that 
particular treatment) +1  
x 
If a subject does not have an event, exposure time for that AE 
is: 
o 
Treatment stop date (of that particular treatment) – 
Treatment start date (of that particular treatment) + 1 
+ 30 days (if subject discontinued or subject 
completed Period 3 and is not rolling into IM011075 
study) 
o 
Treatment stop date (of that particular treatment) – 
Treatment start date (of that particular treatment) + 1 
(if subject completed Period 3 and is rolling into 
IM011075 study) 
x
Total exposure time = sum of exposure time for each AE 
within a treatment 
First Dose Date – Study 
The date a subject received their first dose on Day 1 as recorded 
in the eCRF Week 0 
 dosing date or the earliest drug 
dispensation date. 
Last Dose Date – Study 
The date of last recorded dose on the eCRF for a randomized 
subject. 
First Dose Date – Period 
The date a subject received their first dose as recorded in the eCRF 
Week 0 
 dosing date or the earliest drug dispensation date for 
Treatment Period 1 and the earliest drug dispensation date for 
Treatment Periods 2 and 3. 
Last Dose Date – Period  
The date of the last visit in the periods – 1. If a subject prematurely 
discontinues study treatment within a period, the date of last 
recorded dose on the eCRF will be used as the last dose date for 
the period. 
Percent Change from Baseline 
Percent change from baseline is defined as ([value at post-baseline 
visit – value at baseline]/value at baseline) x 100. 
If the baseline value is 0 and the post-baseline value is also 0, then 
the percent change from baseline is set to 0. 
If the baseline value is 0 and the post-baseline is >0, then the 
percent change from baseline value will be missing. 
8.2 Calculation of Key Measures 
The following efficacy assessments will be used to assess subjects’ disease activity and severity during the 
study. Outcomes are reported via an eCOA tool at various times throughout the study as described in the 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 38 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
protocol Schedule of Activities. At study visits, assessments by the investigator or subjects and 
results/responses will be reported directly into the eCOA tool at the time of the visit. The tool will open 
assessments in a sequential manner, meaning that the full assessment is to be completed prior to moving 
forward to the next assessment. This limits the possibility of partially missing data. Also, as 
investigators/subjects are prompted to enter data for each assessment for the visit, the possibility of a full 
assessment being missing is also negated.  
Scoring of assessments where validated algorithms are not required will be derived in SAS datasets. 
Scoring of assessments where validated scoring tools are required, licenses for these tools will be 
purchased and used for scoring prior to incorporating into the SAS datasets. 
8.2.1 Investigator-Administered Assessments 
Assessments will be performed by a qualified physician or dermatologist or trained designee who is 
experienced in the assessment of psoriasis patients. To limit variability, every effort will be made so that 
the same individual conducts the assessment at all subsequent visits. 
8.2.1.1 static Physician’s Global assessment (sPGA) 
The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, 
and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking 
into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe 
(4). A higher score equates to higher severity of disease. 
The individual scores at each visit for erythema (E), induration (I) and scaling (S) will be captured via the 
eCOA system. Scores will range from 0 to 4. A total score will also be computed based on the average of 
the 3 characteristic scores. 
ܶ݋ݐ݈ܽܽݒ݁ݎܽ݃݁ݏܿ݋ݎ݁ൌܧ൅ܫ൅ܵ
͵
 
The total average score will be calculated in the eCOA system. The average score will be rounded to the 
QHDUHVWZKROHQXPEHU)RUH[DPSOHLIWKHWRWDODYHUDJHVFRUHLVWKHVFRUHZLOOEHURXQGHGWR,I
thHVFRUHLVWKHVFRUHZLOOEHURXQGHGWR7KHSULPDU\HQGSRLQWLVGHULYHGIURPWKHWRWDODYHUDJH
score.  
sPGA 0 is derived as the binary indicator for sPGA from the calculation above equal to 0 or not; 
sPGA 0/1 is derived as the binary indicator for sPGA from the calculation above equal is less than 2 or not; 
 
All individual scores and total average score assessed at each week throughout the study will be transferred 
to 
 for analysis. The endpoint derivations will be performed in the analysis datasets. 
8.2.1.2 Psoriasis Area and Severity Index (PASI) 
The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each 
graded on a 0–4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, arms, 
trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 
72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores 
and a final total score that will be provided by the eCOA system. Individual plaque characteristic rating 
scores are provided for each body region as well as the weighted score. Additionally, the degree of 
involvement of each body region is assessed and that score is multiplied by the weighted plaque 
characteristic score for a final score for each body region. The total PASI score is a sum of the 4 body 
regions: Head, Upper Extremities, Trunk and Lower Extremities.  
The PASI Total score will be used to assess response to treatment. The percent change from baseline will 
be calculated at each visit. The PASI 75 endpoint is the proportion of subjects who experience at least a 
75% improvement in PASI score as compared with the baseline value.  
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 39 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
1 = ܫ݂ ቀ
஻௔௦௘௟௜௡௘௉஺ௌூି௏௜௦௜௧௉஺ௌூ
஻௔௦௘௟௜௡௘௉஺ௌூ
ቁݔͳͲͲ ൒͹ͷݐ݄݁݊ݏݑܾ݆݁ܿݐ݅ݏܽܲܣܵܫ͹ͷݎ݁ݏ݌݋݊݀݁ݎ 
0 = otherwise 
The PASI 50, PASI 90, and PASI 100 are defined similarly. The endpoint derivations will be performed in 
the analysis datasets. 
8.2.1.3 Body Surface Area (BSA) 
Measurement of psoriasis BSA involvement is estimated using the handprint method with the size of a 
subject’s handprint (including fingers and thumb) representing 1% of BSA involved. The total BSA = 100% 
with breakdown by body region as follows:  
x 
Head and neck = 10% (10 handprints),  
x 
Upper extremities = 20% (20 handprints),  
x 
Trunk including axillae and groin = 30% (30 handprints),  
x 
Lower extremities including buttocks = 40% (40 handprints).  
The Total BSA is the sum of each body region and is assessed at each visit and recorded in the eCOA 
system.  
The product of BSA and sPGA will be calculated. At baseline, baseline BSA will be multiplied by baseline 
sPGA score. The derivation will be performed at each subsequent visit. 
8.2.1.4 scalp specific Physician’s Global Assessment (ss-PGA) 
The scalp specific assessment will only be performed in subjects with scalp involvement. If there is evidence 
of scalp involvement, scalp lesions are evaluated in terms of clinical signs of redness, thickness, and 
scaliness and scored on the following 5-point ss-PGA scale: 
0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease. 
The ss-PGA is assessed at each visit throughout the study in subjects that have evidence of scalp psoriasis 
at baseline. The score will be collected in the eCOA system. 
8.2.1.6 Physician’s Global Assessment-Fingernails (PGA-F) 
In this assessment, fingernail psoriasis is evaluated. The PGA-F will be performed at baseline. If a subject 
shows evidence of psoriatic fingernail involvement, the assessment will be performed at each subsequent 
visit to assess severity and improvement over time. Only subjects with PGA-F at baseline will be assessed 
throughout the study. The overall condition of the fingernails is rated on a 5-point scale: 
0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe 
The rating score will be collected in the eCOA system. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 40 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.2.1.8 Palmoplantar PGA (pp-PGA) 
This measure will be used for subjects with palmoplantar (finger and toe surfaces) involvement at baseline. 
Only subjects with baseline palmoplantar involvement will continue to have these assessments at each 
subsequent visit throughout the study. The pp-PGA uses a 5-point (0-4) overall severity scale: 
0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe. 
Scores are collected at each visit and entered in the eCOA system. 
 
 
 
 
 
 
 
 
 
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 41 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 
8.2.2 Subject-Reported Assessments 
8.2.2.1 Psoriasis Symptoms and Signs Diary (PSSD) 
The PSSD is an 11-item subject-reported instrument that assesses severity of symptoms and subject-
observed signs commonly associated in plaque psoriasis. It has been shown to be reliable and valid in 
measuring symptoms and signs of subjects with moderate-to-severe plaque psoriasis in the clinic and has 
strong psychometric properties in assessing treatment effects in clinical trials. The PSSD assesses severity 
of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 subject-observed signs (skin dryness, 
cracking, scaling, shedding or flaking, redness, bleeding) using 0–10 numerical ratings. The severity of 
each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable).  
The following questions in the instrument are included in the symptom score: Q1, Q4, Q9, Q10, Q11 
The following questions in the instrument are included in the sign score: Q2, Q3, Q5, Q6, Q7, Q8 
Two versions of the PSSD were developed, one with a 24-hour recall period (PSSD-24h) and one with a 7-
day recall period. The PSSD-24h will be administered daily in this trial to avoid recall bias with a longer 
recall period. Individual scores to each question are collected daily in the PSSD. For visit PSSD scoring, 
the daily scores (with 24-h recall periods) over the prior 7 day will be used and the average score to each 
of the 11 questions will be used as the score at that visit. In case missing data arise during the 7 days prior 
to the visit, daily scores of at least 4 days out of the 7 can be used. If >3 scores are missing, the average 
score will be missing. Baseline PSSD score is calculated based on the daily diary collected data during the 
screening period. Baseline for each PSSD question will be calculated as the average value over the 7 days 
prior to the randomization visit.  In the event of missing values in the 7 days prior to the randomization visit, 
daily scores from at least 4 days out of the 7 days can be used to calculate the average score. If > 3 daily 
scores in the last 7 days are missing for a particular question, then the baseline value for that question will 
be missing.  If any questions are missing baseline after using the described rule, then the baseline value 
for the subscore using that question and the baseline value for the total score will be missing. 
A symptom score will be derived by averaging the 5 questions included in the symptom score and 
multiplying by 10. To obtain a symptom score on a given day, responses to at least 2 of the 5 questions 
must be available. If 3 or more questions are missing, the symptom score is considered missing.  
A sign score will be derived by averaging the 6 questions included in the sign score and multiplying by 10. 
Responses to at least 3 of the 6 questions must be available in order to obtain a sign score for a given day. 
If more than 3 questions are missing, the sign score is considered missing. 
Both scores range from 0-100, where 0 representing the least severe symptom/sign and 100 the most 
severe. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and 
sign scores.  
8.2.2.2 Dermatology Life Quality Index (DLQI) 
The DLQI is a subject-reported quality of life index which consists of 10 questions concerning symptoms 
and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last 
week. Each question is scored on a scale of 0 to 3 where 0="not at all", 1="a little", 2="a lot", or 3="very 
much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum 
impairment). Question 7 includes 2 questions, if the subject answers ‘Yes’ to Q7, the score given is a 3. If 
the subject answers ‘No’ to Q7, they are asked the second question where a score of 0=’not at all’, 1=’a 
little’, or 2=’a lot’ is given. Certain questions include an option for not relevant. When scoring, any questions 
deemed ‘not relevant’ will take on a value of 0. 
. Interpretation of DLQI scores is as follows: 
x 
0-1 = no effect at all on patient’s life 
x 
2-5 = small effect on patient’s life 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 42 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
6-10 = moderate effect on patient’s life 
x 
11-20 = very large effect on patient’s life 
x 
21-30 = extremely large effect on patient’s life 
Individual scores for each question will be provided by the eCOA system. The DLQI score will be derived 
in the analysis datasets. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 43 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
8.2.2.8 Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire 
The PASE questionnaire will be administered at Screening in subjects with peripheral joint complaints. The 
PASE questionnaire is a self-administered tool that is used to screen for psoriatic arthritis among subjects 
who have psoriasis. The PASE questionnaire consists of 15 questions subdivided into 7 questions focusing 
on symptoms of psoriatic arthritis, and 8 questions focusing on the impact of psoriatic arthritis on function. 
Each question is scored on a 1 to 5 scale, with a maximum symptom sub-scale score of 35, a maximum 
function sub-scale score of 40 giving a total maximum score of 75. A score of 47 or above has been shown 
to distinguish between psoriatic arthritis and non-psoriatic arthritis. This questionnaire is only intended to 
be a screening tool for psoriatic arthritis and does not replace a comprehensive musculoskeletal exam 
performed by a rheumatologist. This information will not be summarized. 
8.2.2.9 Eight-Item Patient Health Questionnaire (PHQ-8) 
The PHQ-8 is established as a valid diagnostic and severity measure for depressive disorders in large 
clinical studies. Each of the 8 questions is based on a 2-week recall and scored on a scale of 0 to 3 by a 
tick box as: 0=Not at All, 1=Several Days, 2=More than Half the Days, and 3=Nearly Every Day. A PHQ-8 
score is derived by summing the scores for the 8 questions. The total PHQ-8 score ranges from 0-24. 
Scoring interpretation is as follows: 
x 
0-4 = no significant depressive symptoms 
x 
5-9 = mild depressive symptoms 
x 
10-14 = moderate depressive symptoms 
x 
15-19 = moderately severe depressive symptoms 
x 
20-24 = severe depressive symptoms 
Response to each individual question is collected in the eCOA system. The total score will be derived in 
the analysis datasets. 
8.2.2.10 electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) 
The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a computer-automated, patient-
reported version of the C-SSRS instrument that defines 11 categories of suicidal ideation and behavior 
(SIB) events. Categories and definitions are provided in Appendix 23 of the protocol. The categories are as 
follows: 
x 
Suicidal ideation 
1. Wish to be dead 
2. Non-specific active suicidal thoughts 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 44 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
3. Active suicidal ideation with any methods without intent to act 
4. Active suicidal ideation with some intent to act, without specific plan 
5. Active suicidal ideation with specific plan and intent 
x 
Suicidal behavior 
1. Preparatory acts or behavior 
2. Aborted attempt 
3. Interrupted attempt 
4. Actual attempt (Non-fatal) 
5. Completed suicide 
x 
Self-injurious behavior, no suicidal intent 
8.3 Missing, Unknown, or Partial Dates 
Start Date 
Stop Date 
Complete: 
yyyymmdd 
Partial: yyyymm 
Partial: yyyy 
Missing/
Ongoing 
<1st
dose 
st 
dose 
<1st dose 
yyyymm 
st dose 
yyyymm 
<1st dose 
yyyy 
st dose 
yyyy 
Partial: 
yyyymm 
= 1st dose 
yyyymm 
2 
1 
n/a 
1 
n/a 
1 
1 
st dose 
yyyymm 
2 
2 
2 
2 
2 
2 
Partial: 
yyyy 
= 1st dose 
yyyy 
3 
1 
3 
1 
n/a 
1 
1 
st dose 
yyyy 
3 
3 
3 
3 
3 
Missing 
4 
1 
4 
1 
4 
1 
1 
1 = Impute as the date of first dose 
2 = Impute as the first of the month 
3 = Impute as January 1 of the year 
4 = Impute as January 1 of the stop year 
Note: If the start date imputation leads to a start date that is after the stop date, then there is a data error 
and do not impute the start date. 
Imputation rules for partial or missing stop dates: 
1. Initial imputation 
a. For partial stop date “mmyyyy”, impute the last of the month. 
b. For partial stop date “yyyy”, impute December 31 of the year. 
c. For completely missing stop date, do not impute. 
2. If the stop date imputation leads to a stop date that is after the death date, then impute the 
stop date as the death date. 
3. If the stop date imputation leads to a stop date that is before the start date, then there is a 
data error and do not impute the stop date. 
Imputation rules for partial or missing death dates: 
1. If death year and month are available but day is missing: 
a. If “mmyyyy” for last contact date = “mmyyyy” for death date, set death date to the day 
after the last contact date. 
b. If “mmyyyy” for last contact date < “mmyyyy” for death date, set death date to the first 
day of the death month. 
c. If “mmyyyy” for last contact date > “mmyyyy” for death date, data error and do not 
impute. 
If both month and day are missing for death date or a death date is totally missing, set death date to the 
day after the last contact date. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 45 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
8.4 Study Periods
Period 1 = Week 0 to Week 16 visit date  
Period 2 = Week 16 visit date +1 to Week 24 visit date  
Period 3 = Week 24 visit date +1 to Week 52 visit date 
Follow-up = 4-week follow-up period 
8.5 Day Ranges for Analysis Visits 
Below are the day ranges for the analysis visit definitions. If more than one visit occurs within an analysis 
visit, then the visit that is closest to the target date should be used for analysis. 
Period                            
Week 
Target Day 
Day Range 
Baseline
Screening, 1
Period 1 
 
 
Week 1 
8 
2, 11 
Week 2 
15
12, 18 
Week 4 
29
19, 43 
Week 8 
57
44, 71 
Week 12
85
72, 99
   Week 16 
113 
100, 127 (or Week 16 drug dispense date) 
Period 2 
 
 
Week 20 
141 
1st day after Week 16 drug dispense date, 155 
Week 24 
169 
156, 183 (or Week 24 drug dispense date) 
Period 3 
 
 
Week 28
197
1st day after Week 24 drug dispense date, 211
   Week 32 
225 
212, 239 
   Week 36 
253 
240, 267 
   Week 40 
281 
268, 295 
   Week 44 
309 
296, 323 
   Week 48 
337 
324, 351 
Week 52
365
352, last visit date prior to Safety Follow-up
Safety Follow-up 
393 
Safety Follow-up visit 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 46 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 References 
x 
Campbell G, Pennello G, Yue L. Missing data in the regulation of medical devices. Journal of 
Biopharmaceutical Statistics 2011;21:180-195. 
x 
Yan X, Lee S, Li N. Missing data handling methods in medical device clinical trials. Journal of 
Biopharmaceutical Statistics 2009;19:1085-1098. 
x 
Kenward MG, Roger J. Small sample inference for fixed effects from restricted maximum likelihood. 
Biometrics 1997;53(3):983-997. 
x 
Rubin, DB (1987). Multiple Imputation for Nonresponse in Surveys. New York, J. Wiley & Sons. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 47 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 Document History 
Version Number 
Version Date 
Summary of Changes 
1.0  - Original 
Document 
09-Jun-2019 
Not applicable 
2.0 – Amendment 
01 
30-Sep-2020 
Revisions provided below.
Revisions for Amendment 01: In addition to the revisions specified below, there were some minor 
typographical and formatting changes made. Additions are noted by bold text. Removals are noted by 
strikethrough. 
SAP Section 
Revised Text 
Rationale for 
Change 
2.0 Study 
Description 
2.1 Study Design 
Following a screening period of up to 4 weeks, qualified 
subjects who have completed the screening procedures and 
have met the inclusion/exclusion criteria will be randomized in 
a blinded manner in a 2:1:1 ratio via interactive response 
technology (IRT) to one of the following 3 treatment groups: 
Dummy tablets (placebo for the BMS-986165 6 mg tablet, 
placebo for apremilast 30 mg tablet BID, and placebo for 
apremilast 10 mg, 20 mg, 30 mg during titration) will be 
administered to the subjects to maintain blinding in a double-
dummy fashion. Note that apremilast will not be used as a 
treatment arm in China. 
Week 16 activities 
The coprimary endpoints, static Physician Global Assessment 
(sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75 
will be assessed at Week 16. Subjects receiving placebo will 
be switched in a blinded manner to BMS-986165 6 mg QD at 
Week 16. Subjects who are randomized to BMS-986165 6 mg 
QD or apremilast will continue on their assigned treatment 
regimen in a blinded manner. 
Clarified 
randomization is 
done is a blinded 
fashion. 
Removed 
reference to 
apremilast in 
China as this is 
only applicable to 
IM011046, 
2.5 Changes in 
Statistical 
Considerations 
from the Protocol 
There are no changes in statistical considerations from the 
protocol at this time. The following is a list of the important 
changes in the SAP from the Statistical Considerations 
section in the protocol: 
x 
The hierarchical testing order for the key secondary 
endpoints has been updated and two separate 
hierarchies have been provided, one for US 
The definition for 
the Full Analysis 
Set was modified 
to include all 
randomized 
subjects. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 48 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
submission and one for ex-US submission (see 
Tables 1 and 2 in Sec. 6.1.3).  The hierarchies 
presented here supersede the one that is in the 
protocol. 
x 
Key secondary endpoints were added for the 
comparison of BMS-986165 to apremilast for sPGA 
0/1, PASI 75, and PASI 90 at Week 24. 
x 
Imputation methods were updated to remove the 
prohibited medication/therapy criteria for binary 
and continuous endpoints. 
x 
The Full Analysis Set was changed from “all 
subjects who were randomized to receive assigned 
study treatment” in the protocol to “all subjects 
who are randomized”. 
x 
The list of relevant protocol deviations provided in 
the protocol was updated for determination of the 
Per Protocol population. 
x 
Logistic regression analyses for binary endpoints 
were removed as these are similar to the CMH 
analyses. 
Noted that the 
relevant deviation 
list was updated 
from the list in the 
protocol. 
Additional Week 
24 endpoints 
were added. 
Imputation 
methods were 
updated to 
remove 
prohibited 
medication/ 
therapy criteria. 
Hierarchical 
testing order of 
key secondary 
endpoints were 
updated and 
accounting of 
regional 
regulatory needs.  
Removed logistic 
regression 
analyses. 
3.2 Secondary 
 
Objectives 
x 
Assess whether BMS-986165 is superior to 
apremilast in scalp psoriasis through Week 16 in 
those subjects who have baseline ss-PGA score 3 
x
Assess 
whether 
BMS-986165 
is 
superior 
to 
placeboapremilast in nail psoriasis through Week 16 in 
those subjects who have baseline PGA-F psoriasis 
score 3 
Aligned 
objectives with 
the most recent 
protocol 
amendment. 
4.1.2 Secondary 
Endpoints 
4.1.2.1 Key 
Secondary 
Endpoints for 
Comparisons to 
Placebo 
The key secondary efficacy endpoints for BMS-986165 
compared to placebo at Week 16 are defined as: 
x 
PASI 90 response assessed as a proportion of subjects 
who achieve a 90% improvement from baseline in PASI 
score 
x 
sPGA 0 response assessed as a proportion of subjects 
with an sPGA score of 0 
x
Scalp specific Physician’s Global Assessment (ss-
PGA) 0/1 assessed as a proportion of subjects with a 
ss-PGA score of 0 or 1 with at least a 2-point 
improvement from baseline among subjects with a 
baseline ss-PGA score 3 
x 
PSSD symptom score of 0 assessed as a proportion of 
subjects with a PSSD symptom score of 0 among 
subjects with a baseline PSSD symptom score 1 
Updated key 
secondary 
endpoints 
compared to 
placebo and re-
ordered. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 49 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
PASI 100 response assessed as a proportion of 
subjects who achieve a 100% improvement from 
baseline in PASI score 
x 
Physician Global Assessment-Fingernails (PGA-F) 0/1 
assessed as a proportion of subjects with a PGA-F 
score of 0 or 1 with at least a 2-point improvement from 
baseline among subjects with a baseline PGA-F score 
3 
x 
Change from baseline in Psoriasis Symptoms and 
Signs Diary (PSSD) symptom score 
x 
DLQI 0/1 assessed as a proportion of subjects with a 
DLQI score of 0 or 1 among subjects with a baseline 
DLQI score 2 (Ex-US submission only) 
x 
Palmoplantar Physician’s Global Assessment (pp-PGA) 
0/1 assessed as a proportion of subjects with a pp-PGA 
score of 0 or 1 with at least a 2-point improvement from 
baseline among subjects with a baseline pp-PGA score 
3 
An additional key secondary endpoint to assess the 
maintenance and durability of efficacy of BMS-986165 during 
the randomized withdrawal period through Week 52 among 
Week 24 PASI 75 responders compared with re-randomized 
placebo is defined as: 
x 
MediantTime-to-relapse (where relapse is defined as  
50% loss of Week 24 PASI percent improvement from 
baseline) until Week 52 for Week 24 BMS-986165 PASI 
75 responders (Ex-US submission only) 
4.1.2.2 Key 
Secondary 
Endpoints for 
Comparisons to 
Apremilast 
The key secondary endpoints for BMS-986165 compared to 
apremilast at Week 16 are defined as: 
x 
sPGA 0/1 response assessed as a proportion of 
subjects with an sPGA score of 0 or 1 with at least a 2-
point improvement from baseline 
x 
PASI 75 response assessed as a proportion of subjects 
who achieve a 75% improvement from baseline in the 
PASI score 
x 
PASI 90 response assessed as a proportion of subjects 
who achieve a 90% improvement from baseline in the 
PASI score 
x 
Change from baseline in PSSD symptom score 
x 
ss-PGA 0/1 assessed as a proportion of subjects with a 
ss-PGA score of 0 or 1 with at least a 2-point 
improvement from baseline among subjects with a 
baseline ss-PGA score 3 
x 
PASI 100 response assessed as a proportion of 
subjects who achieve a 100% improvement from 
baseline in the PASI score 
Updated key 
secondary 
endpoints 
compared to 
apremilast and 
re-ordered. 
Added some 
clarifying 
language. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 50 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
sPGA 0 response assessed as a proportion of subjects 
with an sPGA score of 0 
x 
PSSD symptom score of 0 assessed as a proportion of 
subjects with a PSSD symptom score of 0 among 
subjects with a baseline PSSD symptom score 1
The key secondary endpoints for BMS-986165 compared to 
apremilast at Week 24 are defined as: 
x 
sPGA 0/1 response assessed as a proportion of 
subjects with an sPGA score of 0 or 1 with at least 
a 2-point improvement from baseline at Week 24 
x 
PASI 75 response assessed as a proportion of 
subjects who achieve a 75% improvement from 
baseline in the PASI score at Week 24 
x 
PASI 90 response assessed as a proportion of 
subjects who achieve a 90% improvement from 
baseline in the PASI score at Week 24 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 51 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 52 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
4.2 Safety 
x 
Treatment-emergent adverse events (TEAEs) – defined 
as: 
o 
New nonserious AEs which first occur after the 
first dose of study treatment through 30 days 4 
weeks after the final dose of the study 
treatment or subject’s participation in the study 
if the last scheduled visit occurs at a later time.;  
New serious adverse events (SAEs) which first 
occur after the first dose of study treatment 
through 4 weeks after the final dose of the study 
treatment or subject’s participation in the study 
if the last scheduled visit occurs at a later time;  
Removed 
redundant 
language for 
treatment-
emergent 
adverse events. 
Clarified final list 
for adverse 
events of interest. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 53 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
o 
SAEs reported prior to first dose of study 
treatment that increase in severity or frequency 
after first dose of study treatment through 4 
weeks after the final dose of the study 
treatment or subject’s participation in the study 
if the last scheduled visit occurs at a later time.  
o 
Treatment-emergent adverse events of interest (AEIs) as 
determined through the Clinical Safety Program (CSP) for 
the following events: 
 
Skin-related AEs 
 
Infection AEs, including influenza 
 
Creatine kinase (CK) elevation (evaluated as lab toxicity 
grade 2 or higher) 
 
Malignancy 
 
 
Deaths 
 
o
Laboratory abnormalities (as determined by Common
Terminology Criteria for Adverse Events [CTCAE v5.0] 
grading) presented as the worst postbaseline toxicity 
group 
o 
Shifts from baseline to maximum postbaseline value  
 
o 
ALT or AST elevation >5 times ULN 
msec 
 
Males: < 450 msec,  450 msec 
)HPDOHVPVHFPVHF 
 
In cases where the QT interval is corrected using Bazett’s 
(QTcB) formula is captured instead of QTcF, then QTcB 
will be converted to QTcF for analyses. 
 
x 
Eight-Item Patient Health Questionnaire (PHQ-8) total 
score 
o 
Absolute and change from baseline values 
o 
Shifts from baseline scores 
o 
PHQ-ϴƚŽƚĂůƐĐŽƌĞƐшϭϱ 
 
o 
Electronic Columbia-Suicide Severity Rating Scale (eC-
SSRS) 
o 
eC-SSRS itemsSuicidal ideation and suicidal 
behavior responses by visit  
o 
Shifts from baseline to postbaseline value for 
suicidal ideation and suicidal behavior 
Specified that 
deaths would be 
evaluated. 
Version number 
added for 
CTCAE. 
Added missing 
msec for ECG 
category, new 
categories for 
ECG by males 
and females, and 
clarification that 
QTcB will be 
converted to 
QTcF for 
analysis.Remove
d PHQ-8 total 
scores >=15 as 
this is provided in 
the shift table. 
Clarified the 
variables for eC-
SSRS to be 
summarized. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 54 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
o 
Worst postbaseline value for suicidal ideation 
and behavior through Week 16 
5.0 Populations 
for Analysis 
Full Analysis Set (FAS): All subjects who are randomized 
subjects who are assigned study treatment. 
Per Protocol Set (PPS): A subset of the FAS who are 
compliant with study treatment and who do not have any 
statistically relevant protocol deviations that may impact the 
coprimary efficacy endpoint assessments.  
The definition for 
the Full Analysis 
Set was modified 
to clarify that the 
population 
includes all 
randomized 
subjects. 
Removed 
“statistically” from 
relevant 
deviations in the 
PPS description 
to align with 
standard naming. 
5.1 Relevant 
Protocol 
Deviations 
Relevant protocol deviations are deviations that can have an 
impact on the primary efficacy endpoints. The impact of relevant 
protocol deviations on the primary efficacy results will be 
assessed by excluding subjects from the FAS to define the PPS 
in supportive analyses of the primary efficacy endpoints. 
Relevant protocol deviations to be considered regarding 
exclusion of subjects from the FAS will include the following: 
• 
Randomized but did not take any study treatment 
• 
No postbaseline PASI or sPGA 
• 
Baseline BSA involvement < 10% 
• 
Baseline PASI score < 12 
• 
Baseline sPGA < 3 
• 
Did not have non-plaque psoriasis at baseline 
 
• 
Poor compliance to study medication within the first 16 
weeks of treatment defined as <8075% compliant with 
study   
• 
Failure to adhere to prohibited concomitant medication 
restrictions as described below: 
o 
Investigational drug or placebo taken 
outside of the study any time between Day 
1 and the Week 16 assessment 
o 
Phototherapy within 4 weeks prior to the 
Week 16 assessment 
o 
Biologic medications (eg, adalimumab, 
etanercept, infliximab, ustekinumab) any 
time between Day 1 and the Week 16 
assessment  
o 
Oral 
psoriasis 
medications 
any 
time 
between Day 1 and the Week 16 assessment 
o 
Oral 
corticosteroids 
(unless 
for 
the 
treatment of an adverse event) within 4 
weeks prior to the Week 16 assessment 
Deviations were 
updated with final 
categories. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 55 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
o 
Topical medications/treatments that could 
affect psoriasis evaluations within 2 weeks 
prior to the Week 16 assessment 
o 
Medicated shampoos within 2 weeks prior 
to the Week 16 assessment 
• 
Subject overdosed, misused or abused study treatment 
prior to Week 16 
• 
Actual treatment received is different than randomized 
treatmentSubject received treatment that was 
different than intended treatment at any visit prior 
to Week 16. 
All subjects with relevant protocol deviations will be identified 
prior to database lock and unblinding of treatment assignment 
with the exception of subjects where actual treatment 
received is different than randomized treatment which will 
be determined after treatment unblinding. Relevant protocol 
deviations will be summarized by treatment group and deviation 
category for the FAS population. 
Additionally, all important protocol deviations, which are 
deviations that may impact the efficacy and safety of subjects, 
will be identified prior to database lock and unblinding of 
treatment assignment. Important protocol deviations will be 
summarized by treatment group and deviation category for the 
FAS population. 
6.1 Efficacy 
Analyses 
Tests of significance of BMS-986165 6 mg QD vs. placebo for 
the coprimary endpoints will be two-sided with a significance 
level of 0.05. Both coprimary endpoints need to demonstrate 
statistical significance to result in a successful study. 
The key secondary endpoints will be tested with a two-sided 
with a significance level of 0.025 to compare BMS-986165 
6mg QD vs. placebo and vs. apremilast (equivalent to 0.05 
level of significance). A hierarchical testing approach will be 
used in for testing of key secondary endpoints (see Section 
6.1.3)within each comparison branch. Two-sided 95% 
confidence intervals (CIs) will be provided for all efficacy 
estimates. 
 
 
Coprimary and key secondary efficacy endpoints will be 
displayed graphically by treatment group and visit, as 
applicable. Binary endpoints will be displayed using bar charts 
and continuous endpoints will be displayed using line plots. All 
efficacy endpoints will be summarized descriptively. 
 The stratified levels are provided below: 
 
US/PRIOR USE/< 90 KG 
 
US/PRIOR USE/>=90 KG  
 
US/NAÏVE/<90 KG  
 
US/NAÏVE/>=90 KG  
 
ROW/PRIOR USE/< 90 KG 
 
ROW/PRIOR USE/>=90 KG  
Removed plot 
description to 
allow flexibility in 
data presentation 
plan. 
Clarified the 
language for 
testing of 
secondary 
endpoints. 
Updated the 
stratification 
levels to a 
combination 
stratification 
factor to align 
with IM011046. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 56 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
 
ROW/NAÏVE/<90 KG  
 
ROW/NAÏVE/>=90 KG 
6.1.1 Primary 
Endpoints 
6.1.1.1 Primary 
Analysis 
Analysis Model 
A stratified Cochran-Mantel-Haenszel (CMH) test will be used 
to compare the sPGA 0/1 response rates at Week 16 between 
BMS-986165 6 mg QD and placebo using the stratification 
factors from IRT specified in Section 6.1. The following 
prognostic factors are included in the model: geographic 
region (U.S. and Rest of World), body weight (<90 kgNJ
and prior biologic use (yes/no). The odds ratio (ratio of odds in 
BMS-986165 6 mg QD group to the odds in the placebo group) 
and the corresponding 2-sided 95% CIs and p-values will be 
reported. Additionally, treatment differences in proportions and 
the 95% CI for the treatment difference will be provided. The 
common treatment difference in proportion with the confidence 
interval, common odds ratio with the confidence interval and p-
value will be estimated by the Mantel-Haenszel method 
consistently. A similar analysis will be performed to compare 
the PASI 75 response rates at Week 16 between BMS-986165 
6mg QD and placebo. 
 
A similar analysis will be performed to compare the PASI 75 
response rates at Week 16 between BMS-986165 6mg QD and 
placebo. 
Imputation Methodology 
Non-responder imputation (NRI) will be used for coprimary 
efficacy endpoints for subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x 
Start a protocol prohibited medication/therapy that 
could improve psoriasis during the first 16 weeks of 
treatment, or 
x 
Have missing Week 16 endpoint data for any reason 
Subjects taking protocol prohibited medications during the first 
16 weeks of treatment will be identified prior to database lock 
and treatment unblinding. NRI will be used as the primary 
method of imputation for the coprimary efficacy endpoints. 
Clarified 
stratification to be 
used and 
removed 
prohibited 
medication 
criteria. 
6.1.1.2 
Sensitivity 
Analyses 
As a method to assess the sensitivity of the primary imputation 
method for the coprimary endpoints, further imputation 
methods will be used to impute Week 16 data in subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x
Start a protocol prohibited medication/therapy that 
could improve psoriasis during the first 16 weeks of 
treatment, or 
x 
Have missing Week 16 endpoint data for any reason 
Tipping Point Analysis 
Tipping point analysis will further be used to assess the 
robustness of the primary study results. Different number of 
Removed 
prohibited 
medication 
criteria. 
Added some 
clarification for 
the tipping point 
analysis. 
Added a 
sensitivity 
analysis for 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 57 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
events between treatment groups will be assessed until the 
study conclusion is changed. Each imputed value is initially 
imputed as a responder. The imputed values in the placebo 
group will remain as responders while the BMS-986165 imputed 
values are replaced as a nonresponders one at a time, therefore 
changing the number of events between groups. Once all 
imputed values in the BMS-986165 group have been replaced 
with nonresponders values, the data will reset to where the 
BMS-986165 group imputed values are all responders and one 
by one the imputed values in the placebo group are replaced 
with a nonresponder until all placebo are nonresponders and all 
BMS-986165 are responders. Furthermore, every pair of 
imputations between the placebo and BMS-986165 groups will 
be assessed similarly, creating a matrix of possible patterns.  
At each iteration, the statistical analysis is assessed, and the 
direction of the analysis is recorded. A graph will be provided to 
identify at what point to which the difference in events cause a 
direction shift in study results. The tipping point analyses will 
be based on a two-sample chi-square test approach rather 
than a stratified CMH test approach for simplicity of the 
analysis.  
Multiple Imputation 
Multiple imputation (MI) will be used for sensitivity analyses 
for each of the coprimary efficacy endpoints, PASI 75 
response at Week 16 and sPGA 0/1 response at Week 16. 
Multiple imputation of missing data for PASI 75 response 
and sPGA 0/1 response will be performed by fully 
conditional specification (FCS) using PROC MI in SAS with 
the FCS option. The FCS MI specifies the multivariate 
imputation model on a variable-by-variable basis by a set 
of conditional densities. For each missing value at Week X, 
the FCS MI will generate values from a conditional 
distribution for the missing data given the other data prior 
to Week X. The FCS MI model will include treatment group 
and stratification factors for randomization. A total of 1000 
imputed (complete) datasets will be generated for the MI 
analysis. The same test procedure used for the main 
analysis (CMH test), will be used to analyze the responder 
endpoint 
from 
each 
imputed 
dataset. 
SAS 
PROC 
MIANALYZE will be used to pool the results from the CMH 
tests and generate an overall result by Rubin’s rules (1987). 
multiple 
imputation. 
6.1.1.3 
Supportive 
Analyses 
Additional Analysis 
Additionally, a logistic regression model will be used to 
compare the sPGA 0/1 response rates at Week 16 between 
BMS-986165 6mg QD and placebo. The prognostic factors will 
be included in the model as covariates. The estimated odds of 
response with corresponding 2-sided 95% CIs and p-values 
will be reported. A similar analysis will be performed on the 
PASI 75 response rates at Week 16. These analyses will be 
performed on the FAS. 
Removed this 
analysis since it 
similar to CMH 
analysis. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 58 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.1.2 Key 
Secondary 
Endpoints 
6.1.2.1 Binary 
Endpoints 
Analysis Model 
CMH tests will be used to compare response rates between 
either BMS-986165 6mg QD and placebo or apremilast using 
the stratification factors from IRT specified in Section 6.1. 
The following prognostic factors are included in the model: 
geographic region (U.S. and Rest of World), body weight (<90 
NJNJ) and prior biologic use (yes/no). The odds ratio (ratio 
of odds in BMS-986165 6 mg QD group to the odds in the 
placebo or apremilast group) and the corresponding 2-sided 
95% CIs and p-values will be reported. Additionally, treatment 
differences in proportions and the 95% CI for the treatment 
difference will be provided from Chi-square tests. 
Imputation Methodology for Week 16 Endpoints 
NRI will be used for coprimarykey secondary efficacy 
endpoints for subjects who: 
x 
Discontinue treatment or study prior to Week 16 
x
Start a protocol prohibited medication/therapy that 
could improve psoriasis during the first 16 weeks of 
treatment, or 
x 
Have missing Week 16 endpoint data for any reason 
Subjects taking protocol prohibited medications during the first 
16 weeks of treatment will be identified prior to database lock 
and treatment unblinding. NRI will be used as the primary 
method of imputation for the coprimaryefficacy endpoints. 
Imputation Methodology for Week 24 Endpoints (for 
comparison of BMS-986165 6 mg QD to apremilast) 
NRI will be used for key secondary efficacy endpoints for 
subjects who: 
x 
Discontinue treatment or study prior to Week 24 
x 
Have missing Week 24 endpoint data for any reason 
Subjects taking protocol prohibited medications will be 
identified prior to database lock and treatment unblinding. 
Clarified 
stratification to be 
used and 
removed 
prohibited 
medication 
criteria. 
Corrected 
coprimary to key 
secondary. 
Added imputation 
for Week 24 
endpoints. 
 
6.1.2.2 
Continuous 
Endpoints 
Analysis Model 
Analysis of covariance (ANCOVA) models will be used to 
compare the change between BMS-986165 6 mg QD and 
placebo or between BMS-986165 6 mg QD and apremilast at 
Week 16. Treatment group will be included in the model as well 
as the stratification factors from IRT specified in Section 
6.1following baseline prognostic factors: geographic region 
(U.S. and 5HVWRI:RUOGERG\ZHLJKWNJNJDQGSULRU
biologic use (yes/no) and will be considered as fixed effects. The 
baseline value will be added into the model as a covariate. The 
adjusted least-squares (LS) means as well as the treatment 
differences based on LS means and the corresponding 2-sided 
95% CIs will be provided for the difference between BMS-
986165 6 mg QD and placebo or apremilast. 
Clarified 
stratification to be 
used and 
removed 
prohibited 
medication 
criteria. 
Added a 
clarification that 
subjects with 
missing baseline 
values will be 
excluded from 
the analysis for 
change from 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 59 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Imputation Methodology for Week 16 Endpoints 
For continuous key secondary endpoints, a modified baseline 
observation carried forward (mBOCF) approach will be used for 
missing data. The baseline observation will be carried forward 
for subjects who discontinue study treatment prior to Week 16 
due to: 
x 
Lack of efficacy 
x 
AEs 
Subjects who discontinue study treatment prior to Week 16 for 
other reasons or who have a missing Week 16 value will have 
the last valid observation carried forward (including the baseline 
value as applicable).  
For subjects who start a protocol prohibited medication/therapy 
that could improve psoriasis prior to the endpoint will also have 
their endpoint value imputed as the baseline value. The last 
valid observation will be carried forward for all other subjects 
with missing data. Subjects with a missing baseline value 
will be excluded from the analysis for the change from 
baseline endpoint. 
baseline 
endpoint. 
6.1.2.3 Time-to-
Relapse 
Endpoint 
PASI 75 response will be assessed at each visit between Week 
24 and Week 52. Subjects who experience a relapse as defined 
above at any visit between Week 24 and Week 52 will be 
considered as having an ‘event’. Subjects who discontinue 
study (or treatment) during this time, start a protocol prohibited 
medication/therapy that could improve their response or 
otherwise have missing data, and subjects that do not have 
relapse by Week 52 will be censored and the date they 
experienced the above criteria, will be used as their ‘event’ date. 
The Kaplan-Meier product limit method will be used to estimate 
the survival curves for time-to-relapse during the randomized 
withdrawal period. Treatment comparisons between BMS-
986165 6 mg QD and placebo for subjects re-randomized during 
the randomized withdrawal period will be performed using the 
log-rank test stratified using the stratification factors from 
IRT specified in Section 6.1by geographic region (U.S. and 
5HVWRI:RUOGERG\ZHLJKWNJNJDQGSULRUELRORJLF
use (yes/no). 
Removed 
prohibited 
medications 
criteria.  
Clarified 
stratification 
factors. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 60 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 61 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 62 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.1.4 Subgroup 
Analyses 
Subgroup analyses will be performed on the coprimary 
endpoints using the FAS. The primary imputation method will be 
applied for these analyses. The CMH test The CMH test using 
the stratification factors from IRT will be the analysis method 
used where the stratification factor is the specified subgroup will 
be the analysis method used where the stratification factor is the 
specified subgroup. The following subgroups will be considered: 
x 
Geographic region (U.S., Japan, China, Rest of World) 
x 
Country 
x 
Sex (male, female) 
x 
Age group (<65 years\yearsy) 
x 
Body weight (<90 kg, 90 kg) – from case report form 
x 
Race 
x 
Prior biologic use for psoriasis, psoriatic arthritis and 
other inflammatory diseases only (yes, no) – from case 
report form 
x 
Prior systemic treatment use (yes/no) 
x 
Prior phototherapy use (yes/no) 
x 
sPGA (3, 4) 
x 
PASI score (20, >20) 
x 
BSA involvement (10-20, >20)  
x 
DLQI (0-5, 6-10, 11-30) 
x 
Duration of disease (< 10 y,  10 y) 
x 
Age at disease onset (<18, 18-39, 40) 
x 
Smoking status: 
Currently non-smoker – never smoked or quit smoking t6 
months from the 1st treatment 
Currently non-daily smoker or light smoker - smoked on no more 
than 25 days in the previous 30 days to < 5 cigarettes per day 
x 
Currently moderate to heavy smoker – FLJDrettes 
per day 
 
Removed some 
subgroups that 
will not be 
analyzed. 
Clarified weight 
and prior biologic 
use to be taken 
from CRF and 
stratification 
factors for the 
CMH statement 
will use IRT 
stratification 
factors. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 63 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 64 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 65 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 66 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.2.1 Adverse 
Events 
Adverse events (AE) will be presented for the number and 
percentage of subjects and the number of events. All adverse 
events (tTreatment-emergent [TEAE] and non-treatment 
emergent) will be provided in listings. Summary tables will be 
reported in decreasing frequency based on the total BMS-
986165 column. Counting for frequency analysis will be by 
subject and not by AEs, and subjects are only counted once 
for recurring AEs within each system organ class (SOC) or 
preferred term (PT); however, the number of total AEs per 
subject, including multiple occurrences of individual AEs, will 
also be presented. For summaries of severity, AEs will be 
reported only at their maximum severity in each subject. 
Subjects with multiple AEs within a particular SOC or PT will 
be counted under the category of their most severe event 
within that SOC or PT. 
An overall summary for the following categories will be 
presented: 
x 
Subjects with at least one TEAE  
x 
Subjects with at least one related TEAE 
x 
Subjects with at least one treatment-emergent SAE 
x 
Subjects with at least one related treatment-emergent 
SAE 
x 
Subjects discontinuing study treatment due to a TEAE 
x 
Subjects discontinuing from study due to a TEAE  
x 
Subjects who died due to an AE 
x 
Subjects who died due to a TEAE 
x 
Deaths 
x 
SAEs 
x 
Related SAEs 
x 
AEs 
x 
Related AEs 
x 
Discontinued treatment due to AEs 
 
A summary of TEAEs leading to discontinuation of study 
treatment or study will be provided, grouped by SOC and PT 
for all TEAEs and treatment-related TEAEs. 
Modified text for 
overall summary 
to align with the 
data presentation 
plan. 
TEAEs leading to 
discontinuation 
was removed 
from this section 
as this is 
described in a 
separate section. 
6.2.1.1 Adverse 
Events of 
Interest (AEI) 
and Other 
Important AEs 
Summaries for treatment-emergent AEIs events will be provided 
by PT for each AEI categoryfor the following:
x 
TEAEs by SOC and PT 
Skin Events 
Modified the text 
for the final list of 
adverse events of 
interest and the 
adjudicated 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 67 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
The number and percentage of subjects reporting each type of 
skin event and the corresponding location will be summarized.  
Infections 
The number and percentage of subjects reporting infections will 
be summarized.  
Creatine kinase (CK) elevation 
The number and percentage of subjects reporting CK elevations 
will be summarized.  
Malignancies 
The number and percentage of subjects reporting malignancies 
will be summarized.  
Cardiovascular 
The number and percentage of subjects reporting 
cardiovascular event will be summarized. 
x 
Skin-related events 
x 
Infection events 
x 
Malignancy events 
Creatine kinase (CK) elevation for CK elevation >2.5 upper 
limit of normal will be summarized as CTCAE grade 2 or 
higher in the clinical laboratory summaries. 
Additional information collected for some events as part 
of the clinical safety program and adjudicated events will 
also be summarized. 
cardiovascular 
events. 
6.2.1.2 Serious 
Adverse Events 
Summaries for treatment-emergent SAEs will be provided for 
the following: 
x 
Treatment-emergent SAEs by SOC and PT 
Treatment-related treatment-emergent SAEs by SOC and PT 
Aligned with the 
Data 
Presentation Plan 
6.2.1.3 Adverse 
Events Leading 
to 
Discontinuation 
of Study 
Treatment or 
Study 
Treatment 
Interruption  
Summaries for TEAEs leading to discontinuation of study 
treatment will be provided for the following: 
x 
TEAEs by SOC and PT 
x 
Treatment-related TEAEs by SOC and PT 
Summaries for TEAEs leading to study treatment 
interruption will be provided for the following: 
x 
TEAEs by SOC and PT 
Added summary 
for TEAEs 
leading to study 
treatment 
interruption and 
aligned with the 
Data 
Presentation 
Plan. 
6.2.3 Clinical 
Laboratory Data 
Laboratory parameters will be summarized using the 
International System (SI) of Units, unless otherwise specified 
and US conventional units. Data will be summarized by time 
point, as applicable. The following summaries will be provided 
for each parameter: 
x
Absolute and change from baseline values for continuous 
parameters 
Added 
summaries for 
US conventional 
units. 
Removed 
urinalysis 
categorical 
summaries to 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 68 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
Number and percentage of subjects for the following: 
o 
Categorical urinalysis parameter results 
o 
Maximum postbaseline CTCAE grade for each applicable 
laboratory parameter through Week 16 
o 
Shifts from baseline based on maximum postbaseline 
CTCAE grade through Week 16 
x 
Drug-induced Liver Injury (DILI) and Hy’s Law summaries 
All laboratory data specified in the summary tables will be 
present in listings. 
align with data 
presentation 
plan. 
Added additional 
clarifications to 
align with data 
presentation 
plan. 
6.2.4 Vital Signs 
and Physical 
Findings 
Vital signs, including weight, will be summarized by time point, 
as applicable. The following summaries will be provided for each 
parameter: 
 
Clarified that 
weight will be 
summarized. 
6.2.6 Other 
Safety Data 
6.2.6.1 PHQ-8 
PHQ-8 total score will be summarized by time point, as 
applicable. The following summaries will be provided: 
x 
Absolute and change from baseline values 
x 
Number and percentage of subjects: 
o 
Shifts from none, mild, moderate, moderately 
severe and severe scores at baseline and at 
each time point 
o
PHQ-WRWDOVFRUHV
Removed PHQ-8 
total score >=15 
summaries as 
this is provided in 
the shift 
summary. 
6.2.6.2 eC-
SSRS 
Suicidal ideation and behavior individual item responses will be 
summarized by time point, as applicable. The following 
summaries will be provided: 
x 
Number and percentage of subjects with positive 
responses on suicidal ideation and/or suicidal behavior 
questionsresponses for each question and overall 
all questions within suicidal ideation and suicidal 
behavior 
x 
Shifts 
from 
baseline 
based 
on 
maximum 
postbaseline response through Week 16 
x
Worst postbaseline value for suicidal ideation and 
behavior through Week 16 
Additional 
analyses have 
been added for 
eC-SSRS. 
6.3.2 
Demographic 
and Baseline 
Characteristics 
Demographic and baseline characteristics will be summarized 
by treatment group for the FAS all of the analysis populations. 
Demographic and baseline characteristics include the 
following: 
x 
Prior systemic treatment use (yes/no) 
x 
Prior phototherapy use (yes/no) 
x 
Geographic Regionregion (U.S., Japan, China, Rest 
of World) 
x 
DLQI (0-5, 6-10, 11-30) 
x 
Smoking status (Current daily smoker and whether 
heavy vs. light, Current occasional smoker, former 
Updated 
populations to be 
used for 
summaries and 
removed baseline 
characteristic that 
will not be 
summarized. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 69 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
smoker, never smoker, smoker current status 
unknown, unknown if ever smoked) 
 
Additional demographics or baseline data may be added to 
summary tables. 
 
General medical history and medical history related to PsA will 
be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) (version 21.0 or an updated version at the time of 
database lock). General medical history data will be 
summarized for each SOC and PT by treatment group and 
overall for the FAS and Safety Set populations. Separate 
tables will be provided for general psoriasis medical history. 
6.3.3 Prior and 
Concomitant 
Medications 
Prior and concomitant medications will be coded according to 
World Health Organization-Drug Dictionary WHO-DD (version 
at the time of DBL) and will be summarized by Anatomic 
Therapeutic Classification (ATC) and preferred term (PT) by 
treatment group for the As-treated populationFAS. The 
number and percentage of subjects using at least one 
medication and each medication will be displayed by treatment 
group. Subjects taking more than one medication within the 
same ATC or PT will be counted once. 
Summaries will be provided for prior medications and 
medications that started prior to first treatment and were 
ongoing after first treatment start date as well as 
concomitant medications. 
Clarified 
summaries to be 
provided and the 
population to be 
used for the 
summaries. 
6.3.3.1 
Psoriasis, 
Psoriatic Arthritis 
and Other 
Inflammatory 
Disease Related 
Systemic 
Medications 
Prior medications and medications that started prior to 
first treatment and were ongoing after first treatment start 
date for systemic biologic and non-biologic medications will be 
summarized as described above for the number and 
percentage of subjects using each reported medication. 
Concomitant use of DMARDs like methotrexate will be 
summarized. 
Added 
clarification for 
prior and ongoing 
medications to be 
summarized. 
6.3.3.2 
Concomitant 
Corticosteroid 
Use 
Additionally, corticosteroids will be summarized by ATC and 
PT for the FAS. 
Removed 
reference to 
analysis 
population as this 
is redundant 
information with 
Section 6.3.3. 
6.3.4 Exposure 
6.3.4.1 Duration 
of Treatment 
Duration by Group 
Overall duration of each treatment, in days, will be calculated for 
each subject in each treatment group. Subjects are dispensed 
study treatment at each visit, starting with Day 1 (Week 0) and 
at each subsequent visit. Subjects are also to record daily 
dosing in an eDiary. The Day 1 dispensed date will be 
considered as the date of first dose of study treatment is the 
Week 0 
 dosing date and is recorded on the eCRF. If this 
date is missing, then the earliest drug dispensation date 
will be used. The last dose date of dose is defined as the last 
Updates to 
duration of 
exposure 
formula’s were 
made to align 
with the manner 
in which data will 
be summarized. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 70 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
day a subject received drug and is recorded on the end of 
treatment page in the eCRF. If this date is missing, then the 
latest date from the 
 page or drug 
accountability return date will be used. 
If the date of last dose of study treatment is missing, i.e.: subject 
lost to follow-up, the end of study date or last contact date 
(whichever comes first) will be used to calculate duration of 
treatment. 
Duration 
of 
treatment 
will 
be 
summarized 
descriptively by randomized treatment group. 
Subjects randomized to BMS-986165 and re-randomized to 
placebo at Week 24 will have their duration of treatment 
derived as: 
x 
BMS-986165 (Wk 0 through Wk 24) = Week 24 
dateDate of last dose of BMS-986165 prior to first 
placebo dose date – date of first dose +1 
x 
Placebo (Wk 24 through final week on placebo) = Date 
of last dose of placebo - Week 24 datedate of first 
dose of placebo + 1 
x 
BMS-986165 (First dose after relapse on placebo or 
switched to BMS-986165 due to COVID-19 through 
Wk 52) = Wk 52 Date of last dose of BMS-986165 – 
first BMS-986165 dose date after relapse + 1; only 
calculated for subjects that relapse or are switched 
to BMS-986165 due to COVID-19 placebo 
x 
Total BMS-986165 = Sum BMS-986165 exposure 
over entire treatment period Wk 0-Wk 24 + BMS-
986165 first dose after switch from placebo-Wk 52 
Placebo and placebo switches:For subjects randomized to 
placebo, the Week 16 date will be used as the date of last dose 
of placebo. Formula for duration is defined as: 
x 
Placebo = date of last dose of placebo Week 16 date 
– date of first dose +1 
x 
BMS-986165 = Date of last dose of BMS-986165 – 
Week 16 datedate of first dose of BMS-986165 +1 
If a placebo subject discontinues study treatment on or before 
the Week 16 visit, the date of last dose will be used to calculate 
the duration of placebo. 
Apremilast: 
For subjects randomized to apremilast, the Week 24 date will 
be used as the date of last dose of apremilast and the date of 
first dose of either apremilast or BMS-986165 (for PASI 75 non-
responders on apremilast). Subjects who continue on 
apremilast from Week 24 through to Week 52 will be counted as 
a sum of the first 24 weeks of treatment and the next treatment 
period from Week 24 to Week 52.duration is defined as: 
x 
Apremilast (Wk 0 through Wk 24) = Week 24 dateDate 
of last dose of apremilast – date of first dose +1 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 71 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
x 
Apremilast (Wk 24 through Wk 52) = Date of last dose 
 Week 24 date 
x 
Total Apremilast = Apremilast Wk 0-24 + apremilast Wk 
24-52 
x 
Placebo (PASI 75 nonresponders) = Date of last 
dose of placebo – date of first dose of placebo + 1 
x 
BMS-986165 (switched from apremilast or switched 
from placebo to BMS-986165 after relapse or due to 
COVID-19) = Date of last dose of BMS-986165  Week 
24 datedate of first dose date of BMS-986165 + 1 
x 
Placebo = Date of last placebo dose – Week 24 date 
Total apremilast duration of treatment will be displayed as well 
as BMS-986165 and placebo treatment duration. If subject 
discontinues their study treatment during the initial 24 weeks of 
apremilast treatment, the date of last dose will be used as the 
duration of apremilast. 
Duration by Period 
Overall duration (in days) of each treatment received within 
each study period will be calculated. Duration within each period 
is defined for each treatment group as: 
ܮܽݏݐ݀݋ݏ݁݀ܽݐ݁࢏࢔࢖ࢋ࢘࢏࢕ࢊെ݂݅ݎݏݐ݀݋ݏ݁݀ܽݐ݁࢏࢔࢖ࢋ࢘࢏࢕ࢊ൅ͳ 
Subjects are dispensed study treatment at each visit, starting 
with Day 1 (Week 0) and at each subsequent visit. Subjects are 
also to record daily dosing in an eDiary. The dispensed drug 
date of Day 1 of the study period will be considered as the date 
of first dose of study treatment for that period and is recorded 
on the eCRF. The last date of dose within the period will be 
considered as the day prior to the next period start date. 
If the date of last dose of study treatment is missing, i.e.: 
subject lost to follow-up, the end of study date or last contact 
date (whichever comes first) will be used to calculate duration 
of treatment. 
6.3.4.2 Summary 
of Dosing 
The number of doses taken for each subject for each period will 
be determined using the eCRF drug accountability data and is 
defined as: 
ܦ݋ݏ݁ݏܶܽ݇݁݊
ൌሺ݊ݑܾ݉݁ݎ݋݂ݐܾ݈ܽ݁ݐݏ݀݅ݏ݌݁݊ݏ݁݀െ݊ݑܾ݉݁ݎ݋݂ݐܾ݈ܽ݁ݐݏݎ݁ݐݑݎ݊݁݀ሻ
͵
The number of doses taken will be summarized descriptively 
by treatment group within each study period and overall.  
Clarified how 
data will be 
summarized. 
6.3.4.3 
Compliance 
Treatment compliance will be determined from data captured on 
the Drug Accountability eCRF.  
The number and percentage of subjects who have missed at 
least one dose will be provided. 
Additionally, descriptive statistics for the number of missed 
doses within each treatment period and overall will be provided 
Clairfied how 
data will be 
summarized. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 72 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
by treatment group. The number of missed doses for each 
subject will be calculated for each period.  
ܰݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݀݋ݏ݁ݏǣ ሺ݀ܽݐ݁݋݂݊݁ݔݐݒ݅ݏ݅ݐ
െ݀ܽݐ݁݋݂ܿݑݎݎ݁݊ݐݒ݅ݏ݅ݐሻݔ͵ 
ܰݑܾ݉݁ݎ݋݂݉݅ݏݏ݁݀݀݋ݏ݁ݏǣܰݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݀݋ݏ݁ݏ
െ݊ݑܾ݉݁ݎ݋݂݀݋ݏ݁ݏݐܽ݇݁݊
Treatment compliance will be derived for each period and 
overall. Compliance is defined as: 
൬ܰݑܾ݉݁ݎ݋݂݀݋ݏ݁ݏݐܽ݇݁݊
ܰݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݀݋ݏ݁ݏ൰ݔͳͲͲ 
Period compliance will be calculated by summing over all visits 
within the period and overall compliance will be calculated by 
summing each visit in the study and summarized using 
descriptive statistics by treatment group. The number and 
percentage of subjects with <8075%, 8075% to 1200%, and 
>1200% compliance will be provided by treatment group for 
each visit, period and overall. If a subject does not return the 
container, then this dispensation event will be excluded in 
the calculation for the total number of doses taken, total 
number of expected doses, and total compliance. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 73 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 74 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.6 Statistical 
Impacts Due to 
COVID-19 
Statistical Impacts Due to COVID-19 
Impact on Efficacy Endpoints 
There are no COVID-19-related impacts to the Week 16 
efficacy endpoints as all subjects remaining in the trial 
completed the Week 16 visit prior to COVID-19 site 
New section 
added to address 
COVID-19. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 75 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
6.61 Impact on 
Efficacy 
Endpoints 
 
restrictions. Efficacy endpoints involving Week 24 and later 
visits may be impacted by COVID-19 in the form of missing 
data and/or a treatment assignment defaulting to BMS-
986165. 
Censoring rules will be applied to the PASI 75 time-to-
relapse endpoint for re-randomized subjects due to the 
following COVID-19-related issues post Week 24: 
x 
Subject study treatment assignment was defaulted 
to BMS-986165 because they had a remote safety 
monitoring visit and efficacy assessments were not 
performed. The subjects will be censored at the 
time of the remote visit if relapse had not been 
observed already; 
x 
Subject 
has 
missing 
visits 
(ie, 
efficacy 
assessments not performed) after Week 24 and 
assuming relapse was not observed prior to 
missing visits:
o 
If the subject returns at a later visit and is 
found 
to 
have 
relapsed, 
midpoint 
imputation will be used to determine time-
to-relapse (ie, midpoint of the censoring 
interval). 
o
If the subject returns at a later visit and has 
not relapsed, then the subject will continue 
to be evaluated for relapse. 
o 
If the subject is discontinued from the study 
treatment, then the subject will be censored 
at 
the 
time 
of 
study 
treatment 
discontinuation.
Similar data handling rules will be applied to the following 
time-to-event endpoints: 
x 
Time to first loss of PASI 75 among subjects that 
are PASI 75 responders at Week 24 
x 
Time to first loss of sPGA 0/1 among subjects that 
are sPGA 0/1 responders at Week 24 where loss of 
sPGA 0/1 is defined as an sPGA score  2 
x 
Time to rebound as defined above among subjects 
re-randomized to placebo 
x 
Time-to-relapse for Week 24 PASI 75 apremilast 
responders switched to placebo 
Additional efficacy endpoints involving later visits may be 
impacted by COVID-19 in the form of missing data and/or a 
treatment assignment defaulting to BMS-986165. If a 
subject has missing data or is switched to BMS-986165 
from a different treatment due to Covid-19 during the Week 
24 through Week 52 period, the subject will be excluded 
from the analysis.  
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 76 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Additional efficacy endpoints that may be impacted include 
the following: 
x 
 
 
 
x 
 
 
 
 
x 
Disease relapse assessed as the proportion of 
subjects who have  50% loss of Week 24 PASI 
percent improvement from baseline 
x 
 
 
 
 
 
 
 
 
 
 
6.6.2 Impact on 
Safety 
Endpoints 
Impact on Safety Endpoints 
No modifications will be made for the analysis of safety 
data due to COVID-19-related issues. There will not be any 
additional safety data handling considerations for missing 
data or treatment interruptions due to COVID-19. 
New section 
added to address 
COVID-19. 
7.2 Sequence of 
Planned 
Analyses 
Any exploratory analyses completed to support study analyses 
in the Clinical Study Report (CSR), which were not identified in 
the statistical analysis plan, will be documented as such in the 
CSR. 
Removed text for 
exploratory 
analyses. 
Added 
clarification for 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 77 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
7.2.2 Final 
Analyses and 
Reporting 
Analyses of the palmoplantar pp-PGA 0/1 endpoint are 
provided for descriptive purposes within the individual 
CSR due to small sample sizes. A pooled analysis of data 
from IM011046 and IM011047 will be conducted for the 
submission. 
the analyses of 
palmoplantar (pp-
PGA 0/1 
endpoint). 
8.1 General 
Definitions 
Study day is calculated as: 
assessment date – date of first dose the subject is 
randomized + 1 
Baseline - Unless otherwise stated, Baseline is defined as the 
last measurement prior to dosing on Day 1 at the 
randomization visit (Week 0). If the measurement at the 
randomization visiton Day 1 is missing or not available, then a 
prior measurement during the screening period may be used as 
baseline. Baseline assessments must be performed per 
protocol and standard of care assessments may not be used for 
baseline. 
Baseline for each PSSD question will be calculated as the 
average value over the 7 days prior to the randomization 
visit.  In the event of missing values in the 7 days prior to 
the randomization visit, daily scores from at least 4 days 
out of the 7 days can be used to calculate the average 
score. If > 3 daily scores in the last 7 days are missing for 
a particular question, then the baseline value for that 
question will be missing.  If any questions are missing 
baseline after using the described rule, then the baseline 
value for the subscore using that question and the 
baseline value for the total score will be missing. 
First Dose Date – Study: The date a subject received their first 
dose on Day 1 as recorded in the eCRF as date study 
treatment was dispensedWeek 0 
 dosing date or the 
earliest drug dispensation date. 
First Dose Date – Period: The date a subject received their 
first dose in the defined study period as recorded in the eCRF 
as date study treatment was dispensedWeek 0 
 dosing 
date or the earliest drug dispensation date for Treatment 
Period 1 and earliest drug dispensation date for Treatment 
Periods 2 and 3. 
Change from baseline in the maximum post-baseline value is 
defined as highest observed value or grade post-baseline. 
The change is calculated using this value as the post-baseline 
value. 
Change in the maximum post-baseline value or change in the 
worst post-baseline value: Change from baseline in the 
worst post-baseline value is defined as worst observed 
value post-baseline. The change is calculated using this 
value as the post-baseline value. 
If the baseline value is 0 and the post-baseline is >0, then 
the percent change from baseline value will be missing. 
EAIR: 
Updated first and 
last dose date 
definitions and 
other definitions. 
Added an 
additional rule for 
percent change 
from baseline. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 78 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
EAIR = 100*The number of subjects with a specific event 
divided by the total exposure-time (in years) among the subjects 
in the treatment group, where the total exposure time in years is 
calculated by dividing the sum of exposure time in days over all 
subjects included in the treatment group*365.25*(total number 
of subjects with the AE)/total exposure time for the selected 
AE under each treatment that a subject is exposed. Where 
total exposure time for each AE within a treatment is 
calculated as follows: 
x 
If a subject has at least 1 event while on a particular 
treatment, then the exposure time for that subject and 
AE on that treatment is: 
o 
First AE onset date – treatment start date (of 
that particular treatment) +1  
x 
If a subject does not have an event, exposure time for 
that AE is: 
o 
Treatment stop date (of that particular 
treatment) – Treatment start date (of that 
particular treatment) + 1 + 30 days (if subject 
discontinued or subject completed Period 3 
and is not rolling into IM011075 study) 
o 
Treatment stop date (of that particular 
treatment) – Treatment start date (of that 
particular treatment) + 1 (if subject completed 
Period 3 and is rolling into IM011075 study) 
x 
Total exposure time = sum of exposure time for each 
AE within a treatment 
8.2.1.3 Body 
Surface Area 
(BSA) 
The product of BSA and sPGA will be calculatedderived as a 
potential proxy measure to PASI scores. 
Updated the 
product score 
language. 
8.2.2.1 Psoriasis 
Symptoms and 
Signs Diary 
(PSSD) 
Baseline for each PSSD question will be calculated as the 
average value over the 7 days prior to the randomization 
visit.  In the event of missing values in the 7 days prior to 
the randomization visit, daily scores from at least 4 days 
out of the 7 days can be used to calculate the average 
score. If > 3 daily scores in the last 7 days are missing for 
a particular question, then the baseline value for that 
question will be missing.  If any questions are missing 
baseline after using the described rule, then the baseline 
value for the subscore using that question and the baseline 
value for the total score will be missing. 
Clarified baseline 
definition for 
PSSD. 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 79 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
8.2.2.8 Psoriatic 
Arthritis 
Screening and 
Evaluation 
(PASE) 
Questionnaire 
The PASE questionnaire will be administered at Screening in 
subjects 
with 
peripheral 
joint 
complaints. 
The 
PASE 
questionnaire is a self-administered tool that is used to screen 
for psoriatic arthritis among subjects who have psoriasis. The 
PASE questionnaire consists of 15 questions subdivided into 7 
questions focusing on symptoms of psoriatic arthritis, and 8 
questions focusing on the impact of psoriatic arthritis on 
function. Each question is scored on a 1 to 5 scale, with a 
maximum symptom sub-scale score of 35, a maximum function 
sub-scale score of 40 giving a total maximum score of 75. A 
score of 47 or above has been shown to distinguish between 
psoriatic arthritis and non-psoriatic arthritis. This questionnaire 
is only intended to be a screening tool for psoriatic arthritis and 
does not replace a comprehensive musculoskeletal exam 
performed by a rheumatologist. This information will not be 
summarized. 
Individual score to each of the 15 questions will be collected in 
the eCOA system. The sub-scale scores and total score will be 
derived in the analysis datasets. 
Clarified that 
PASE information 
will not be 
summarized. 
8.2.2.10 
electronic 
Columbia-
Suicide Severity 
Rating Scale 
(eC-SSRS) 
The electronic Columbia-Suicide Severity Rating Scale (eC-
SSRS) is a computer-automated, patient-reported version of the 
C-SSRS instrument that defines 11 categories of suicidal 
ideation and behavior (SIB) events. Categories and definitions 
are provided in Appendix 23 of the protocol. The categories are 
as follows: 
x 
Suicidal ideation 
6. Wish to be deadPassive 
Updated 
descriptions of 
categories to 
align with data 
presentation plan 
and put behavior 
categories in 
proper ascending 
order.  
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020  
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 80 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
7. Non-specific active suicidal thoughtsActive: 
Nonspecific (no method, intent, or plan) 
8. Active suicidal ideation with any methods 
without intent to actActive: Method, but no intent 
or plan 
9. Active suicidal ideation with some intent to act, 
without specific planActive: Method and intent, 
but no plan 
10. Active suicidal ideation with specific plan and 
intentActive: Method, intent, and plan 
x 
Suicidal behavior 
6. Preparatory acts or behaviorCompleted suicide 
7. Aborted attemptSuicide attempt 
8. Interrupted attempt 
9. Actual attempt (Non-fatal)Aborted attempt 
10. Completed suicidePreparatory actions toward 
imminent suicidal behaviors 
Self-injurious behavior, no suicidal intent 
8.4 Study 
Periods 
Period 1 = the first 16 weeks of treatmentWeek 0 to Week 16 
visit date 
Period 2 = Week 16 visit date +1 to Week 24 visit date after 
Week 16 to Week 24  
Period 3 = Week 24 visit date +1 to Week 52 visit dateafter 
Week 24 
Follow-up = 4-week follow-up period 
Clarified study 
periods. 
 
 
8.5 Day Ranges 
for Analysis 
Visits 
Week 16 
100, 127 (or Week 16 drug dispense date if 
earlier) 
Week 24            156, 183 (or Week 24 drug dispense date if 
earlier) 
Clarified Week 16 
and Week 24 
analysis range 
criteria 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 81 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Appendix 1 Planned Analyses 
List of Planned Analyses: Comparisons of BMS-986165 6 mg QD vs. Placebo 
Measure of Interest 
Population 
Analysis at Week 16 
sPGA 0/1 – coprimary 
PASI 75 - coprimary 
FAS 
NRI+CMH - primary 
sPGA 0/1 – coprimary 
PASI 75 – coprimary 
FAS 
LOCF+CMH – sensitivity 
LOCF/NRI+CMH – sensitivity 
Tipping Point+CMH – sensitivity 
Multiple Imputation + CMH - 
sensitivity 
sPGA 0/1 – coprimary 
PASI 75 – coprimary 
PPS 
NRI+CMH - supportive 
sPGA 0/1 – coprimary 
PASI 75 - coprimary 
FAS 
NRI+CMH – subgroups 
PASI 90 – key secondary 
FAS 
NRI+CMH 
sPGA 0 – key secondary 
FAS 
NRI+CMH 
ss-PGA 0/1 among subjects 
with a baseline ss-PGA  3 – 
key secondary 
FAS 
NRI+CMH 
PSSD symptom score of 0 – 
key secondary 
FAS 
NRI+CMH 
DLQI 0/1 – key secondary 
(EX-US submission only) 
FAS 
NRI+CMH 
PGA-F 0/1 among subjects 
with a baseline PGA-F  3 
FAS 
NRI+CMH 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 82 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
List of Planned Analyses: Comparisons of BMS-986165 6 mg QD vs. Apremilast 
Measure of Interest 
Population 
Primary Analysis at Week 16/24 
sPGA 0/1 at Week 16 – key 
secondary 
PASI 75 at Week 16 – key 
secondary 
FAS 
NRI+CMH 
PASI 90 at Week 16 – key 
secondary 
FAS 
NRI+CMH 
Change from baseline in 
PSSD symptom score at 
Week 16 – key secondary 
FAS 
mBOCF+ANCOVA 
ss-PGA 0/1 among subjects 
with a baseline ss-PGA  at 
Week 16 – key secondary 
FAS 
NRI+CMH 
sPGA 0 at Week 16 – key 
secondary 
FAS 
NRI+CMH 
PSSD symptom score of 0 at 
Week 16 – key secondary 
FAS 
NRI+CMH 
sPGA 0/1 at Week 24 – key 
secondary 
PASI 75 at Week 24 – key 
secondary 
FAS 
NRI+CMH 
PASI 90 at Week 24 – key 
secondary 
FAS 
NRI+CMH  
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 83 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Appendix 2 Summary of Efficacy Assessments 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
sPGA 
(Sec 8.2.1.1)
sPGA 0/1 with 
at least 2 point 
improvement 
from baseline 
W16 
BMS vs. PBO 
CMH, sensitivity analyses including tipping 
point analysis, multiple imputation (Sec 
6.1.1.1-3) 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
W24 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
Baseline->W24 over time 
BMS vs. 
apremilast 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
sPGA 0 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
BMS vs. 
apremilast
CMH (Sec 6.1.2.1) 
 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
PASI 
(Sec 8.2.1.2) 
PASI 75 
W16 
BMS vs. PBO 
CMH, sensitivity analyses including tipping 
point analysis, multiple imputation (Sec 
6.1.1.1-3) 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
 
 
W24 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 84 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
 
 
Time-to-first loss of PASI 75 
response between W24 and W52 
BMS only 
Kaplan-Meier (Sec 6.1.5.3) 
 
 
Baseline->Week 16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
 
 
Baseline->Week 24 over time 
BMS vs. 
apremilast 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
 
PASI 90 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
 
 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
 
 
Baseline->W24 over time 
BMS vs. 
apremilast 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
 
PASI 100 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
 
 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
 
 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 85 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
ss-PGA 
(Sec 8.2.1.4) 
ss-PGA 0/1 
among subjects 
with a baseline 
ss-PGA η3 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
PGA-F 
(Sec 8.2.1.6) 
PGA-F 0/1 
among subjects 
with a baseline 
PGA-F score η3 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 86 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
pp-PGA
(Sec 8.2.1.8) 
pp-PGA 0/1
among subjects 
with a baseline 
pp-PGA η3 
W16
BMS vs. PBO
CMH (Sec 6.1.2.1)
Baseline->W16 over time 
BMS vs. PBO 
CMH by Week (Sec 6.1.5.1) 
PSSD / 
Symptom 
Score 
(Sec 8.2.2.1) 
PSSD/Symptom 
0 among 
subjects with 
baseline 
PSSD/symptom 
score η1 
W16
BMS vs. PBO
CMH (Sec 6.1.2.1)
BMS vs. 
apremilast 
CMH (Sec 6.1.2.1) 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 87 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
DLQI 
(Sec 8.2.2.4) 
DLQI 0/1 among 
subjects with a 
baseline DLQI 
score η2 
 
W16 
BMS vs. PBO 
CMH (Sec 6.1.2.1) 
Baseline->W16 over time 
BMS vs. PBO 
Binary GEE & CMH by Week (Sec 6.1.5.1) 
Approved
2.0
v
Approved
2.0
v


Statistical Analysis Plan 
Version Date: 30-Sep-2020 
Sponsor: Bristol-Myers Squibb 
Protocol no: IM011047 
 
Page 88 of 88 
Strictly Confidential.  © 2017, 
.  All rights reserved. 
Assessment 
Outcome 
Measure 
Endpoint 
Comparison 
Analyses 
PASE 
(Sec 
8.2.2.11)    
PASE 
Screening only 
 
No Analysis 
Approved
2.0
v
Approved
2.0
v